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Abstract 
Routine cytogenetic and molecular genetic investigations aid the diagnosis of 
acute myeloid leukaemia (AML) and are critical for prognostic stratification to optimise 
therapy and enhance survival of patients. Advances in the understanding of the genomics 
of AML by next generation sequencing (NGS) technology have identified a mutational 
landscape, which has the potential to improve risk assessment and identify new targets 
for therapy. This project developed a novel, custom-designed NGS panel for the 
resequencing of genomic DNA (gDNA), to identify multiple types of genetic lesion in AML. 
Regions of recurrent genetic abnormalities were targeted, to reproduce the output of 
conventional testing in a single assay. Solution hybrid capture and Illumina-based NGS 
were used to analyse 36 AML samples, without use of normal control to represent the 
typical diagnostic workflow. A panel of 42 genes, including those most frequently 
mutated, was used to test for clinically relevant abnormalities, including common 
duplications and gene fusions. Sequence data was analysed with a pipeline of relevant 
bioinformatic tools and the output was compared to standard results and sequencing 
from an alternative NGS platform.  
 Following variant annotation, a total of 143 likely oncogenic variants were 
detected across all samples. This included all 13 NPM1 insertions, 10 FLT3-ITD, and the 7 
fusion genes found by routine tests. There was strong concordance between NGS 
platforms for mutation detection. Multiple new findings included two KMT2A-PTD, a TP53 
mutation in a patient with a complex karyotype, and a rare NUP98-DDX10 gene fusion. 
Patients were regrouped by a new prognostic scheme based on genomic features. Eight 
patients were reclassified; seven changed from the Intermediate group, three to 
Favourable and four to Adverse. The successful detection of genomic lesions 
demonstrated the principle that the new NGS assay could reliably detect a variety of 
genomic abnormalities and that it could be refined for use in the diagnostic laboratory, 
with the potential to rationalise multidisciplinary workflows. The feasibility of 
implementation is discussed. A potential clinical utility was inferred and suggests that 
benefit could be derived for its validation for mainstream diagnosis for the clinical 
management of AML. 
4 
 
 
 
 
 
 
 
5 
 
Acknowledgements 
I would like to thank my supervisors, Dr Stefan Meyer and Dr Chris Murgatroyd, 
my Director of Studies, Dr Ciaren Graham and former Director of Studies, Professor Bill 
Gilmore. My thanks also go to Dr Carol Taylor, Programme Leader for the Professional 
Doctorate and to all who gave their time to teaching on the modular components of the 
course. 
I am indebted to The Christie NHS Foundation Trust for allowing me to study for 
the Professional Doctorate and for their financial support. I am extremely grateful to the 
Alan Gowenlock bursary, which partly supported tuition fees. 
I would like to thank all staff of the Oncology Cytogenetics for their hard work and 
dedication providing an excellent service and for performing the routine investigations 
that were used for the project. In particular, I would like to thank Pragnya Patel who 
coordinated the collection of surplus samples and helped with DNA extraction. 
Technical advice in the new technology was gratefully received from many sources 
and the following deserve particular mention; Lee Silcock and Ivan Lesende (Agilent), 
Freddie Sharkey and Kicki Bergefall (Thermo Fisher Scientific), Matthew Bashton and 
Sarra Ryan (Newcastle University). In particular, Matthew provided bioinformatics advice 
and support by allowing me use of Newcastle University Pindel and Lumpy analytical 
software. Erica Ashton, kindly accessed NHS Summary Care Record for missing overall 
survival data. 
The main next generation sequencing was performed in the Core Facility of the 
CRUK Manchester Institute. The Ion Torrent sequencing was performed in the Thermo 
Fisher Scientific laboratory in Darmstadt, Germany. All sample preparation and post 
sequencing data processing and analysis was performed by me. 
And last but by no means least, to Karen, Cerys, Elise and George. The project 
would not have been possible without their love and support. 
 
6 
 
7 
 
Contents 
Abstract .................................................................................................................................. 3 
Acknowledgements ................................................................................................................ 5 
Contents ................................................................................................................................. 7 
1.0 Introduction ................................................................................................................... 11 
1.1 Genomic Science and the Human Genome Project ................................................... 12 
1.1.1 Genomics and Cancer .......................................................................................... 14 
1.1.2 Technological advances in genomic testing ........................................................ 18 
1.2 Acute Myeloid Leukaemia; the potential clinical utility of genomic investigations .. 24 
1.2.1 Current standard of AML care ............................................................................. 25 
1.3 Genetic, cytogenetic and genomic influences in AML ............................................... 27 
1.3.1 Cytogenetics of AML ............................................................................................ 27 
1.3.2 Limitations of Cytogenetic analysis ..................................................................... 29 
1.3.3 The WHO Classification of AML ........................................................................... 29 
1.3.4 Cytogenetic and molecular genetic risk factors and treatment outcomes ......... 32 
1.3.5 Refinement of cytogenetic profiling from molecular genetics evidence ............ 34 
1.3.6 Complex karyotype and Monosomal karyotype ................................................. 41 
1.3.7 Different considerations in Childhood AML ........................................................ 42 
1.3.8 Genetics factors predictive of therapeutic response .......................................... 44 
1.3.9 Genetics to monitor Minimal Residual Disease (MRD) ....................................... 45 
1.4 The development of next generation sequencing for AML and other cancers ......... 48 
1.4.1 Traditional genomic approaches to cancer investigation; cytogenetics ............. 48 
1.4.2 Microarray technology ........................................................................................ 49 
1.4.3 Gene Expression Profiling .................................................................................... 50 
1.4.4 Next Generation Sequencing ............................................................................... 52 
1.5 Genomics strategy in the UK ...................................................................................... 65 
1.5.1 The need to modernise cancer molecular pathology .......................................... 65 
1.5.2 The 100,000 Genomes Project ............................................................................ 67 
8 
 
1.5.3 Genomic Services Reconfiguration in England .................................................... 68 
1.5.4 Challenges for the new testing paradigm ........................................................... 68 
1.6 Project aims and what it adds to scientific field ........................................................ 73 
2.0 Methods ......................................................................................................................... 77 
2.1 Sample selection and processing ............................................................................... 78 
2.2 Ethical Approval ......................................................................................................... 78 
2.3 Routine genetic testing .............................................................................................. 79 
2.3.1 Cytogenetics ........................................................................................................ 79 
2.3.2 FISH ...................................................................................................................... 80 
2.3.3 PCR for NPM1 and FLT3-ITD mutations .............................................................. 80 
2.4 Next Generation Sequencing ..................................................................................... 81 
2.4.1 Target Selection ................................................................................................... 81 
2.4.2 DNA Library Construction and Hybrid Capture ................................................... 88 
2.4.3 DNA Sequencing .................................................................................................. 90 
2.5 Data Analysis .............................................................................................................. 90 
2.5.1 Run Parameters and Quality Control .................................................................. 90 
2.5.2 Analysis of data for SNVs and short indels .......................................................... 91 
2.6 Rationale for Variant Selection .................................................................................. 93 
2.6.1 Base call quality score (Q Score) ......................................................................... 93 
2.6.2 P-value ................................................................................................................. 94 
2.6.3 Read Depth .......................................................................................................... 94 
2.6.4 Variant read number and Variant Allele Frequency (VAF) .................................. 94 
2.6.5 Variant Quality Scores (QUAL) ............................................................................ 94 
2.6.6 Strand Bias ........................................................................................................... 95 
2.7 Clinical Validation of Variants .................................................................................... 95 
2.7.1 Filtering benign germline polymorphisms (SNPs) ............................................... 95 
2.7.2 Filtering non-pathogenic variation ...................................................................... 96 
2.7.3 Identification of actionable cancer-associated somatic mutations .................... 97 
2.8 Variant Annotation using SureCall ............................................................................. 97 
9 
 
2.8.1 Analysis of data for SNVs and short indels using GATK HaplotypeCaller ............ 98 
2.8.2 Indel and Structural Variations Calling using Pindel ............................................ 98 
2.8.3 Gene fusions and Structural Variation Calling using LUMPY ............................... 99 
2.9 Orthogonal sequencing using Ion Torrent ...............................................................101 
3.0 Results ..........................................................................................................................105 
3.1 Patient population ....................................................................................................106 
3.2 Cytogenetic and standard molecular testing ...........................................................107 
3.3 Illumina sequencing of the custom NGS panel ........................................................111 
3.3.1 Run level performance of custom panel sequencing ........................................111 
3.3.2 Sample level post-alignment quality statistics from SureCall BWA-MEM ........113 
3.3.3 Sample level quality statistics from FASTQC and BAM QC reports ...................114 
3.3.4 SureCall suite of software for sequence alignment and variant annotation ....114 
3.3.5 Variant Annotation from SureCall, Pindel and Lumpy alignments ....................115 
3.3.6 Comparison of SureCall to GATK Haplotyper and Ion Torrent AML Ampliseq ..126 
3.3.7 Pindel for ITD classification ................................................................................128 
3.3.8 LUMPY for detection of gene fusions ................................................................137 
3.4 Functional classification of diseases, complementation groups and mutual 
exclusivity .......................................................................................................................145 
3.5 Influence of genomic profiling on the outcomes of the AML patients ....................146 
4.0 Discussion .....................................................................................................................153 
4.1 Introduction; the potential for routine use of NGS in AML diagnosis .....................154 
4.2 Improved detection of clinically relevant genomic profiles .....................................155 
4.3 Clinical significance of genomic evidence on AML management ............................157 
4.4 Clonal heterogeneity and cooperating mutations ...................................................158 
4.5 Performance of the NGS assay for AML diagnosis ...................................................160 
4.5.1 Detection of Somatic Mutations ........................................................................160 
4.5.2 Detection of FLT3 and CEBPA insertions ...........................................................161 
4.5.3 Detection of gene fusions and structural variation ...........................................163 
4.6 Bioinformatics ..........................................................................................................167 
10 
 
4.6.1 Single versus Paired analysis ............................................................................. 168 
4.7 Variant annotation and the most useful determinants of pathogenicity ............... 169 
4.8 Experimental design and future considerations ...................................................... 170 
4.8.1 Patient cohort .................................................................................................... 170 
4.8.2 Choice of target genes ....................................................................................... 171 
4.8.3 CNV .................................................................................................................... 174 
4.8.4 Minimal residual disease ................................................................................... 175 
4.9 Feasibility of introducing NGS protocol into routine practice ................................. 175 
5.0 Conclusion .................................................................................................................... 179 
6.0 References ................................................................................................................... 181 
7.0 Appendices .................................................................................................................. 219 
7.1. Appendix 1. Concentration of DNA from samples used in the project .................. 220 
7.2. Appendix 2. Read Metrics from Main Sequencing Run on Illumina Nextseq ......... 222 
7.3. Appendix 3. Life Technologies Ion Torrent PGM sequencing ................................. 224 
7.4. Appendix 4. Published work.................................................................................... 225 
7.4.1 Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma 
with ETV6-LYN gene fusion. ....................................................................................... 225 
7.4.2 Germline GATA2 mutation in three siblings with familial Myelodysplastic 
syndrome .................................................................................................................... 226 
 
 
11 
 
1.0 Introduction 
12 
 
1.1 Genomic Science and the Human Genome Project 
Modern biomedical and clinical practice is in the midst of a revolution in genomic 
science which has the potential to transform healthcare. Personal genomics is set to 
transform health decision making for individuals by customising disease assessment and 
by designing specific therapeutic plans accordingly. Treatment can be optimised by 
providing personalised risk information about cancer and other diseases such as diabetes, 
heart disease and obesity. Pharmacogenomics will inform how individuals metabolise 
conventional drugs and a better understanding of the molecular basis of their disease will 
provide specific targets for therapy. A different landscape for healthcare is envisaged, in 
which treatment will be tailored to a patient’s particular constitutional and disease profile 
and they would actively participate in directing their care. This is set to challenge our 
understanding about what constitutes health and well-being and represents a paradigm 
shift in the way disease is defined and managed for the 21st Century. 
We have come a very long way with our knowledge of genomics since DNA was 
first isolated in 1869 and Watson and Crick described the structure of the DNA double 
helix in 1953 (Watson & Crick, 1953). Since the Human Genome Project (HGP) delivered 
the first draft sequences of the human genome, a period of intense genomic research 
activity and discovery ensued; the start of a “Genomic Era” (Guttmacher & Collins, 2003). 
HGP was hailed as one of the greatest, collaborative scientific achievements ever; 
Biology’s first ‘Big Science’ project (Hood & Rowen, 2013; Green et al., 2015; Vermeulen, 
2016). Amidst the highest profile publicity, it was promised that the new understanding of 
genetics would reveal the causes of common diseases, including cancer, and transform 
therapeutic medicine, enabling cures previously impossible (Collins, 2010b; Hood & 
Rowen, 2013). There is no doubt that the biosciences have been “profoundly and 
irreversibly affected by access to the complete DNA sequence of the human genome” 
(Collins, 2010b; Green et al., 2015). An immense amount of information has been accrued 
by elucidating the structure of the human genome and the function encoded in it. 
Furthermore, HGP led to the development of an infrastructure for a new technoscience 
and facilitated a new way of performing scientific investigations, which represented a 
departure from traditional scientific method (Barnes & Dupre, 2008; Hood & Rowen, 
2013; Green et al., 2015). One of the key achievements of HGP has been the generation 
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of large, publicly available, comprehensive sets of reference data providing the scientific 
resources that comprise a toolkit for genomics-based research, the most obvious 
examples being genomic maps and databases of DNA sequence and variation (Butler, 
2010; Hood & Rowen, 2013). This has necessitated a parallel drive to upgrade 
computational functionality and Information Technology infrastructure to provide the 
analytical resource required for genomic study.  
The rhetoric that accompanied the release of the draft human genome sequence 
was accompanied by scepticism about the scientific validity of HGP, which was reinforced 
in subsequent years by the apparent anti-climax that the promised health benefits did not 
move into general public awareness or contribute to health and social change. The 
revolution in personalised medicine that has been anticipated for almost two decades has 
been slow to deliver. Unexpected findings and the extreme complexity of the genome has 
confounded the understanding of the data, even challenging the concept of the gene 
itself (Barnes & Dupre, 2008; Butler, 2010; Griffiths & Stotz, 2013; Arney, 2016). This has 
resulted in a re-evaluation of the original estimates of the timelines for the delivery and 
general adoption of personalised medicine (Collins, 2010a; Hamburg & Collins, 2010).  
The investigation of common inherited conditions requires further intensive study and it 
may take many more years to transform medical practice in the way it was first conceived 
(Manolio et al., 2009; Collins, 2010a). It has been argued that there have been few 
intellectual or economic benefits, relative to the huge outlay of HGP (US$ 3 billion over 13 
years) (Vermeulen, 2009; Wade, 2010). However, the limited success needs to be 
weighed against the technological, financial, ethical and cultural challenges encountered 
and the scientific advances that are emerging and still have the potential to be revealed. 
Perhaps HGP promised too much, too soon. It is now recognised that HGP was only the 
starting point on the path to genomic medicine (Butler, 2010; Eric Green director of 
NHGRI quoted in Wadhwa, 2014). Very gradually, new genetic techniques and 
modernised information technology are being used to interpret the information encoded 
in the genome, and are being translated into new diagnostic procedures, which will lead 
to the optimisation of treatment and improvements in clinical practice. 
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1.1.1 Genomics and Cancer 
Cancer is understood to be a genomic disease, involving multiple genes and 
genomic regions and their interrelationships, with a combined influence on the growth 
and development of a tumour, rather than single genes having an isolated effect (World 
Health Organization, 2017). New treatments will benefit from increasing knowledge of 
the molecular mechanisms of the control of cell growth in healthy individuals and in 
disease processes, placing oncological clinical practice at the vanguard of personalisation 
of medicine. For many years, some cancers have been categorised not solely by 
traditional methods of microscopic examination of tissue morphology and techniques to 
determine cell type, but by their genetic characteristics (Roug et al., 2014; Arber et al., 
2016). This has intensified with the accumulation of evidence that certain genetic defects 
can define a patient’s specific cancer type and therefore provide the most accurate 
diagnosis (Harris & McCormick, 2010). This has been particularly relevant for the 
haematological malignancies; for example, the chromosomal translocation t(15;17) in 
acute promyelocytic leukaemia (APML) (Zelent et al., 2001) is characteristic of the disease 
entity and whilst not specific, t(9;22) in chronic myeloid leukaemia and the V600E 
mutation in hairy cell leukaemia are found almost exclusively as the disease-driving 
genetic changes associated with a morphological subtype (Arber et al., 2016; Swerdlow et 
al., 2016). Conversely, the emergence of genetic driver mutations, as some of the most 
powerful diagnostic characteristics, is leading to disease classifications being reframed, 
making genetic abnormalities, rather than morphological appearance, the main diagnostic 
determinants of a subtype (Arber et al., 2016; Swerdlow et al., 2016).  
Importantly, genetic prognostic biomarkers offer information about the likelihood 
of survival when patients are given the standard of care for their disease, influencing the 
choice of conventional treatment if options exist. Increasingly, genetic lesions identified in 
tumour tissue have predictive value for response to a specific type of therapy. Improved 
cancer outcomes will result not just from better treatment stratification but also from 
recognition of clinically actionable targets and implementation of highly specific therapies 
that are tailored to an individual's cancer mutational profile. This ‘precision medicine’ 
could improve cancer outcomes by neutralising the core molecular defects that cause the 
disease, offering the opportunity of more effective therapy by specifically retarding the 
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growth of cancer cells from disruption of their metabolism and inducing cell death. This 
has the added benefit of reducing the undesirable side-effects of damage to a patient’s 
normal cells.  
Genome analysis is now starting to guide more treatment decisions in cancer and 
the revolution in disease diagnosis and therapy is gradually revealing itself to improve  
patients’ treatment outcomes (Tian et al., 2012). Development pipelines for drug and 
biomarker discovery are becoming aligned, offering an increasing armoury of drug 
candidates and the opportunity to salvage previously failed products by presenting new 
targets to examine (Miles et al., 2015). We are moving from the one-size-fits-all approach 
of cytotoxic chemotherapy to strategies based upon molecularly targeted drugs that 
exploit the particular genetic addictions, dependencies and vulnerabilities of cancer cells 
(Hoelder et al., 2012; Hollingsworth & Biankin, 2015). Despite remarkable progress in the 
identification and characterisation of novel oncogenic mechanisms, conventional 
randomised clinical trials take time to demonstrate the efficacy of a particular approach 
and the conversion of genomic information to clinical validated therapies is slow (Rubin & 
Gilliland, 2012). Furthermore, individual molecular markers can be uncommon which 
would be unworkable for accrual of patients and the cost of sequencing multiple patients 
to find those eligible would be unacceptable (Hollingsworth, 2015). Cancer genomics is 
therefore driving innovation in study design whereby potential participants are 
sequenced in ‘umbrella’ or ‘basket’ trials in which  multiple treatment arms are possible, 
depending on the genetic composition of a tumour (Hollingsworth & Biankin, 2015). The 
uniqueness of each patient’s tumour and intense customisation of therapy essentially 
results in a single person (N-of-1) approach but with standardisation of design the data 
can be cumulative across different trials (Schork, 2015). 
 Tumour clonal heterogeneity and the evolution of resistance from selective 
pressure to drive clonal development along new pathways with secondary mutations are 
recurrent themes, confounding targeted drug development and thereby the precision 
medicine philosophy (Fisher et al., 2013). Nevertheless, a large and increasing number of 
targeted or biological agents have been approved by the US Food and Drug 
Administration (FDA), many for the same and most common tumour types (National 
Cancer Institute, 2014). However, less than 20 specific molecular genetic targets that also 
require a companion diagnostic test have been demonstrated to be reliable biomarkers 
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for selecting patients (see Table 1.1, adapted from Dietel et al., 2015; Mertens et al., 
2015; Abramson, 2016). 
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Table 1.1. Targeted drugs in clinical use requiring companion diagnostic genetic tests (Compiled from Dietel et al., 2015; Mertens et al., 
2015; Abramson, 2016; McDermott, 2017) 
Tumour type Affected gene(s) Type of alteration Method for detection Related treatment 
Acute lymphoblastic leukaemia BCR-ABL1 Gene fusion Cytogenetics, FISH, PCR Imatinib, Dasatinib, Bosutinib, Ponatinib 
Breast cancer HER2 Amplification IHC, FISH Trastuzumab, Ado-trastuzumab, Lapatinib, 
Pertuzumab 
  PIKCA SNV Sequencing Reduced response to anti-HER2 treatment 
Chronic lymphocytic leukaemia CD52 n/a TP53 deletion (FISH) Alemtuzumab, Venetoclax 
Chronic myeloid leukaemia BCR-ABL1 Gene fusion Cytogenetics, FISH,  Imatinib, Dasatinib, Bosutinib, Ponatinib, Nilotinib 
Colorectal cancer RAS (KRAS, NRAS) SNV Sequencing Cetuximab, Panitumumab 
Dermatofibrosarcoma protuberans COL1A1–PDGFRB Gene fusion FISH, PCR Imatinib 
Gastric adenocarcinoma HER2 Amplification IHC/FISH Trastuzumab 
Gastro-Intestinal Stromal Tumour  KIT SNV, indel Sequencing Imatinib, Sunitinib 
(GIST) PDGFRA SNV Sequencing Imatinib, Sunitinib 
Hairy cell leukaemia BRAF V600E mutation Sequencing Vemurafenib 
Chronic eosinophilic leukaemia FIP1L1–PDGFRA Gene fusion FISH, PCR Imatinib 
Lymphoma MYC Gene fusion, amplification IHC, FISH BET & Protein translation inhibitors 
 BCL2 Gene fusion, amplification IHC, FISH BH3 mimetics 
Malignant melanoma BRAF SNV Sequencing Vemurafenib, Dabrafenib, Trametinib 
  KIT SNV, indel Sequencing Sunitinib, Dasatinib, Imatinib 
  MEK     Cobimetinib, Trametinib 
MDS/MPN PDGFR fusions     Imatinib 
NSCLC EGFR SNV, MNV, indel Sequencing Gefitinib, Erlotinib, Afatinib, Dacomitinib 
  ALK Gene fusion FISH, IHC, Sequencing Crizotinib, Ceritinib, Alectinib 
  ROS1 Gene fusion FISH, Sequencing Crizotinib 
  MET Amplification FISH, Sequencing Resistance to EGFR TKIs 
Ovarian cancer BRCA1/BRCA2 SNV, MNV, indel Sequencing Olaparib 
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1.1.2 Technological advances in genomic testing 
The sequencing of the human genome was not only the start of an era of great 
understanding of genomic science but it also stimulated a significant development in 
technology. Completion of the first human whole genome sequences were performed by 
Sanger DNA sequencing, which had dominated the science for almost two decades and 
resulted in many key advances (Sanger et al., 1977). During the HGP, this procedure was 
scaled up and made more efficient by evolutionary technical advances, such as automation 
and miniaturisation and using new methods, such as capillary-based sequencing and single 
nucleotide polymorphism (SNP) genotyping (Metzker, 2010). Despite many technical 
improvements during this era, the limitations of automated Sanger sequencing showed a 
need for new and improved technologies to increase the capacity for genomic analyses; to 
sequence larger regions and greater numbers of human genomes, in reasonable timescales, 
at lower cost.  
A significant breakthrough in genomic investigation has been ‘Next Generation 
Sequencing’ (NGS) of nucleic acids (also known as second generation, massively parallel or 
clonal sequencing), referring to a technology developed concurrently by several commercial 
companies (Metzker, 2010; Goodwin et al., 2016). Similar to traditional sequencing methods, 
NGS uses DNA polymerase to catalyse the incorporation of deoxyribonucleotide 
triphosphates (dNTPs) using a DNA template strand during sequential cycles of DNA 
synthesis. Although the precise methodology varies, NGS instruments share the common 
principle of miniaturisation of sequencing reactions so that clusters of millions of DNA 
fragments, fixed on a stable substrate, can be scanned and sequenced at the same time in 
the flow cell of a sequencing machine (see Figure 1.2) (Bentley et al., 2008). NGS requires the 
preparation of amplified libraries of template DNA prior to the sequencing of these DNA 
clones; however, the need for laborious fragment-cloning methods that were used with 
Sanger sequencing is obviated. Thus, the capability of NGS to produce multiple parallel reads 
facilitates high-throughput sequencing that can reproduce the output of capillary 
electrophoresis sequencing many times over, accurately determining the sequence of short 
lengths of DNA in much faster timescales. NGS also offers the opportunity for achieving 
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‘deep’ DNA sequencing, a large number of sequence reads covering  each base or region of a 
genome, and sequencing of multiple samples at much reduced cost (Metzker, 2010). 
The increase in scale not only lends itself to more efficient sequencing, but also to 
new applications not possible by the Sanger method. This offers enormous opportunities and 
will be the main transformative benefit from NGS. The sequencing of multiple genomic 
targets in a single assay enables characterisation of large regions or whole genomes in 
practical timescales, and also the detection of large scale structural variation. The magnitude 
of sequencing reactions permits evaluation of the relative frequency of reads to detect copy 
number variation and improves depth of sequencing, enabling the detection of low 
frequency gene aberrations such as minor cancer clones. This facilitates novel applications, 
such as the detection of low level circulating tumour DNA in ‘liquid biopsies’ for cancer 
diagnosis where a solid tumour cannot be identified or biopsied (Siravegna et al., 2017; Wan 
et al., 2017). Variation of NGS techniques can be used for wide scale RNA sequencing (e.g. 
whole transcriptome shotgun sequencing or RNA-seq) (Wang et al., 2009; Ozsolak & Milos, 
2011) to characterise coding and noncoding transcriptional activity in a specimen or to target 
a specific subset of transcripts. Furthermore, analysis of target DNA by methylation-sensitive 
sequencing can study the epigenetic regulation of gene expression and its emerging 
significance in neoplastic disease (Hirst, 2013).  
Therefore, NGS is not simply the next step in the evolution to more efficiently derive 
short read sequence information, but has the potential to revolutionise how all genetic 
information is derived. NGS will transform the provision of laboratory diagnostic services and 
make possible novel applications in healthcare. NGS can improve on existing laboratory 
techniques by replacing single gene testing where, increasingly, panels of multiple genetic 
targets are necessary for comprehensive diagnosis of disorders. Additional information can 
be simply obtained, facilitating the use of genomic profiling rather than single mutations to 
more accurately diagnose conditions and stratify treatment. It can be envisaged how 
cytogenetic investigations could be improved by increasing the resolution of testing to the 
ultimate DNA sequence level and making the detection of low level variants feasible, 
improving on the accuracy and sensitivity of traditional analysis. It is possible to identify 
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different types of genomic variation by a single methodology. In time, multiple technologies 
will be replaced, with laboratory diagnostics converging for most applications in a single 
technology, challenging how laboratory services are organised and delivered, thereby 
reducing the requirement for multidisciplinary workflows. 
NGS is in a developmental phase whereby it is being refined into a robust and 
reproducible technology for clinical applications. Assays are being validated for use in the 
accredited diagnostic laboratory environment. NGS has been used extensively in research, 
generating vast quantities of genomic information in health and disease. During this time, the 
technology has been under continual development and commercial companies are 
developing instruments and analytical pipelines that are applicable to routine laboratory 
practice; such as Illumina® (e.g. NextSeq™ and MiniSeq™), Thermo Fisher Scientific (e.g. Ion 
Torrent PGM™) and QIAGEN (e.g. GeneReader®) (Goodwin et al., 2016). There is a definite 
change of focus amongst equipment suppliers towards NGS being applied to routine clinical 
practice to improve genetic diagnosis (Metzker, 2010; ten Bosch & Grody, 2008; Tucker et al., 
2009; Voelkerding et al., 2009; Pareek et al., 2011; Kohlmann et al., 2012) and competition 
amongst suppliers is driving down costs (Mardis, 2011). Cost effective bench-top analysers 
are commercially available that are practical for use in routine laboratory diagnosis (Loman et 
al., 2012), meaning that NGS technology is indeed egalitarian, by allowing both small and 
large medical laboratories to use the technology in diagnostic investigations, if they can 
demonstrate the cost efficiency benefits to justify the change. 
Generating the sequence data is no longer a limitation. The cost of routine 
sequencing is still challenging for regular applications, but genomics has recently celebrated 
achieving the much-coveted “$1000 genome” milestone (Vertitas Genetics, 2015), illustrating 
that DNA sequencing is becoming more affordable (see Figure 1.1). Furthermore, it is 
possible to be selective about the amount of sequencing performed on each sample, by using 
a variety of targeted or candidate gene sequencing systems as opposed to sequencing whole 
genomes (Mamanova et al., 2010; Samorodnitsky et al., 2015). Whole genome sequencing 
(WGS) provides more sequence information, including from non-coding regions (Lam et al., 
2011). WGS is not subject to biases intrinsic to the target selection process, which leads to 
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better uniformity of read coverage (Meynert et al., 2014). However, target enrichment prior 
to DNA sequencing makes optimal use of the capacity of clinical grade sequencers. This can 
dramatically reduce costs and the turnaround time for diagnostic investigations, making 
routine sequencing realistic. Target selection also permits greater depth of sequencing of 
selected regions, which is necessary for the detection of low level allele frequencies in cancer 
samples. In particular, whole exome sequencing (WES) strategies are available to provide a 
global screen of the protein-coding DNA. By targeting the regions of the genome, which 
contain the majority of the known clinically significant mutations, WES provides a cost-
effective alternative to WGS (Rabbani et al., 2014). 
 
 
 
 
 
 
Figure 1.1. The decreasing cost ($ logarithmic scale) of DNA sequencing from 
September 2001 – October 2015 (data from National Human Genome Research 
Institute ( National Human Genome Research Institute, 2016) 
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Figure 1.2. Outline of Illumina sequencing process. Adaptors are ligated to the ends of DNA 
fragments. Fragments bind to primer-loaded flow cell and bridge PCR reactions amplify each 
bound fragment to produce clusters of fragments. During each sequencing cycle, one 
nucleotide with an attached base-specific fluorophore is added to the elongating 
complementary DNA strand. The fluorphores in all the fragments that are being sequenced in 
the flow cell are simultaneously excited by a laser and an optical scanner records the signals 
from each fragment cluster. The sequencing terminator is then removed and another 
sequencing cycle begins. Multiple rounds of additional nucleotides are incorporated until the 
programmed cycles of sequencing is complete (adapted from Lu et al., 2016). 
DNA fragments Fragments attach to primer-loaded flow cellLigate adaptors
Fragments bind to primer Bridge PCR extension Dissociation
Further amplification to form clusters
Signal scanningSequencing
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The simultaneous development of the bioinformatics tools for interpretation of genomic data 
has been necessary to permit the confident detection of mutations for clinical grade assays 
(Delon & Scott, 2016). This includes the development of robust algorithms for the accurate 
alignment, mapping and filtering sequencing data and the calling and annotation of variants. 
Bioinformatics for genomics has needed to advance rapidly, to parallel the dramatic increase 
in NGS activity. For research purposes, bioinformatics has become highly sophisticated and 
capable of producing high-quality, reliable data. Research institutes have made custom 
pipelines which are made publicly available. Commercial manufacturers of sequencing 
equipment and reagents provide access to pre-made bioinformatics tools for the analysis of 
sequence data. These computational scripts can be tailored to specific analytical applications 
but require bioinformatics expertise to operate. Significant further development is required 
to make these tools convenient and practical to use for genomic scientists and universally 
applicable for use in routine diagnostics.  
The interpretation of the clinical significance of sequence data is also a developing 
area. The systematic collection and publication of genomic variation in the normal population 
and in specific disease cohorts is necessary to continue to investigate and understand its 
occurrence, and its functional and clinical impact. The further clarification of uncertain and 
incidental sequence findings, to reduce ambiguity in clinical interpretation, is also necessary. 
The current challenge, therefore, is not lack of availability of a technology primed to improve 
genetic diagnosis or its affordability. The principle of precision medicine is sound but 
supporting practices need to be developed further, to fulfil the unmet clinical need in many 
diseases where conventional approaches have reached their potential. We are now truly 
entering a period where NGS technology is ready for the transition to diagnostic laboratories. 
In this environment, NGS needs to meet clinical standards for speed and accuracy and be 
validated in robust diagnostic protocols to rigorous accreditation standards. This 
development will parallel the greater understanding of disease and move to provide 
universal applications for precision medicine, making genomics accessible for more clinical 
applications and a greater number of deprived patients.  
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1.2 Acute Myeloid Leukaemia; the potential clinical utility of genomic investigations 
Acute myeloid leukaemia (AML) is a heterogeneous group of haematopoietic 
neoplastic diseases, resulting from the clonal expansion of immature myeloid cells in the 
bone marrow and blood. There is a worldwide incidence of approximately 3 in 100,000 
people, with a slight male predominance (Swerdlow et al., 2008). AML occurs at any age but 
is generally considered a disease of the elderly; the incidence rises steeply after 55 years with 
a median age of ~70 years. However, AML is also found in children with a peak incidence of 
3~4 years (Heim & Mitelman, 2009). The overgrowth by malignant blood precursor cells 
suppresses normal haematopoiesis and leads to a reduction in numbers of functional mature 
cells in the peripheral blood, which is responsible for the main symptoms of the disease. Very 
high numbers of leukaemia cells in the blood can cause problems with circulation from 
leucostasis. 
One or more myeloid cell lineages can be involved and, by definition, a minimum of 
20% myeloid blast cells in the bone marrow are required for the diagnosis of AML, although 
this is no longer critical  if a recurrent genetic abnormality is present (see Table 1.2 below). 
Morphological appearance varies depending on the predominant cell type and the degree of 
cellular maturation, as well as the proportion of abnormal cells and infiltration of different 
tissues. Therefore, traditionally, the diseases were characterised by cell morphology 
supplemented by cytochemical staining; a number of different morphological subgroups 
were defined by cell specificity and stage of maturation. This formed the basis of the original 
French-American-British (FAB) classification of AML which, over a number of iterations and 
addition of immunophenotyping, became the prominent functional classification of the 
disease for more than two decades (Bennett et al., 1976; Bennett et al., 1985). The 
recognition that there are genetic hallmarks of certain morphological subtypes led to the 
inclusion of genetic factors and resulted in a major revision of leukaemia classification in the 
current World Health Organisation Classification of Tumours of Haematopoietic and 
Lymphoid Tissues (WHO Classification) (Arber et al., 2016; Rose et al., 2017). A post-modern 
approach utilising a full range of recurrent genetic abnormalities as the main determinants of 
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disease subtype, including those at single-nucleotide resolution, is predicted to be the next 
phase of disease classification  (Roug et al., 2014). 
AML is now understood to be a number of different diseases, with varying underlying 
characteristics (Arber et al., 2016). The somatic cell theory of cancer (Hanahan & Weinberg, 
2011) dictates that AML must originate from a mutation in a growth regulating gene in a 
single progenitor cell, resulting in the clonal expansion of the cell. More genetic 
abnormalities accumulate, with further dysregulation of growth and cell maturation, until 
full-blown neoplastic disease results. Genetic alterations are therefore the molecular drivers 
and, to differing degrees, influence the appearance and clinical characteristics of the 
diseases. This underpins the current disease classification (Arber et al., 2016) (see also 
Section 1.3 below). 
1.2.1 Current standard of AML care 
Conventional treatment of AML typically comprises an induction phase of high-dose 
chemotherapy, usually consisting of two cytotoxic drugs, cytarabine (Ara-C) and an 
anthracycline (daunorubicin or idarubicin), in attempt to achieve remission; the 
morphological absence of leukaemic cells in the bone marrow and elimination of symptoms 
of leukaemia. Remission status can also be assessed more specifically and sensitively by flow 
cytometry, molecular genetics or cytogenetics, if a suitable biomarker of the disease is 
available (Ommen, 2016). Induction is followed by a consolidation phase of additional 
chemotherapy, allogeneic stem cell transplantation (SCT), or occasionally autologous SCT, 
with the aim of prolonging remission and ultimately curing the disease (Tutt, 2012; Dombret 
& Gardin, 2016; Cornelissen & Blaise, 2016; Döhner et al., 2016). Not all patients are eligible 
for SCT and remission needs to be achieved before transplantation can be performed. 
Regimens comprising these combinations of high dose chemotherapy and SCT have been 
shown to be the most effective treatment in AML, compared to other cytotoxic drugs in 
multiple clinical trials over many years. 
The current AML19 clinical trial (‘Adults with Acute Myeloid Leukaemia or High-Risk 
Myelodysplastic Syndrome’ trial) represents the standard of care in the UK for younger adults 
(aged 18 to 60) and is examining different risk-adapted consolidation therapies. AML19 
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randomises to DA (daunorubicin and cytarabine) or FLAG-IDA (idarubicin and cytarabine, 
with fludarabine, a purine analog interfering with DNA synthesis and granulocyte colony 
stimulating factor, to support neutrophil recovery), and tests the addition of gemtuzumab 
ozogamacin (GO, also known as Myelotarg®, an anti-CD33 monoclonal antibody with 
cytotoxic ligand) (Cardiff University, 2015). However, the clinical biology of AML is highly 
heterogeneous and whilst the disease can be cured in some patients, response to therapy 
varies as a result of patient- and disease-related prognostic factors. In particular, more than 
60 per cent of newly diagnosed patients are older than 60 years, a proportion which is 
increasing. This group is enriched for patients with a higher frequency of high risk genetics, 
increased multidrug-resistance and prior haematological neoplasia and to an extent is 
considered biologically and clinically distinct (Erba, 2015; Döhner et al., 2016). Combined 
with the lower performance status in many elderly patients, the higher prevalence of 
comorbid conditions, and impaired bone marrow stem cell reserve, AML in the over 60s is 
typically difficult to treat. AML treatment is associated with a high treatment-related 
mortality and the common perception is that elderly patients cannot tolerate intensive 
therapy, meaning that they will not have access to the most appropriate treatment for their 
disease and will be incurable. As a result, only 50% of patients older than 60 years achieve 
complete remission after induction treatment compared to 75% of adults less than 60 years’ 
of age (Oran & Weisdorf, 2012; Ossenkoppele & Löwenberg, 2015). In particular, patients 
with high risk cytogenetics have a dismal prospect and conventional treatment is largely 
ineffective in achieving prolonged remission.  
The basic paradigm of therapy for AML has not substantially changed in the past 
three decades (Burnett, 2012), with the exception of anthracycline dose intensification 
during induction (Luskin et al., 2016), modification of schedules and improved SCT 
techniques (Dombret & Gardin, 2016; Cornelissen & Blaise, 2016). As a result outcomes have 
not significantly improved. Conventional chemotherapeutic agents have been successful in 
treating AML but now appear to have reached their maximum potential and it is necessary to 
find more effective and safer treatments for AML. 
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1.3 Genetic, cytogenetic and genomic influences in AML 
AML has been the subject of intense genomic research and more patients have had 
their genomic profiles studied than any other disease. As a result, the genetic landscape of 
AML is now very well-characterised and knowledge is probably more advanced than in any 
other neoplastic disease of this complexity (Figure 1.3). Through genomic research the 
common pathogenic abnormalities of AML have been characterised and now help to define 
the diseases and directly influence the outcome of treatment (Heim & Mitelman, 2009). An 
enormous increase of genomic information has been provided by large scale sequencing 
studies in recent years. Many excellent reviews have described the genetics and genomics of 
AML and the existing clinical utility of genetic profiling (Marcucci et al., 2011; Abdel-Wahab 
et al., 2011; Abdel-Wahab, 2012; Meyer & Levine, 2014; Naoe & Kiyoi, 2014; Ohgami & 
Arber, 2015). This section will focus on the current knowledge of chromosomal abnormalities 
and molecular genetics; their clinical utility and for the potential for integrating molecular 
profiling into clinically relevant, functional diagnostic and prognostic groups. This background 
was used to design the key features of the new diagnostic assay for this research project. 
1.3.1 Cytogenetics of AML 
The earliest genetic abnormalities to be described in cancer were by the appearance 
of chromosomes under the microscope; conventional cytogenetic analysis to demonstrate an 
abnormal karyotype. The seminal report of the first description of a non-random, acquired 
cancer-associated genetic abnormality was the ‘Philadelphia chromosome’ in chronic 
myeloid leukaemia (CML) (Nowell & Hungerford, 1960). This was later found to be a t(9;22) 
chromosomal translocation (Rowley, 1973a) and was followed by the identification of 
translocations t(8;21) and t(15;17) in AML (Rowley, 1973b; Rowley et al., 1977). Several 
hundred recurrent chromosome abnormalities have been identified that can aid the 
diagnosis of AML, which are collected in the Mitelman Database of Chromosome Aberrations 
and Gene Fusions in Cancer. They can show evidence of clonality and cell lineage but also, 
often a specific disease association (Chapter 5; Acute Myeloid Leukaemia in Heim & 
Mitelman, 2009; Mitelman et al., 2017).  
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Figure 1.3. Distribution of cytogenetically and molecularly defined subsets of AML presenting in younger adults (reproduced from 
Grimwade et al., 2016) 
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1.3.2 Limitations of Cytogenetic analysis 
Cytogenetics provides a global genomic screen, albeit at low resolution by NGS 
standards, and is still routinely used in the diagnosis of AML (Roug et al., 2014; Döhner et al., 
2016). Despite the pre-eminence of cytogenetics and its powerful diagnostic and prognostic 
significance, the analysis of structural variation by conventional karyotype analysis does not 
reveal the full range of significant genetic abnormalities. A fresh sample and successful 
growth of leukaemic cells in culture is necessary. Overgrowth by non-cancerous cells and 
variable chromosome morphology are occasional problems. At best, conventional 
cytogenetic analysis will reveal structural genomic rearrangements at a resolution of 5Mb of 
DNA (Heim & Mitelman, 2009) and it requires a trained scientist to provide a subjective 
analysis. Unfortunately many abnormalities are cryptic to conventional analysis. 
Approximately 45% of confirmed AML patients have a normal karyotype (‘cytogenetically 
normal-’ or CN-AML), meaning the driving genetic alterations are submicroscopic. The large 
numbers of cases lacking visible chromosome abnormalities are assigned an intermediate risk 
score but really represent a heterogeneous group in which the genetic lesions have not yet 
been identified. Furthermore, 20~30% have uncommon or apparently non-specific 
abnormalities, the prognostic significance of which are uncertain due to insufficient evidence 
or limited statistical power due to sample size. 
1.3.3 The WHO Classification of AML 
Certain genetic abnormalities now define specific disease subtypes and the 
compendium for tumour diagnosis, the WHO Classification, recognises the category ‘AML 
with recurrent genetic abnormalities’ which includes class-defining balanced translocations 
and gene mutations (Arber et al., 2016) (Table 1.2). In particular, t(8;21) and inv(16) involve 
RUNX1 and CBFB genes respectively, which are heterodimeric components of Core Binding 
Factor (CBF) and are commonly known as CBF-AML with a combined frequency of 7%. The 
t(15;17), present in ~5% of AML, is the most specific genetic abnormality in the disease, 
associated with the distinct subgroup APML. Variant translocations involving RARA with 
different partner genes occur in 1~2% of APML and are important to identify as they may not 
30 
 
respond to standard APML treatment (Adams & Nassiri, 2015). t(9;11) and multiple variant 
translocations of KMT2A at 11q23, involving more than 80 partner genes, have variable 
significance and the classification makes a distinction between these subtypes. The 
ubiquitous t(9;22) with BCR-ABL1 gene fusion is included as a provisional entity. The current 
classification also includes ‘AML with mutated NPM1’ and ‘AML with biallelic CEBPA 
mutations’ (Arber et al., 2016). The classification has also newly included de novo AML with 
RUNX1 molecular mutations as a provisional entity (Arber et al., 2016); this disease appears 
to be biologically distinct with a worse prognosis than other AML types (Tang et al., 2009; 
Gaidzik et al., 2011; Schnittger et al., 2011b; Mendler et al., 2012; Gaidzik et al., 2016). 
Although not specific to these subtypes, cytogenetic profiles also help to define other 
disease subclasses; ‘AML with myelodysplasia-related changes’ and ‘Therapy-related myeloid 
neoplasms’ (Arber et al., 2008; Vardiman et al., 2008). Whilst most cases of Myelodysplastic 
Syndrome (MDS) and AML are sporadic, there is increasing recognition of familial disease 
which is associated with predisposing germline mutations (West et al., 2014a). The category 
‘Myeloid neoplasms with germline predisposition’ is now defined (Arber et al., 2016). 
Different disease types are involved including MDS, MDS/MPN, as well as AML. The range  
includes AML with germline CEBPA and myeloid malignancies with DDX41, RUNX1, ANKRD26, 
ETV6 and GATA2 mutations, as well as myeloid neoplasms associated with BM failure 
syndromes. With an underlying genetic defect and often with a leukaemia-predisposition 
syndrome, the diseases have quite different dynamics from sporadic disease and screening of 
asymptomatic family members for mutations is indicated (Arber et al., 2016). GATA2 can 
have initiating mutations and is mainly associated with familial MDS and AML (Hou et al., 
2015). A draft report of a family with three siblings with an inherited GATA2 germline 
mutation is presented in Appendix 7.4.2. 
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Table 1.2. WHO classification of acute myeloid leukaemia (AML) and related neoplasms 
and acute leukaemias of ambiguous lineage (Arber et al., 2016) 
 
 
Acute myeloid leukaemia (AML) and related neoplasms 
1. AML with recurrent genetic abnormalities 4. AML, NOS 
  AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1   AML with minimal differentiation 
  AML with inv(16)(p13.1q22); CBFB-MYH11   AML without maturation 
  APL with PML-RARA   AML with maturation 
  AML with t(9;11)(p21.3;q23.3); MLLT3-KMT2A   Acute myelomonocytic leukaemia 
  AML with t(6;9)(p23;q34.1); DEK-NUP214   Acute monoblastic/monocytic leukaemia 
  AML with inv(3)(q21.3q26.2); GATA2, MECOM   Pure erythroid leukaemia 
  AML with t(1;22)(p13.3;q13.3); RBM15-MKL1   Acute megakaryoblastic leukaemia 
  Provisional entity: AML with BCR-ABL1   Acute basophilic leukaemia 
  AML with mutated NPM1   Acute panmyelosis with myelofibrosis 
  AML with biallelic mutations of CEBPA 5. Myeloid sarcoma 
  Provisional entity: AML with mutated RUNX1 6. Myeloid proliferations related to Down syndrome 
2. AML with myelodysplasia-related changes   Transient abnormal myelopoiesis (TAM) 
3. Therapy-related myeloid neoplasms   Myeloid leukaemia associated with Down syndrome 
  
Acute leukaemias of ambiguous lineage  
Acute undifferentiated leukaemia  
Mixed phenotype acute leukaemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 
MPAL with t(v;11q23.3); KMT2A rearranged  
MPAL, B/myeloid, NOS  
MPAL, T/myeloid, NOS  
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1.3.4 Cytogenetic and molecular genetic risk factors and treatment outcomes 
Genetic profiling already has a significant impact on the treatment of AML. 
Chromosomal alterations are the most powerful baseline prognostic factors for response to 
induction therapy and for survival in AML; cytogenetic analysis of the leukemic cells is used 
extensively in risk-stratified treatment regimens to guide standard and investigational 
therapy (Grimwade et al., 2010; Döhner et al., 2016) (see Table 1.3). Younger adult patients 
(aged ≤60) are commonly categorized into 3 risk groups, favourable, intermediate, or 
adverse. The subset with favourable outcomes, including CBF-AML, typically achieve long-
term survival with conventional chemotherapy, dose intensified in some studies. A survival 
benefit using GO in CBF-AML, demonstrated in the MRC AML15 study, requires confirmation 
(Döhner & Gaidzik, 2011). Even within this favourable group, there is some variation in 
disease behaviour. By contrast, high risk patients, such as those with monosomy 7 or 
complex karyotype, typically suffer dismal outcomes with conventional chemotherapy and 
may derive benefit from intensive consolidation therapy in first remission, such as allogeneic 
SCT (Döhner et al., 2016). 
The majority of patients, however, fall within an ‘intermediate’ risk group in which 
the genetic abnormality is classified as neither favourable nor adverse. It is possible that the 
driving genetic alteration truly identifies a disease of moderate severity, as measured by 
relapse free survival and overall survival. In many cases, however, it means that the 
underlying, driving stemline mutation has insufficient statistical evidence for it to be 
classified or that it may not be detected by conventional testing. CN-AML falls within the 
‘intermediate’ group. Substantial outcome variability remains for this group and for many 
patients, treatment cannot optimally be directed. Confirmation of new prognostic markers is 
likely to lead to improved genetic stratification of AML and eventually to better 
prognostication and best treatment of the disease for more patients. 
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Table 1.3. 2017 European LeukemiaNet risk stratification by genetics (Table 5 from Döhner 
et al., 2016) 
 
Genetic group Subsets 
Favourable  
 
 t(8;21)(q22;q22); RUNX1-RUNX1T1 
 inv(16)(p13.1q22) or t(16;16)(p13.1;q22);      
CBFB-MYH11 
 Mutated NPM1 without FLT3-ITD or with       
FLT3-ITDlow 
 Biallelic mutated CEBPA 
 
Intermediate 
 
 Mutated NPM1 and FLT3-ITDhigh 
 Wild-type NPM1 without FLT3-ITD or with     
FLT3-ITDlow (w/o other adverse risk genetics) 
 t(9;11)(p22;q23); MLLT3-KMT2A 
 Cytogenetic abnormalities not classified as 
favourable or adverse 
 
Adverse   inv(3)(q21q26.2) or t(3;3)(q21;q26.2); GATA2, 
MECOM (EVI1) 
 t(6;9)(p23;q34); DEK-NUP214 
 t(v;11)(v;q23.3); KMT2A rearranged 
 t(9;22)(q34.1:q11.2); BCR-ABL1 
 -5 or del(5q); -7; -17/abn(17p) 
 Complex karyotype (≥3 abnormalities)/ 
monosomal karyotype 
 Mutated RUNX1 
 Mutated ASXL1 
 Mutated TP53 
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1.3.5 Refinement of cytogenetic profiling from molecular genetics evidence 
In recent years, molecular genetics studies have investigated the involvement of 
mutations in known oncogenes in AML and a number that are recurrent and common have 
been studied extensively. Several genes that contribute to the pathogenesis of AML and are 
becoming important diagnostic factors are now well-characterised (Marcucci et al., 2011; 
Abdel-Wahab et al., 2011; Abdel-Wahab, 2012; Meyer & Levine, 2014; Naoe & Kiyoi, 2014; 
Ohgami & Arber, 2015). The number of reported mutations has increased dramatically in 
recent years; it is likely that many more biomarkers will be available for assessment for risk 
stratification (see Table 1.4). This will provide better information to redefine the 
conventional ‘intermediate’ risk group, particularly CN-AML. The evaluation in cohort studies 
of multiple, commonly mutated genes in AML, such as IDH1 and IDH2, DNMT3A, RAS, PHF6, 
KMT2A-PTD, WT1, RUNX1, KIT and TP53, gives strong indication that they should be 
considered for more extensive study. 
However, to date, only a few molecular abnormalities have been shown to have 
prognostic significance and are used in laboratory diagnosis (Meyer & Levine, 2014; Döhner 
et al., 2016). In particular, genetic predictors of favourable outcome, especially in patients 
without evidence of cytogenetic markers, include mutated NPM1 without FLT3-ITD (Döhner 
et al., 2005; Suzuki et al., 2005; Thiede et al., 2006) and CEBPA double mutation (Fröhling et 
al., 2004; Wouters et al., 2009; Schlenk et al., 2008). These are incorporated into the 
European LeukemiaNet (ELN) prognostic system (Table 1.3) (Döhner et al., 2016). FLT3-ITD 
(Thiede et al., 2002; Schlenk et al., 2008; Gale et al., 2008; Kottaridis et al., 2001; Whitman et 
al., 2001; Fröhling et al., 2002) but not FLT3-TKD (Mead et al., 2007) is recognised as a 
marker of adverse prognosis. Many other gene mutations have been identified that are 
recurrently involved in AML development and have been strongly suggested to be of 
prognostic significance, requiring further evidence and confirmation of clinical utility (Table 
1.4).   
Several groups of related genes in novel pathways have been identified as mutated in 
AML (Figures 1.4 and 1.5). Individually, genes within their group might be rare but evidence is 
emerging that they are generally mutually exclusive and are thought to be interchangeable 
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with genes of similar function within their group. Mutations in the group of epigenetic 
modifying genes are common and include; DNMT3A (DNA methylation), TET2, IDH1 and IDH2 
mutations (DNA hydroxymethylation) and EZH2, KMT2A and ASXL1 mutations (histone 
modification) (Abdel-Wahab et al., 2011). Spliceosome complex genes encode proteins which 
catalyse splicing of precursor mRNA which is an essential step in the control of gene 
expression (Will & Lührmann, 2011). Mutations are thought to lead to transcriptional 
dysfunction (Inoue et al., 2016; Joshi et al., 2017). Spliceosome mutations are particularly 
associated with MDS and AML that has evolved from MDS (Cho et al., 2015).  
Recent genome-wide sequencing studies have identified frequent mutations in 
members of the cohesin complex gene group, in AML and other myeloid malignancies. These 
may act by increasing chromatin accessibility to transcription factors, altering the growth 
characteristics of haematopoietic progenitor cells (Fisher et al., 2017; Mazumdar & Majeti, 
2017). Several genes are involved in the four core subunits of the cohesion complex, 
including STAG1, STAG2, SMC1A, SMC3, and RAD21. Each gene mutation is mutually 
exclusive, suggesting that any one mutation in the group is sufficient to disrupt the cohesion 
complex and promote AML. 
The conventional approach to genetic diagnosis of AML, therefore, relies on a 
combination of different techniques for classification and prognostication; cytogenetic 
analysis, supplemented by FISH and molecular genetics techniques (PCR) for individual gene 
rearrangements. An argument against generalised mutation profiling of AML as part of the 
standard diagnostic work-up, is the complexity of the information derived; by breaking 
genomic groups down into increasingly small and statistically indistinguishable sub-fractions, 
any diagnostic and prognostic significance will be lost (Fig. 1.3). However, a number of 
powerful studies have combined NGS of AML genomes with patients’ outcomes in large 
clinical trials which have revealed important patterns of gene interactions and the 
recognition of biologically and clinically distinct subgroups (Grossmann et al., 2012; Patel et 
al., 2012; The Cancer Genome Atlas Research Network, 2013; Papaemmanuil et al., 2016; 
Metzeler et al., 2016). The findings of The Cancer Genome Atlas of co-occurring and mutually 
exclusive mutations in genes and gene groups is shown in Figure 1.5. In a recent study of 
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1,540 patients with AML who were analysed by targeted NGS, where data was combined 
with cytogenetic results, it was possible to segregate patients with AML into 11 distinct 
phenotypic, clinical and prognostic groups (see Figure 1.4) (Papaemmanuil et al., 2016). In 
addition to the standard groups, three more functional groups emerged; 
Chromatin/spliceosome, TP53 mutation/chromosomal aneuploidy and a provisional group 
with IDH2R172 mutation, as the sole class-defining lesion. This new classification scheme was 
able to unambiguously categorise at least 80% of AML into single groups based upon the 
underlying genetic abnormalities. This classification is used to redefine the diagnostic profiles 
for the patients in this research (see Results, Table 3.13). 
 
 
 
  
 
 
 
Fig 1.4. Genomic classification of 1,540 AML patients from Papaemmanuil et al (2016). 86% 
were classified with minimal overlap into 11 clinically relevant groups (including six genomic 
groups characterised by translocations and/or inversions which are displayed as one group) 
(Bullinger et al., 2017) 
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Table 1.4.  Frequently mutated genes in the genomic landscape of AML 
 
Gene Molecular background Other clinical and pathology features 
NPM1 Nucleophosmin (NPM1) protein, mutations altered nuclear signal transduction 
((Döhner et al., 2005; Schnittger et al., 2005; Suzuki et al., 2005). Found in 33% of AML 
and ~85% of cases have a normal karyotype. Heterozygous mutations in exon 12 and 
rarely exons 9 or 11. 70~80% are a specific TCTG tetranucleotide duplication at codons 
956 to 959 (“mutation A”) but about 40 mutant variants are described (Falini et al., 
2007; Albiero et al., 2007). ~40% have FLT3-ITD 
Distinctive monocytoid phenotype. Favourable prognosis in the absence of cytogenetic 
prognostic indicators and FLT3-ITD (Haferlach et al., 2009; Döhner & Gaidzik, 2011). 
Prognosis may be age-dependant and lost in the elderly (Ostronoff et al., 2015). 
Indicates against HSCT in first CR (Döhner et al., 2016) and in elderly patients who may 
benefit from intensive chemotherapy (Falini et al., 2005; Falini et al., 2007). Variants 
may be shown to have differing diagnostic significance (Alpermann et al., 2016). 
FLT3 FLT3 encodes a receptor transmembrane tyrosine kinase. Occurring in 20~30% of cases 
of AML, most commonly Internal Tandem Duplications (ITD) of 15~180 bp (multiples of 
3 base pairs) in the juxtamembrane domain (exons 14 and 15) FLT3-ITD result in auto-
dimerization and autophosphorylation and constitutive activation of the receptor. 
FLT3-ITD is associated with t(6;9)/DEK-NUP214 and NUP98-NSD1. Missense mutations 
in the tyrosine kinase activation domain (TKD) at codon 835 and 836 (FLT3-TKD) in 
5~10% (Lagunas-Rangel & Chavez-Valencia, 2017). 
FLT3-ITD is the most significant prognostic marker in CN-AML, predicting poor 
outcomes (Nakao et al., 1996; Gilliland & Griffin, 2002). The highest risk may be 
conferred by high allelic dosage (Schnittger et al., 2011a), or in patients with high 
aberrant FLT3 expression (Fitzgibbon et al., 2005).  Allogeneic HSCT is recommended 
(Pfeiffer et al., 2013; Döhner et al., 2016). FLT3 is potentially an actionable therapeutic 
target (reviewed in Meyer & Levine, 2014) and inhibitors are being evaluated as 
supplements to conventional chemotherapy in randomised phase III trials such as MRC 
AML19 (Cardiff University, 2015). The prognostic significance of FLT3-TKD is uncertain 
(Mead et al., 2007; Whitman et al., 2008; Marcucci et al., 2011). 
CEBPA CCAAT/enhancer binding protein alpha (CEBPA) is a transcription factor involved in 
myeloid differentiation. Mutations are specific to AML and occur in 6~18% of de novo 
AML, but with a higher frequency in CN-AML. 5~10% of cases are germline mutations. 
CEBPA mutations occur as single or double mutations and at multiple positions in the 
coding sequence of the gene (Pabst et al., 2001; reviewed in Bienz et al., 2005). Most 
frequent mutations are (1) N-terminal frame-shift (nonsense/out of frame indels) 
dominant-negative protein or (2) C-terminal in-frame indel affecting DNA-binding 
function. 40–50% of CEBPA mutated cases are bi-allelic. Single allelic mutation 
frequently are associated with FLT3 (30–35% of cases) or NPM1 mutations (30–35% of 
cases). 
Double mutations are associated with more specific features and are class-defining. Bi-
allelic mutations are associated with improved prognosis; single allelic mutation shows 
no prognostic significance (Wouters et al., 2009; Taskesen et al., 2011; Fasan et al., 
2014). HSCT is not recommended in CN-AML with double CEBPA mutations. 
KIT Receptor tyrosine kinase; acts as a receptor for stem cell factor. Mutations found in 
20~30% of CBF-AML (Lavallée et al., 2015). Frequently in the kinase domain at D816, 
primarily in exon 17 (31%) and exon 8 (6%).  
Do not respond to tyrosine kinase inhibitors. Exon 17 mutations have a strong adverse 
effect on the relapse and survival of adult t(8;21) AML patients (Park et al., 2011; Qin 
et al., 2014) and inv(16) patients (Paschka et al., 2006).  
WT1 Wilms Tumour protein (WT1) is a zinc finger transcription factor (Krauth et al., 2015). Clinical significance is uncertain. WT1mut had an independent adverse impact on EFS 
(Krauth et al., 2015). 
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JAK2 Janus-kinase-2 (JAK2) is a non-receptor tyrosine kinase frequently mutated in 
myeloproliferative neoplasms; mutations result in activation which is independent of 
upstream cytokine signalling. 
Rare mutations in de novo AML. Associated with CBF-AML with 
t(8;21)(q22;q22); RUNX1-RUNXT1 or AML with inv(16)(p13.1q22) or 
t(16;16)(p13.1;q22); CBFB-MYH11. 
KRAS & NRAS Membrane associated signal transduction GTPase; activating mutations increase 
cellular proliferation and decrease apoptosis. NRAS and KRAS mutations, typically in 
codons 12, 13 and 61, are present in about 25% and 15% of AML. Common findings 
(30%) in paediatric CBF-AML (Goemans et al., 2005). 
Mutations may not have an impact on clinical prognosis. 
TP53 Tumour suppressor protein, inactivating point mutations and indels associated with 
complex karyotype and therapy-related AML. 
Mutations associated with poor prognosis (Rucker (Rücker et al., 2012). 
RUNX1 Transcription factor. Intragenic mutations lead to a pre-leukaemic state that 
predisposes to AML. RUNX1 mutation occurs in approximately 10% of AML, with an 
incidence increasing with age, peaking in the elderly (Gaidzik et al., 2016). Associated 
with trisomy 13 and mutations in ASXL1, IDH2, and EZH2, the spliceosome genes 
(SRSF2 and SF3B1), the cohesin complex gene STAG2 (Thota et al., 2014) and BCOR6 
and PHF6  (Gaidzik et al., 2016). 
RUNX1 mutations are class-defining recurrent genetic abnormalities associated with 
specific presenting clinical and pathologic features, including immature disease 
phenotype, male predominance and an inferior prognosis. 
Mutations of epigenetic modifiers (Abdel-Wahab et al., 2011) 
DNMT3A DNA methylation. DNA methyltransferase 3A (DNMT3A), inactivating point mutations 
most commonly at amino acid D882 occur in up to 25% of AML, particularly monocytic 
subtypes. 
Mutations associated with inferior survival in CN-AML, independent of FLT3 mutation 
status (Ley et al., 2010; Thol et al., 2011), particularly without NPM1 or FLT3 mutations 
(Ribeiro et al., 2012) and in monocytic subtypes (Yan et al., 2011).  
KMT2A Histone modification. Histone methyltransferase that also interacts with RUNX1 to 
effect cellular functions. Fusion genes from chromosomal translocations and partial 
tandem duplications (PTD) between exons 5 and 11 or 12 is inserted, in frame, into 
intron 4. Found in 8~10% of CN-AML (Basecke et al., 2006). 
Prognostic impact still under study but may confer poorer prognosis. Reported to 
confer an adverse prognosis in CN-AML (Schnittger et al., 2000; Döhner et al., 2002) 
but not in elderly patients (Whitman et al., 2012). Better outcomes are reported 
following early allogeneic and autologous HSCT transplant (Whitman et al., 2007). 
TET2 DNA hydroxymethylation to reverse methylation effects on DNA. Mutually exclusive 
to IDH1 and IDH2 mutations and can be accompanied by deletion of the second allele 
(Bacher et al., 2010; Bacher et al., 2012; Weissmann et al., 2012). 
Some studies point to poorer prognosis. An adverse prognosis has been demonstrated 
in CN-AML patients without NPM1 or FLT3 mutations (Chou et al., 2011) or favourable 
risk CN-AML NPM1+ or  CEBPA+/FLT- AML (Bacher et al., 2010; Metzeler et al., 2011b; 
Weissmann et al., 2012) but some studies are equivocal (Damm et al., 2014). 
IDH1 & IDH2 DNA hydroxymethylation. Isocitrate dehydrogenase -1 and -2 (IDH1, IDH2) are 
enzymes that convert isocitrate to alpha-ketoglutarate in the Krebs cycle; mutations 
result in production of 2-hydroxyglutarate which inhibits hydroxymethylation of DNA. 
Three mutually exclusive recurrent mutations in IDH1 and IDH2 
Mutations are likely to have different prognostic implications; IDH1 R132 adverse 
prognosis with wild-type FLT3 (Abbas et al., 2010; Green et al., 2010; Paschka et al., 
2010), IDH2 R140 favourable (Green et al., 2011) and the IDH1 R172 mutation is 
neutral. Clinical trials with IDH targeted inhibitors are ongoing. 
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ASXL1 Histone modification. Additional sex combs-like gene (ASXL1) is a chromatin-binding 
protein likely involved in methylation of histone proteins. Mutations of exon 12 are 
mutually exclusive of NPM1 mutations and absence of FLT3-ITD mutated CEBPA. ASXL1 
have been found most commonly in patients >60 years and AML with myelodysplasia 
related changes (Devillier et al., 2012).   
ASXL1 mutations are markers of poor prognosis in some studies, in favourable and 
intermediate risk AML and in AML overall (Metzeler et al., 2011a; Pratcorona et al., 
2012). 
EZH2 Histone modification. Enhancer of zeste homologue 2 (EZH2) is the catalytic 
component of the PRC2 complex and functions to trimethylate histone tails 
Rarely mutated in AML, mutations associated with poor prognosis in some studies. 
Cohesin Complex  
Cohesin 
Complex Genes 
STAG1, STAG2, SMC1A, SMC3, and RAD21 genes involved in the control of sister 
chromatid separation. Individually mutations uncommon but overall the group is 
mutated in 5~10% of AML and >50% of Down Syndrome-AMKL. Mutations are 
mutually exclusive with others within Cohesin group. Loss of function / null mutations 
are common, complete protein deficiency in the X-linked genes (STAG2 and SMC1A) in 
males. Co-occur with NPM1, DNMT3A, TET2 or RUNX1 mutations (Fisher et al., 2017; 
Mazumdar & Majeti, 2017). 
Included in a high risk group in recent genomic risk stratification (Papaemmanuil et al., 
2016). 
Spliceosome Complex 
Spliceosome 
Complex Genes 
The genes of the ribonucleoproteins of the spliceosome complex involved in the 
control of gene expression (Will & Lührmann, 2011). SF3B1, U2AF1, SRSF2, ZRSR2, 
SF3A1, PRPF40B, U2AF2, and SF1 mutated in AML and associated with evolution from 
MDS (Cho et al., 2015).  
U2AF1 mutation results in abnormal splicing of genes involved in myeloid 
differentiation and proliferation and confer a poor prognosis and may be associated 
with multilineage dysplasia. SF3B1 mutations are common (20%) in MDS with ring 
sideroblasts, and associated with a favourable prognosis (Papaemmanuil et al., 2011). 
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Figure 1.5. Co-occurring and mutually exclusive mutations in genes/groups. Boxes 
represent genes, gene groups, or cytogenetic risk groups. Green lines edges connect genes 
that co-occur in a significant number of samples. Red dashed lines connect nodes that are 
mutually exclusive. Black lines indicate gene fusions that define favourable cytogenetics. The 
thickness of each green line approximately corresponds to the strength of the association as 
determined from the frequency from TCGA dataset (adapted from The Cancer Genome Atlas 
Research Network, 2013). 
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1.3.6 Complex karyotype and Monosomal karyotype 
Complex karyotype (CK) is an important category in AML because it identifies a group 
of usually elderly AML patients consistently associated with very poor treatment outcomes 
after chemotherapy, achieving highest risk in prognostic scoring systems. This occurs in up to 
12% of AML and is defined by the number of visible karyotypic abnormalities in the cells, 
variably defined by different studies as having between 3 and 5 cytogenetic abnormalities 
regardless of type, in the absence of favourable cytogenetics. However, the pattern of 
abnormalities within complex karyotypes is non-random and is frequently characterised by 
chromosomal imbalances, such as deletions of 5q, 7q and 17p, and gains of 8q, 11q, and 21q 
(Mrózek, 2008). The descriptive numerical definition of complex karyotype is non-specific 
and there is no single cytogenetic hallmark of the subgroup. Recently, an entity ‘Monosomal 
karyotype’ (MK) has been defined as multiple chromosome loss (or any single chromosome 
loss with structural abnormalities) (Anelli et al., 2017). Many of these karyotypes qualify as 
both CK and MK but they achieve prognostic distinction in some scoring systems (Breems & 
Löwenberg, 2011; Kayser et al., 2012; Grove & Vassiliou, 2014) but not in the largest UK 
study (Grimwade et al., 2010). MK may best be used to identify patients that have an 
extremely poor prognosis (Haferlach et al., 2012).  
CK and MK are necessarily defined by conventional cytogenetic studies and any 
attempt to progress to a molecular definition of this highest risk group of patients requires 
identification of a reliable molecular marker of karyotype instability. Recently, it was 
reported that approximately 70% of patients with CK have missense mutations or biallelic 
deletions of the TP53 gene, and the absence of regulatory properties of functional p53 would 
explain genomic instability (Schoch et al., 2005; Haferlach et al., 2008; Seifert et al., 2009; 
Rücker et al., 2012). TP53 mutations are uncommon in other cytogenetic subgroups (2%). 
TP53 alterations define a subgroup of AML with the worst overall survival (OS at 3 years of 
0%). TP53 mutation was therefore used as a surrogate marker for these patients in a 
molecular genetic classification of AML (Grossmann et al., 2012). However, ~30% of AML 
patients with CK lack TP53 mutation and it is unclear if other genes in the p53 signaling 
pathway are also involved and have the same effect (Medeiros, 2012) or if patients with CK 
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but without TP53 have the same predictive value (Lazarus & Litzow, 2012). Inevitably, the 
significance of other mutations will be identified and a more specific and relevant 
classification will emerge.  
1.3.7 Different considerations in Childhood AML 
Paediatric AML has a different profile of cytogenetic abnormalities to the disease of 
young adults and the elderly, including a number of abnormalities that are not found outside 
of this group (see Table 1.6) (Harrison et al., 2010; Creutzig et al., 2016). Outcome data from 
children treated in paediatric AML trials confirmed similar prognosis as adults, e.g. CBF-AML 
and monosomy 7 (Harrison et al., 2010). t(9;11) and other KMT2A translocations are the 
most frequent abnormalities (16%), particularly in infants (50%) (Harrison et al., 2010). An 
independent international study reported an adverse prognosis in children with specific 
KMT2A rearrangements (Balgobind et al., 2009). The presence of 12p abnormalities 
predicted a poor outcome (von Neuhoff et al., 2010; Harrison et al., 2010). Recently, rare 
cryptic chromosomal abnormalities have been described, specific to paediatric AML, which 
confer a poor outcome; t(5;11)(q35;p15.5)/NUP98-NSD1 is associated with FLT3-ITD (Akiki et 
al., 2013; Hollink et al., 2011; Shiba et al., 2013), t(7;12)(q36;p13)/MNX1-ETV6 occurs mainly 
in infants and is often accompanied by a deletion of the long arm of chromosome 7 (von 
Bergh et al., 2006; Tosi et al., 2000) and inv(16)(p13.3q24.3)/CBFA2T3-GLIS2 (Gruber et al., 
2012; Masetti et al., 2013). The current MyeChild 01 trial combines prognostic information 
from these key studies for cytogenetic risk group stratification (Table 1.6) (University of 
Birmingham, 2015). 
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Table 1.6. The cytogenetic and molecular risk group assignment for MyeChild 01; expected 
incidence and estimated number of cases Paediatric AML cytogenetic risk groups (MyeChild 01 
Protocol v1.0, University of Birmingham, 2015) 
 
Good Risk  Incidence Poor Risk Incidence 
t(8;21)(q22;q22)/ 
RUNX1-RUNX1T1 
12% -7 4% 
inv(16)(p13q22)/ 
t(16;16)(p13;q22)/CBFB-MYH11 
6% -5/del(5q) ~1% 
Double mutation of CEBPA without 
FLT3-ITD 
5% inv(3)(q21q26)/ 
t(3;3)(q21;q26)/abn(3q26) 
~1% 
Mutation of NPM1 without  
FLT3-ITD 
5% t(6;9)(p23;q34)/DEK-NUP214 ~1% 
  t(9;22)(q34;q11)/BCR-ABL1 ~1% 
Intermediate risk  12p abnormalities  2~4% 
t(9;11)(p21;q23)/KMT2A-MLLT3 
 
t(11;19)(q23;p13.3)/KMT2A-MLLT1  
Other KMT2A rearrangements not 
classified as poor risk 
11% KMT2A rearrangements 
classified as poor risk; 
t(6;11)(q27;q23)/ 
KMT2A-MLLT4 
t(4;11)(q21;q23)/ 
KMT2A-AFF1  
t(10;11)(p11-p14;q23)/ 
KMT2A-MLLT10  
5% 
All other abnormalities which are 
neither good nor poor risk 
25% t(5;11)(q35;p15.5)/ 
NUP98-NSD1  
<5% 
t(7;12)(q36;p13)/ 
MNX1-ETV6  
<1% 
inv(16)(p13.3q24.3)/ 
CBFA2T3-GLIS2 
<2% 
FLT3-ITD without NPM1 or CBF  10% 
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1.3.8 Genetics factors predictive of therapeutic response 
Significant advances in the management of AML are possible by evaluating genomic 
profiles for their efficacy as predictive markers of outcome with specific treatments or 
targeted therapies. The major success is exemplified in APML, defined by PML-RARA gene 
fusion, which indicates a specific treatment regimen of ATRA combined with idarubicin, 
daunorubicin or arsenic trioxide. Excellent responses are achieved with long term, complete 
remission rates in 90% and cure rates of at least 80% (Coombs et al., 2015).  
Using standard chemotherapy without the need for stem cell transplantation, CBF-
AML patients typically achieve high CR rates in the region of 88% and 42% cure rate (relapse 
free survival (RFS) at 10 years) (Solh et al., 2014; Sinha et al., 2015). However, a third of 
patients have KIT mutations, worsening prognosis in some studies (Paschka et al., 2006). 
Clinical trials are examining the use of the tyrosine kinase inhibitor, dasatinib as supplement 
to conventional treatment (Döhner & Gaidzik, 2011). The frequency and high risk associated 
with FLT3-ITD makes this mutation a compelling drug target, and whilst a durable treatment 
has proved elusive to date, several second generation inhibitors are showing more promise 
in clinical trials (Stein & Tallman, 2016; Grunwald & Levis, 2015). IDH1 and IDH2 mutations 
are in use as a target in early phase trials which are showing significant promise of improved 
outcomes (Stein & Tallman, 2016; Dombret & Gardin, 2016). There are currently no effective 
therapies to target the common NPM1 mutations but GO and ATRA have been used to treat 
these leukaemias with mixed results so far (Grunwald & Levis, 2015). Although epigenetic 
modulators have been used in the treatment of AML with modest effect (Engen et al., 2016), 
cytogenetic aberrations are markers predicting best response in azacytidine (Fenaux et al., 
2009) and also lenalidomide (Ades et al., 2009). In practice, however, targeted therapies 
have been slow to translate into the clinical arena and the identification of more therapeutic 
targets combined with a pipeline of early phase trials will be needed to accelerate the use of 
personalisation of treatment in AML (Lawler & Sullivan, 2015; Hollingsworth & Biankin, 2015; 
Bertier et al., 2016). 
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1.3.9 Genetics to monitor Minimal Residual Disease (MRD) 
In addition to baseline prognostic factors (see sections 1.3.4 & 1.3.5), an important 
area in AML management is testing for response-related risk factors for monitoring disease 
course, to predict relapse and offer the option of early pre-emptive intervention. Monitoring 
minimal residual disease (MRD) in AML patients has been studied for many years and a 
number of reliable methods are possible, depending on the availability a suitable marker for 
disease evaluation. These include quantitative PCR (qRT-PCR) and flow cytometry but other 
methods are used, usually determined by the most sensitive method available for the patient 
(Hourigan & Karp, 2013; Roug et al., 2014; Ommen, 2016). Early complete remission 
indicates the best post treatment response whilst persistent disease may indicate treatment 
failure and short survival. The depth of response following induction therapy provides 
independent prognostic information and prediction of the risk of relapse to guide 
consolidation therapy (Jourdan et al., 2013). The genetic hallmarks of AML provide 
convincing targets for the detection of MRD in post-treatment samples, such as the 
leukaemia-specific transcripts and common gene fusions from chromosomal translocations, 
e.g. PML-RARA, RUNX1-RUNX1T1 and CBFB-MYH11 are typically monitored by qRT-PCR. 
Unfortunately, only about a third of adults carry informative gene fusions. Inclusion of other 
common leukaemia-specific disease markers, such as NPM1 mutations, increases coverage 
to ∼60% in younger adults but still, elderly patients only have an informative marker one 
third of the time (see Figure 1.6) (Grimwade & Freeman, 2014). 
 The sensitivity for MRD detection is measured relative to the level of expression of an 
endogenous control gene (e.g. ABL1); e.g. RT-qPCR assays for detection of PML-RARA 
transcripts, for example, is at least 1 in 104 cells and 1 in 105 cells is possible when the MRD 
target is more highly expressed than the control, providing a higher baseline level. 
Therefore, molecular genetics is among the most sensitive methods available making 
these techniques ideal for MRD assessment (Grimwade & Freeman, 2014). The desirable 
objective to control the leukaemic clone is a 3 log reduction (e.g. 40% to <0.4% disease cells). 
Measuring disease persistence is complicated by different variables such as 
(Grimwade & Freeman, 2014; Hokland et al., 2015; Ommen, 2016); 
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 Choice of optimal time points for testing 
 Selection of the most informative stemline disease marker 
 The presence of premalignant clones 
 Different genetic drivers have different remission and relapse kinetics 
 Varying persistence of abnormal cells into remission 
 Varying rates of relapse 
 Genotype instability and evolution of the genetic marker over time leading to change 
or loss of the measurable target 
 
Nevertheless MRD monitoring has the potential to be one of the most significant 
mechanisms for prognostication and clinical intervention in AML. The AML19 trial 
incorporates a ‘monitor’ versus ‘no monitor’ randomisation, to test if the process will 
translate into improved outcomes (Cardiff University, 2015). NGS strategies are under 
evaluation to identify genetic variants (and combinations thereof) that can be used for DNA-
based post-treatment MRD measurement and to use the technology as a means to detect 
MRD with the potential that multiple mutations can be used as markers for disease cells, 
obviating the reliance on specific mutational hotspots (Hokland et al., 2015). This would have 
broader applicability than the expression fusion transcripts assays that are currently provided 
(Ommen, 2016). 
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Figure: 1.6. Proportion of AML patients informative for MRD detection by RT-qPCR for leukaemia-specific MRD targets according 
to age (from Grimwade & Freeman, 2014). 
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1.4 The development of next generation sequencing for AML and other cancers  
The rapid advancement in genomic testing has resulted in a large amount of literature 
in cancer genomics and several excellent general reviews of the subject, reflecting different 
authors’ research interests and perspectives. Due to the pace of development and breadth of 
research, a thoroughly comprehensive review is difficult and is certainly beyond the scope of 
this thesis. The following brief review presents a summary of existing genomic techniques 
and their limitations, to outline a case for change. The evolution to NGS and its development 
in AML for diagnostic applications is described, referencing the use of NGS in other cancer 
types where relevant.  There is a particular focus on the development of technology for the 
detection of different classes of genomic variation, including structural variation. 
1.4.1 Traditional genomic approaches to cancer investigation; cytogenetics 
Cytogenetics is the study of genetic material at the cellular level, traditionally 
visualised microscopically as changes in the number and structure of chromosomes, 
representing alterations in the DNA content of cells. Whereas next generation sequencing 
has become synonymous with genomics, the earliest genomic technique could be considered 
to be conventional cytogenetic analysis to provide a karyotype. Cytogenetics provides a 
global screen for gross structural abnormalities and copy number change by examination of 
all chromosome pairs. Conventional techniques have obvious restrictions; a fresh sample is 
required and successful cell culture needs to be initiated to obtain a dividing population of 
malignant cells so that they can be visualised in metaphase of the cell cycle. The natural 
presence of a varying proportion of normal (non-cancerous) cells and limitation in the 
number of cells available or conveniently analysable, restricts the technique’s sensitivity to 
detect clones and significant subclones (Hook, 1977). Overgrowth by normal cells in culture 
can be a problem. The resolution of conventional cytogenetic analysis is limited to 5Mb DNA 
at best (Heim & Mitelman, 2009) and malignant cells with poor chromosome morphology are 
common. Chromosome structure is interpreted perceptually and requires a trained scientist 
to provide a subjective analysis to identify abnormalities. Unfortunately, many structural 
genomic rearrangements will be submicroscopic or cryptic to microscopic analysis. In other 
words, the driving genetic changes are often undetected and some 45% of AML show a 
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normal karyotype (CN-AML). M-FISH or spectral karyotyping is a variant of conventional 
chromosome analysis using multicolour FISH with differentially labelled chromosome ‘paints’ 
for each chromosome with colours artificially assigned in silico. This technique provides a 
global screen with the same limitations as standard karyotyping, albeit with less subjectivity 
due to the colour differential, but with some loss of resolution at chromosome band 
definition and is unable to detect intra-chromosomal abnormalities. M-FISH has not been 
adopted for routine investigation in the UK. 
Despite these shortcomings, when supplemented by targeted techniques to detect 
specific genetic abnormalities; such as fluorescence in situ hybridisation (FISH) with locus 
specific probes and polymerase chain reaction (PCR), karyotyping remains a powerful 
diagnostic test, which has not been supplanted by new technology for leukaemia diagnosis. 
Cytogenetic analysis was pioneered for the study of AML (Grimwade et al., 1998) by 
examination of microscopically visible chromosome abnormalities and the underlying genetic 
abnormalities have been directing clinical decisions for two decades. A higher resolution 
technology which is not reliant on successful cell culture and microscopic detection would 
lead to a dramatic improvement in abnormality detection. 
1.4.2 Microarray technology 
Visualisation of chromosome architecture is not always important per se; it is the 
molecular consequences of structural and numerical rearrangements that drive disease for 
which the visible chromosomal changes are a surrogate marker. Alternative techniques could 
be used once all the relevant genetic consequences are understood. Genomic microarray 
technology, such as array Comparative Genomic Hybridisation (array-CGH) and single-
nucleotide polymorphism (SNP) oligonucleotide microarray, use known DNA sequences 
deposited on to a hard surface for hybridisation with test DNA to detect the presence and 
concentration of sequences of interest. Array-CGH employs co-hybridisation of test (tumour) 
DNA and normal control DNA (Bullinger & Fröhling, 2012), whereas SNP array hybridises a 
single test sample to SNP DNA sequences throughout the genome (Sato-Otsubo et al., 2012). 
Chromosomal Microarray Analysis (CMA) can detect unbalanced chromosomal abnormalities 
at high-resolution, including sub-microscopic abnormalities too small to be detected by 
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conventional karyotyping. This technology has expedited technological reform in 
constitutional (non-cancer) cytogenetic services where, extensively, oligonucleotide 
microarrays have been adopted as a first-line test to detect DNA copy number defects, at 
high resolution, in infants and children with unexplained developmental delay and 
intellectual disability (Shaffer et al., 2007; Miller et al., 2010). This is appropriate for the 
testing of probands of families where genomic imbalances are likely causes of disease and 
the new technology reveals unprecedented fine detail in analysis, with improved detection of 
abnormalities. The same technology does not detect all the abnormalities required of a test 
for cancer, such as balanced chromosomal rearrangements, although modifications such as 
PCR amplification of genomic DNA translocation breakpoints regions prior to array-CGH have 
been piloted (Greisman et al., 2011). Nevertheless, microarray technology has significant 
potential for applications in leukaemia diagnosis (Bullinger & Fröhling, 2012). SNP array is not 
only currently the most cost effective technology for SNP genotyping, e.g. by allele-specific 
discrimination by hybridisation, but can also detect copy number variation and recurrent 
copy-neutral loss of heterozygosity (cnLOH) (Sato-Otsubo et al., 2012). It has gained 
attention for those disorders largely defined by genomic imbalance such as MDS (Tiu et al., 
2011; Arenillas et al., 2013; Mohamedali et al., 2013) and may provide utility for improved 
prognostication in CN-AML (Bullinger et al., 2010; Parkin et al., 2010; Gronseth et al., 2015). 
SNP array is an immensely powerful technology which over a number of years has been 
extensively refined for diagnostic use (Vermeesch et al., 2012; Cooley et al., 2013). SNP array 
for detection of cnLOH can be used alongside other mutational profiling techniques to 
provide an integrated profile (Mohamedali et al., 2015; Parkin et al., 2015), which also 
demonstrates a drawback that multiple platforms are still required to provide a fully 
comprehensive assemblage of diagnostic information. 
1.4.3 Gene Expression Profiling 
Isolated and enriched test RNA can be converted to cDNA, amplified, labelled and 
used to hybridise to microarray for Gene Expression Profiling (GEP). Intuitively, the detection 
of alterations in the transcriptome, which more closely reflects proteomic changes that 
would affect phenotypic change, should provide signatures which characterise patients more 
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effectively than genomic studies. In AML, the expression of individual genes such as EVI1, 
BAALC, MN1 and microRNAs and recognition of alternative mRNA splicing, may offer distinct 
clinical utility to gene expression technology (Baldus & Bullinger, 2008; Shivarov & Bullinger, 
2014). Yet, after much hype and expectation, the only multi-gene GEP classifiers in regular 
diagnostic use in cancer inform the use of adjuvant chemotherapy in breast cancer (Kuchel et 
al., 2016), which are now progressing to second generation assays (Harris et al., 2016). 
Significant challenges have dogged the transition of GEP from interesting and informative 
research technology to the expected transformation of clinical practice, including: Variation 
in tissue handling and preservation of RNA integrity; poor standardisation of assay design; 
selectivity in classification models for subgroup selection and analysis; variability in the 
analysis of complex data; effects of sample size on robustness and prediction accuracy of a 
prognostic gene signature; and the introduction of bias, leading to over-interpretation of 
clinical applicability (Ioannidis, 2005; Ioannidis, 2007a; Ioannidis, 2007b; Ioannidis et al., 
2009).  
An early study (Valk et al., 2004) led to the development of AMLProfiler™ (Skyline 
Diagnostics, Rotterdam, Netherlands) but there is a relative paucity of prospective studies 
supporting the use of GEP in AML (Verhaak et al., 2009; Kohlmann et al., 2010a). GEP has 
been applied successfully to the classification of leukaemia in the landmark Microarray 
Innovations in Leukaemia (MILE) study (Haferlach et al., 2010). Leukaemia gene expression 
profiling allows accurate prediction of certain subtypes and in AML has been shown to 
identify major diagnostic groups defined by the expression of chimeric transcription factors. 
However, detection of mutations affecting signalling molecules and numerical abnormalities 
still requires alternative molecular methods. In short, genomic aberrations can be detected 
by GEP class prediction but only comparable to a range of existing genomic tests and so for 
regular, routine diagnostic purposes, GEP has limited advantage over conventional testing. 
Better standardisation of assays and an international effort to generate the large datasets 
required for validation of such complex combinations of expressed genes for class prediction 
are necessary to make further progress. Microarray-based GEP for clinical investigations have 
generated both unrealistic hype and excessive scepticism and it is debatable whether GEP 
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alone will have a role in diagnosis (Theilgaard-Monch et al., 2011). The technology is shifting 
to RNA sequencing (RNA-seq) which has encouraged a significant upsurge in transcriptome 
analysis, which will revitalise studies in the clinical applications for GEP and in time will 
probably benefit from integration of genomic data and the stratification of different omic 
analyses in clinical studies (Shivarov & Bullinger, 2014; Gerstung et al., 2015). 
1.4.4 Next Generation Sequencing 
Next generation sequencing is at the cutting edge of genomic investigations and 
provided the technology for many genomic studies and an exponential increase in genomic 
knowledge of cancer. NGS has become almost synonymous with genomics and is 
undoubtedly the future of routine genetic diagnosis. NGS will be refined into compact 
analytical systems and provide diagnostic assays, which are being validated for clinical 
purposes. A diagnostic framework is being established to provide a quality system for 
diagnostic laboratories.  
Extensive work has been performed to characterise the genes from NGS studies and 
to distinguish the “driver” mutations that confer a growth advantage from the background of 
“passenger” mutations, acquired during the lifetime of the cell but having no role in 
leukaemogenesis. This is not necessarily straightforward and is primarily performed by 
frequency of mutation in cancer genomes. Other bioinformatics approaches utilise 
information of structural properties of mutations and their position in mutated sub-networks 
of driver pathways, to infer patterns of co-occurrence or mutual exclusivity. A meta-analysis 
of four frequentist studies (reported in Mazzarella et al., 2014) identified 21 drivers common 
to all four studies and a further 32 identified by a single method. Many of these  have already 
been implicated in disease and includes tissue-specific drivers, not implicated in other 
neoplasms. Bioinformatics methods are becoming sophisticated and less frequent driver 
genes will still emerge which might require thousands of samples to catalogue genes of low 
frequency and confirm clinical significance. Several landmark studies but particularly the 200 
cases sequenced by The Cancer Genome Atlas (The Cancer Genome Atlas Research Network, 
2013), have resulted in the identification of most of the recurrent mutations in genes 
involved in AML development (figure 1.7). 
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Figure 1.7.  Significantly mutated genes in the TCGA dataset, showing the proportion 
of samples with each mutation 
 
 
The development in high throughput sequencing technology enhanced researchers’ 
ability to interrogate cancer genomes and there is a concerted effort to bring this new 
capability for the study of neoplastic disease into diagnostic practice, to bring universal 
precision medicine closer to reality. Next generation sequencing encompasses a range of 
different methodologies for the investigation of the genome, transcriptome or epigenome 
(Bentley et al., 2008; Wang et al., 2009; Krueger et al., 2012). Over the last decade, the rapid 
and incremental refinement by different commercial companies has brought large scale 
sequencing of diagnostic standard into routine use (reviewed in Metzker, 2010; Goodwin et 
al., 2016). The major developments have been in short read DNA sequencers, which have a 
restricted facility in the length of a DNA molecule that can be sequenced; read lengths of 
50~150 nucleotides are typical (Goodwin et al., 2016). However, the millions of simultaneous 
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reads increase the throughput and significantly reduce the cost per nucleotide, which is 
several orders of magnitude less than Sanger sequencing. 
De novo genome assembly uses sequencing with no prior information from a 
reference genome for alignment; the genome sequence is reconstructed from overlapping 
contigs and the resulting quality of coverage depends on the size and continuity of the data. 
Accurate de novo assembly is very effective for the characterisation of novel genomes and 
large scale Structural Variation but is very challenging with the typical read lengths from 
short-read instruments. Alternatively, NGS ‘resequencing’ is used extensively for human 
diagnostic applications, which aligns the short sequence reads to the Human Reference 
Genome to detect differences and predict the mutational profile of variants in the test 
genome (Myllykangas & Ji, 2010; Goodwin et al., 2016). The detection of genomic variation is 
demanding due to variability of biological features and complexity of genomic sequence, and 
from technical limitations such as sequencing errors, limited read lengths and insert sizes, 
and sampling biases (e.g. in GC-rich regions). Sophisticated bioinformatic algorithms are 
required to make highly sensitive and specific predictions of genomic variation. This has 
resulted in the development of computational approaches, tailored to specific tasks, for the 
alignment of millions of individual short reads to detect different types of genomic 
rearrangements. (Ding et al., 2014). 
The new technology will eventually have the same (but highly refined) impact on 
cancer diagnosis that cytogenetics has provided, improving on the accuracy of current 
testing, providing information for molecular monitoring in remission (which is not currently 
possible for all tumours) and aiding the detection of biomarkers for targeted therapies 
(Cronin & Ross, 2011; Chin et al., 2011; Majewski & Bernards, 2011). Importantly, using an 
appropriate strategy, NGS can be applied to detect single gene mutations and structural 
abnormalities in a single assay (Grossmann et al., 2011; Graubert & Mardis, 2011) and the 
current range of genetic technologies will eventually converge into different applications of 
clonal sequencing testing, perhaps WGS. However, a significant challenge is how to develop 
the new genomic technology for multiple genetic abnormalities into a single practical and 
affordable assay, for use in the diagnostic environment to aid clinical management. 
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1.4.4.1 Depth of Coverage 
Depth of coverage or read depth is a measure of the number of times each a specific 
nucleotide or genomic feature is covered by the multiple sequence reads in an experiment. 
Analysis detects differences in the number of reads that align to intervals in the reference 
genome. Assuming that reads are sampled uniformly from the genome sequence, the 
Lander-Waterman model (Lander & Waterman, 1988) specifies the number of reads that 
contain a given nucleotide is on average as; 
 
Coverage =  Number of reads x Length of each read 
Length of the Genome 
 
Repetitive sequences in the reference genome and biases in sequencing (e.g. 
different coverage of GC-rich regions) affect depth of coverage calculations. Nevertheless, 
depth of coverage analysis is a key consideration in calculating the efficiency of NGS and 
computational methods for its analysis are a key component of a NGS pipeline. 
1.4.4.2 NGS Stages 
NGS can be considered as a technology providing a single assay to generate a defined 
mutational profile. However, it comprises a number of distinct modules and the variable 
performance of each process can influence the outcome of the results of the sequencing 
assay (Daber et al., 2013; Lee et al., 2015). Figure 1.8 demonstrates a typical NGS workflow. 
 
1. Library Construction – preparation of the nucleic acid target into suitable 
lengths with adapter ligation compatible with the sequencing equipment 
2. Sequencing 
3. Bioinformatics analysis 
a) Base Calling 
b) Alignment 
c) Variant Calling 
d) Variant Annotation 
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Figure 1.8. Typical workflow in a clinical next generation sequencing laboratory (Gullapalli 
et al., 2012) 
 
1.4.4.3 Whole Genome Sequencing (WGS) 
Whole-genome sequencing (WGS) provided genome-wide, unbiased screen of all 
genes including the coding and non-coding regions of the genome (Ross & Cronin, 2011). 
WGS facilitates a comprehensive analysis of all types of genomic feature; single nucleotide 
changes and structural variants, including deletions, amplifications, gene fusions and loss of 
heterozygosity, are all readily identified. Studying the entire cancer genome permitted 
unprecedented global mutation detection and an understanding of cooperation between 
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genes. Research studies of cancer, typically sequenced both the tumour and paired normal 
tissue from the same individual, to help distinguish acquired (somatic) sequence variants 
from the background of inherited polymorphisms, which was important for early cancer gene 
discovery studies. It is clear that this is a powerful yet straightforward technology that will 
have great impact on cancer diagnosis but until recently, the cost has been prohibitive for 
large scale use and difficult to match the requirements for diagnostic turnaround (Welch & 
Link, 2011). 
1.4.4.4 Targeted Sequencing 
Whilst WGS is undoubtedly powerful for novel gene discovery and for the 
investigation of the non-coding genome, the additional breadth of coverage yields limited 
returns relative to expenditure for diagnostic purposes. WGS presents problems for data 
handling and storage which can be reduced if only the genes of interest are examined, then 
the bioinformatics burden is reduced and the excess data is available for possible future 
diagnostic and research use. Alternatively, using target enrichment techniques, regions of the 
genome of interest can be selected prior to sequencing to streamline sequencing and 
simplify data processing and analysis (Mamanova et al., 2010; Mertes et al., 2011), making 
this more relevant for diagnostic use. The enrichment of specific targets is currently 
mandatory for clinical cancer genome sequencing. The trade-off from the reduced breadth of 
coverage by selective sequencing is the cost effective use of instrument capacity to 
accomplish better depth of sequencing. This is necessary for the detection of cancer clones 
and to optimise the specificity and sensitivity of assays, to derive information at sufficient 
depth for effective clinical utility..  
The regions of interest could be a large-scale, standard target, such as the coding 
regions of the genome (exome sequencing) (Ng et al., 2009), cDNA from the transcriptome 
(Fullwood et al., 2009; Ruan et al., 2007; Maher et al., 2009) or a specific subset of genes for 
their cancer diagnostic relevance (e.g. cancer genes or tyrosine kinase genes, the ‘kinome’) 
(Loriaux et al., 2008). A standardised target of relevance to diagnostics may eventually be the 
recognised cancer genome (Fox et al., 2009; Stratton et al., 2009). As well as focussing 
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experiments to the most relevant genomic regions, target selection can overcome coverage 
limitations of certain whole exome approaches (Rehm, 2013). 
Targeted enrichment methods fall broadly into two categories; amplicon capture, 
using PCR or Molecular Inversion Probes (MIP), and hybrid capture, which uses a solid 
surface array or in-solution capture (Mamanova et al., 2010; Hagemann et al., 2013). Both 
techniques however, may struggle to capture regions of low complexity, leading to 
difficulties mapping sequences back to the reference genome. Amplicon-based selection has 
proved successful for selection of mutational hotspots in AML (Kohlmann et al., 2010b; Patel 
et al., 2012) whilst hybrid capture has been shown to be feasible for the detection of base 
pair mutations and structural abnormalities for leukaemia diagnosis (Grossmann et al., 2011; 
Duncavage et al., 2012). 
Target enrichment strategies for NGS have been shown to be reproducible and 
reliable and are becoming widely used in clinical diagnostic laboratories (Mamanova et al., 
2010; Meyerson et al., 2010; Hagemann et al., 2013). An assortment of methods and 
technologies have been described, most of which can now be purchased as commercial 
products (e.g. Fluidigm, Raindance, Haloplex amplicon capture and SureSelect, NimbleGen 
for hybrid capture). The fidelity of capture can vary with different methods and it is 
important to select an appropriate method to minimise off-target enrichment and low 
uniformity of capture and therefore maximise the efficiency of sequencing required to attain 
adequate sequence depth for all targeted regions. Different capture methods can be affected 
by sample quality and the presence of variants within the capture region. Scalability, 
throughput and ease of use are important for diagnostic practicality, whilst the size of the 
region for enrichment will influence the most appropriate method. Finally, the need for 
specialised equipment and the reagent price are also key considerations. 
1.4.4.5 Next Generation Sequencing for the identification of Structural Variation 
Structural variation (SV) of the genome is defined as differences in location, 
orientation or copy number of relatively large genomic segments, typically represented by 
translocations, inversions, tandem duplications, insertions, deletions, and segmental loss of 
heterozygosity. SV has been described as genomic variation of at least 1kb of DNA in size, 
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however, submicroscopic rearrangements revealed by modern sequencing technology has 
redefined SV to >50bp, to distinguish this from the smaller indels and single nucleotide 
variation (Feuk et al., 2006; Alkan et al., 2011; Quinlan & Hall, 2012). SV contributes to the 
phenotypic differences among healthy individuals and is implicated in the causation of 
diseases, including cancer, by disrupting gene function, creating gene fusions or placing 
genes alongside different controlling elements. Therefore, it is crucial to systematically 
profile SV in the genome. The reliable detection of gene fusions resulting from chromosomal 
translocations, and other forms of structural variation, are critical for the accurate 
classification of AML and other cancer subtypes (Arber et al., 2016; Döhner et al., 2016).  
An early experimental approach used ‘shotgun’ sequencing of flow-sorted derivative 
chromosomes followed by NGS (Illumina/Solexa) and with sufficient depth of coverage 
defined three different disease-associated breakpoint cluster regions, in three constitutional 
translocations, in patients with developmental delay. The coverage was attained by bridging 
the breakpoints by PCR amplification, and this procedure allowed for the determination of 
their exact nucleotide positions (Chen et al., 2008). 
1.4.4.6 Paired end technology for structural variation 
A number of approaches are possible for the detection of structural abnormalities as 
well as single nucleotide changes. Paired end and mate pair resequencing protocols were 
developed to increase the effective read length of sequencing with the main incentive being 
the identification of SV by NGS  (Raphael, 2003; Ng et al., 2006; Korbel et al., 2007; Fullwood 
et al., 2009). The basic principle of paired-end mapping is to examine a short sequence read 
from each end of larger, linear genomic nucleic acid fragment or ‘insert’. Most reads result in 
concordant pairs when aligned to the reference genome, where the distance between them 
and their orientation is as expected for the insert fragment. In contrast, mismatched paired 
reads indicate disruption of the spatial relationship between alignments, such as abnormal 
distance, different orientation or location on different chromosomes. This indicates that read 
pairs flank a structural breakpoint within the DNA fragment. Different classes of structural 
variation, such as insertions, deletions, inversions and translocations, produce a distinct 
mapping signature (Raphael, 2012).  
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A variety of methods have been used to generate paired reads using various next-
generation sequencing technologies, although paired-end mapping using modern short read 
NGS platforms is most widely adopted and offers the most efficient technique for diagnostic 
applications. Sequencing libraries are constructed to a uniform length (generally 200~500bp) 
for paired-end libraries (compared to 1~10kb for mate-pair libraries) (Raphael, 2012). 
Routine NGS, therefore, has both limitations in read length and insert size. Paired-end 
analysis provides quantitative, digital information and the ability to sample rare events by 
sequencing DNA to an appropriate depth. In contrast to a complete sequencing strategy, it is 
possible to detect SNV, small indels and structural variation with far fewer sequence reads 
compared to continuous sequencing of linear DNA. However, without continuous sequencing 
of DNA fragments, the discordant mapping patterns from complex SV can be difficult to 
interpret and the chosen fragment sizes can affect the sensitivity (Quinlan & Hall, 2012). 
Some complex SV may remain refractory to detection or accurate characterisation. There is a 
significant benefit of defining specific genomic breakpoints of genomic rearrangements such 
as gene fusions, for the identification of disease-specific junctional fragments for the 
diagnosis and to provide useful molecular markers for monitoring disease course. A paired 
end sequencing strategy does not necessarily define the breakpoints to bp resolution.  
Advanced bioinformatics algorithms are necessary for SV detection and have been 
developed to predict SV by finding clusters of discordant pairs, which are supported by 
multiple discordant paired reads, split reads, or both (Raphael, 2012; Abel & Duncavage, 
2013; Liu et al., 2015; Guan & Sung, 2016). Discordant reads may indicate the presence of a 
sequencing error, however, the recognition of clusters of discordant pairs that indicate the 
same true variant can discount this (Raphael, 2012). Different algorithms consider different 
features of structural variation and specificity is improved by computational methods which 
incorporate multiple signals of structural variation, such as read depth, split reads, or paired 
reads, into a single prediction algorithm (Sindi et al., 2012). That multiple classifiers have 
been produced suggests that the ideal software has not been produced although there is 
increasing sophistication with new generation of algorithms, which upon extensive 
 61 
 
evaluation may be shown to be more accurate (Abel & Duncavage, 2013; Liu et al., 2015; 
Guan & Sung, 2016). 
1.4.4.7 NGS studies in cancer with a focus on detection of gene fusions 
A number of research groups pioneered paired-end NGS for gene expression 
(transcriptome) sequencing (Maher et al., 2009), genomic sequencing (Campbell et al., 2008) 
or both (Fullwood et al., 2009; Ruan et al., 2007). Early studies using paired-end mapping 
studies revealed extensive high resolution maps of structural variation in the human genome 
(Korbel et al., 2007; Kidd et al., 2008) and refined the technology for the identification of 
somatically acquired rearrangements in cancer genomes (Raphael, 2003; Volik et al., 2003; 
Ng et al., 2006; Bignell et al., 2007; Bashir et al., 2008). 
The first WGS of a cancer was an AML of M1 morphology, which used deep, single-
end NGS (Ley et al., 2008). This patient was later sequenced more comprehensively, by 
paired-end WGS (Mardis et al., 2009). This was rapidly followed by sequencing other AML 
genomes (Ley et al., 2010; Welch et al., 2011b) and of other tumour types (reviewed by 
Meyerson et al., 2010). Of particular note were landmark studies of lung tumours (Campbell 
et al., 2008), breast tumours (Stephens et al., 2009), melanoma (Pleasance et al., 2010b), and 
small-cell lung tumours (Pleasance et al., 2010a). In particular, the study by Campbell et al. 
(2008) presented an early, technically sophisticated study in which they used genome-wide, 
paired-end NGS to detect somatically acquired rearrangements in two individuals with lung 
cancer, by comparing tumour cell line and germline DNA to the reference human genome. 
They characterised multiple somatic rearrangements to a base-pair resolution, including 
internal tandem duplications and gene fusions from interchromosomal rearrangements, 
some of which were also demonstrated as expressed abnormal transcripts (Heim & 
Mitelman, 2008). Paired-end NGS was used in an early study and demonstrated the 
feasibility of gene fusion detection by WGS of an acute promyelocytic leukaemia sample to 
show a cryptic, insertional PML-RARA fusion, within a diagnostically relevant timescale (seven 
weeks including PCR confirmation) (Welch et al., 2011a). The study used paired end NGS 
analysed with Breakdancer software (Chen et al., 2009).  
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Cost, analysis of complex data and storage of data are issues for routine application of 
WGS. If only genes of interest are examined following WGS, this reduces the bioinformatics 
burden and the excess data is available for possible future diagnostic and research use. 
However, for diagnostic purposes, clinicians require information on a defined range of 
genetic abnormalities with confirmed clinical significance and therefore only require testing 
of a specific panel of genes, making this more affordable and comprehensible (Godley, 2012). 
More recent studies have been able to capitalise on the streamlining of NGS methodology 
and the capacity of NGS technology to sequence multiple AML genomes, to provide detailed 
analysis of the mutational landscape of the diseases with the result that they have been 
extensively characterised and the common genetic defects leading to the development of 
AML are well understood (Patel et al., 2012; Grossmann et al., 2012; The Cancer Genome 
Atlas Research Network, 2013; Papaemmanuil et al., 2016; Metzeler et al., 2016) (see section 
1.3, below). 
1.4.4.8 The combination of paired end NGS and target enrichment 
Hybrid capture has been shown to be feasible for the detection of base pair 
mutations and structural abnormalities for leukaemia diagnosis (Grossmann et al., 2011; 
Duncavage et al., 2012). An experimental microarray hybrid capture approach identified gene 
fusions involving RUNX1, including a novel fusion partner (Grossmann et al., 2011). An early 
proof of principal study used hybrid capture (Agilent SureSelect target enrichment) of 20 
genes and identified gene fusions in three leukaemia cell lines, as well as a KMT2A-AF9 gene 
fusion and FLT3-ITD in a diagnostic AML specimen (Duncavage et al., 2012). The research 
group then studied sensitivity and specificity of NGS for the detection of gene fusions in 7 
ALK and 6 KMT2A rearranged tumours and validated using multiple negative cases (Abel et 
al., 2014). The same laboratories performed similar studies on FFPE lung 
adenocarcinoma specimens (Spencer et al., 2014) and FFPE from seven ALK rearranged 
tumours (lung adenocarcinoma and ALK lymphoma) and six bone marrow aspirates with 
known KMT2A gene fusions (Abel et al., 2014). A recent international, multicentre 
collaboration developed Karyogene, a targeted resequencing and analytical platform that 
used gDNA in a single assay, similar to the current study, to detect nucleotide substitutions, 
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insertions/deletions, chromosomal translocations (McKerrell et al., 2016). The key to 
successful identification is the adoption of appropriate bioinformatics approaches for the 
detection of the variety of mutational types (Abel & Duncavage, 2013).  
1.4.4.9 Transcriptome analysis for gene fusions 
Analysis of the transcriptome by sequencing of cDNA from expressed transcripts from 
disease cells by RNA sequencing (RNA-seq) is gradually superseding microarray technology 
for gene expression studies (Wang et al., 2009) and has been applied to mutation detection 
(Shah et al., 2009). Transcriptome analysis by RNA-seq provides superior digital information 
to microarray GEP whilst also enabling discovery of novel splice forms, transcripts and RNA-
editing. The better dynamic range of RNA-seq improves detection of low expressed 
transcripts (Meldrum et al., 2011; Kukurba & Montgomery, 2015; Ozsolak & Milos, 2011).  
RNA-seq has proven especially useful for the detection of gene fusions resulting from 
genomic translocations. The conventional method for identifying fusion junctions in single 
gene targets is reverse transcriptase PCR from expressed mRNA from disease cells. By 
sequencing mRNA rather than gDNA, it is possible to exploit the mRNA splicing mechanisms 
of the cell that join exons as single transcripts. Therefore, the intronic, non-coding sequences 
have been excised and sequencing can target the expressed genes only and avoid excessive 
sequencing of repetitive DNA from introns.  An early study of RNA-seq using a novel paired-
end sequencing method identified cancer-associated fusion transcripts and a novel fusion 
transcript, BCAS4-BCAS3 from an unbalanced t(17;20)(q23;q13), in a breast tumour cell line 
(Ruan et al., 2007). Whole transcriptome paired-end sequencing has revealed novel fusion 
transcripts of clinical significance in AML (Wen et al., 2012; Masetti et al., 2013) Special 
consideration much be given to the use of transcriptome analysis to detect structural 
rearrangements as a global analysis of all genes. 
An advantage of RNA-seq for identifying variants compared to gDNA sequencing is 
that the data simultaneously provides functional information about the expressivity of genes 
of clinical significance, and is the most relevant application if gene expression profiling is also 
of interest. However, variable gene expression results in a large dynamic range of expression 
throughout the genome. This is not uniform across all genes and affects the genomic 
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coverage of sequence information and the ability to accurately call variants. The dynamic 
range of gene expression extends over many orders of magnitude and identifying coding 
mutations in genes with moderate to high expression is not a problem (Mortazavi et al., 
2008; Conesa et al., 2016). The large number of transcript copies that can be derived from a 
single cell, may suggest RNA-based methods could have greater sensitivity over those 
interrogating DNA. However, the accurate identification of somatic mutations in genes with 
low levels of expression or that harbour truncating somatic mutations and cause nonsense-
mediated decay presents a challenge to detection. Detection of low level sequences is again 
dependent on read depth, and the sensitivity can be enhanced by targeted hybridisation 
capture of cDNA libraries, similar to that used for DNA sequencing (Levin et al., 2009).  
RNA-seq has proven capability to detect sequence variants and fusion products.  RNA-
seq should therefore reflect the sequence data garnered from WES. However, the 
transcriptome is an imperfect surrogate for the exome and any advantages of RNA-seq in 
preference to DNA for mutation detection have not been demonstrated (Meldrum et al., 
2011). Furthermore, mRNA of adequate quality to prepare sequencing libraries may not 
always be available from fresh samples or from paraffin-embedded solid tissue specimens, 
which is much less likely to be a problem for gDNA (Shendure & Stewart, 2009).  
A significant advantage of RNA-seq is the ability to identify fusion transcripts from 
chimaeric fusion genes, including novel fusions (Levin et al., 2009; Shah et al., 2009) although 
not the sequence disruption from fusion genes causing upregulation without expressed 
chimaeric mRNA. An emerging trend for diagnostic applications, is the combination of exome 
and transcriptome sequencing (Hansen et al., 2016), to derive the benefits of WES from 
gDNA and gene fusion detection from RNA-seq, thereby restricting their deficiencies but by 
increasing the sequencing demand and complexity of the assay. 
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1.5 Genomics strategy in the UK 
The intense activity in the field of genomics in the last decade due to the rapid 
advances in genome analysis technologies has greatly improved the understanding of the 
molecular pathogenesis of cancer. This knowledge, in turn, will provide information for the 
more accurate characterisation, diagnosis, classification and monitoring of neoplastic disease 
of individual patients (PHG Foundation, 2011). Cancer diagnosis will benefit from the 
mainstream adoption of genomic testing but a significant challenge exists of how pressurised 
healthcare systems can establish an infrastructure to constructively integrate molecular 
diagnostics into the routine clinical practice, to achieve the anticipated improvement of 
patients’ clinical outcomes. 
1.5.1 The need to modernise cancer molecular pathology 
Molecular pathology for cancer diagnosis has been recognised in a number of 
reports which represented a groundswell of opinion of the benefits for cancer diagnosis and 
shaped national strategies. The Royal College of Pathologists (2010) recommended a national 
body to approve new molecular diagnostic tests and called for coordination of testing in 
regional centres. The financial issues were highlighted and the report expressed the necessity 
to make funding for molecular diagnostics explicit in local budget planning, in Trusts’ 
Strategies and Local Development Plans. The Inter-Specialty Committee for Molecular 
Pathology (ISCMP) was established to drive this development, with special consideration 
given to training the scientific and medical workforce in the new discipline. It was 
acknowledged that the utility of molecular diagnostics in haemato-oncology is better 
established than for solid tumours and genetic testing by karyotyping and FISH, 
supplemented by real-time reverse transcriptase (RT-PCR) for monitoring of minimal residual 
disease, has been incorporated into NICE guidance since 2003 and service organisation 
assessed as a cancer standard (National Institute for Health and Care Excellence, 2016). This 
is not to say that equitable access of testing across the country has been achieved or that 
significant challenges do not await the transition to the testing of panels of multiple gene 
targets in haematological malignancy. 
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The provision of companion diagnostics for medicines targeted to genetic mutations 
requires significant resources to make this a routine practice. It was suggested in the national 
Cancer Strategy (pg 38-41 Independent Cancer Taskforce, 2015) that centralised 
commissioning would facilitate the coordination of cancer gene testing, as a means to avoid 
the piecemeal adoption of testing and access to corresponding therapies. The Strategy also 
recognises that, to realise the full potential of novel targeted treatments, tumour diagnosis 
would not just require single molecular tests but multiplex panels of genetic markers. 
Importantly, it is also recognised that policy definitions should be sufficiently flexible and 
funding restrictions should not be an impediment to the transition to multi-gene panel-based 
tests at the appropriate time and when cost effective (Cancer Research UK, 2015). The slow 
progress to establish centralised commissioning for single gene companion diagnostics 
demonstrates the challenge for this next phase. The incorporation of routine molecular 
testing into the patient pathway also requires modernisation of the diagnostic infrastructure. 
Adoption of new workflows is necessary to provide tumour specimens of desired quality and 
logistical solutions to create accessibility to testing centres with the modern technology. 
Following from the roadmap developed by the Stratified Medicine Innovation Platform 
consortium of government bodies and leading charities (Technology Strategy Board, 2011), 
Cancer Research UK set up the Stratified Medicine Programme. This was a prototype of a 
coordinated, nationwide system for large scale molecular testing in cancer, providing patient 
sample access to testing centres, whilst promoting research into targeted therapies and 
creating a centralised data repository of paired genetic and clinical data (ECMC website 
accessed 17/11/2016). Programme 1 ran until 2013 and laid a foundation and established 
pathways for routine molecular genetic testing of specific mutations, in a defined set of 
cancer types. Programme 2 followed and is pioneering the use of NGS for pre-screening stage 
3 and 4 lung cancer patients for the National Lung Matrix Trial. This multiplex assay is being 
developed in conjunction with the commercial sequencing company Illumina, which, with 
other sequencing companies, is developing products for use in routine diagnostics for the 
NHS as part of a new market strategy. In 2013, the Medical Research Council (MRC) also 
announced their ambitions for diagnostic molecular pathology in the UK and how this might 
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be achieved (Medical Research Council, 2013). This report also highlighted the need for 
investment in molecular diagnostic services to increase the capacity, in order to realise the 
potential clinical and economic benefits of stratified medicine. The review identified the lack 
of a recognised developmental pathway for diagnostic testing, including shortcomings in 
processes for regulation, evaluation and commissioning. The divide between different 
stakeholding groups and sectors is a recurring theme in reports; in particular, Pathology, 
Research, Industry and the clinical environment are disconnected. The capability for the 
successful translation of innovative genomic laboratory research to clinic would be enhanced 
from collaboration (Human Genomics Strategy Group, 2012). In support of this, the MRC and 
Engineering and Physical Sciences Research Council  (EPSRC) have funded six university-
led Molecular Pathology ‘nodes’, covering various diseases including cancer, for research to 
collaborate with clinicians to introduce new molecular diagnostics, to determine clinical 
validity and utility, and embed this into quality diagnostic provision, to enable disease 
stratification. The Open Targets initiative was developed as a partnership between academia 
(Wellcome Trust Sanger Institute and the European Bioinformatics Institute) and pharma 
(GSK and Biogen) to use NGS to identify candidate mutations and determine their biological 
validity as therapeutic targets (Open Targets, 2017). 
1.5.2 The 100,000 Genomes Project 
The vehicle to deliver the UK governmental strategy has emerged as the 100,000 
Genomes Project (100KGP), which was announced in December 2012. Genomics England, a 
wholly owned company of the Department of Health, was set up in partnership with the 
sequencing industry to deliver the Project. The 100,000 genomes to be sequenced is planned 
to include 50,000 genomes from around 25,000 cancer patients and combining this data with 
their medical records. An important resource for clinical research will be established, which, 
it is hoped, will help inform the precise diagnosis of cancer and personalisation of medicine. 
It is debatable, however, whether so many genome sequences are within budget and when 
normal comparative genomes, multiple tissue samples from the same patient, different 
family members and a diverse range of diseases are tested (including rare diseases, multiple 
subtypes of cancer and infectious diseases) the repository of information on each disease 
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group will be limited. The Project has made an encouraging progress with 31,730 whole 
genomes sequenced to date (as of 1st July 2017; source Genomics England, 2017 website) 
with the full target to be achieved by the end of 2017. It is evident, however, that scientific 
data generation is not the key aim of the project. The main objective is for genomic medicine 
to transform the way all healthcare is delivered and particularly, to use this new paradigm as 
justification to modernise outmoded pathology systems.   
1.5.3 Genomic Services Reconfiguration in England 
The network of GMCs were thought to provide the template for a new network of 
UK regional genetic centres, although this was not explicit in the early communications 
regarding Genetics Services Reconfiguration (NHS England, 2015). The project will re-procure 
NHS genetic testing in November 2017, to restructure laboratories into a national network of 
NHS regional genomics centres in seven geographical pods. The new services will be aligned 
with the Academic Health Science Networks, established genomics research infrastructure, 
including medical schools, universities and research institutions such as the Wellcome Trust 
Sanger Institute and the MRC Institute of Genetics and Molecular Medicine, whilst also 
linking genomic services to local pathology provision at the clinical interface. A hierarchy will 
be defined, therefore, from the GESC, a maximum of seven Genomics Central Laboratory 
Hubs (GCLH) and subcontracted designated local hubs, from which local molecular pathology 
services will be provided. The proposed infrastructure will bring together clinicians, 
diagnostic laboratories and research units into ‘clinical interpretation partnerships,’ to review 
new information and “ensure the legacy of the 100KGP,” uniting different disciplines and 
accelerating translational research into clinical practice. Reconfiguration has been 
preoccupying genetic laboratories for more than two years whilst in development and the 
details of the Invitation to Tender are awaited with interest in 2017.  
1.5.4 Challenges for the new testing paradigm 
Whilst the use of NGS is accelerating and is undoubtedly the direction for genetic 
testing, the technology is currently used in only a small proportion of patients, mainly for the 
diagnosis of Mendelian conditions and as companion diagnostics for few cancer treatments. 
 69 
 
A potential problem with strategies for accelerating genomics into healthcare is the 
assumption that WGS is ready to transfer for all applications. Whilst comprehensive 
sequencing is beneficial for genetic discovery studies and may prove to be cost effective for 
medical genetics, where multiple gene profiling will have long-term future application for the 
patient and their families, this is not the case for the molecular pathology of cancer, where 
rapid diagnosis and prompt assignment of therapy is a key requirement. For the near future, 
cancer genetics services must accommodate conventional testing by simpler, cost effective 
methods, such as cytogenetics, FISH and single gene PCR and small gene panels. Sequencing 
technology is progressing in several directions, and varying applications of NGS will be 
required by different pathology specialties (Cree, 2016). Novel applications of NGS specific to 
cancer, such as ‘liquid biopsy’ (using circulating cells, nucleic acids and proteins for 
diagnosis), and NGS to monitor the efficacy of treatment is gaining evidence to support wider 
adoption and requires special consideration.  
A potential bottleneck is that many diagnostic tests are ready for validation as 
pharmacogenomic applications but that entry into practice is prolonged due to difficulties 
identifying robust drug targets in complex cancer genomes and the length of time required 
for drug development. A changing focus will be to provide screening of the cancer genome, 
rather than sequential single tests, to provide downstream access to the small number of 
approved therapies and also early phase trails of experimental medicines.  
The main obstacle to mainstream adoption of sequencing is no longer technical; it is 
in the interpretation of large amounts of complex data. There will be a growing requirement 
to assess complex signatures, possibly from multiple molecular modalities provided by 
genomic, transcriptomic and proteomic platforms, which collectively will characterise the 
individual make-up of a cancer. This is probably most advanced in AML (The Cancer Genome 
Atlas Research Network, 2013; Papaemmanuil et al., 2016). The evidence base is 
accumulating to give scientists the resources to assess the clinical utility of sequence 
variants, such as the large, internationally coordinated research programmes, The Cancer 
Genome Atlas (Tomczak et al., 2015) and the International Cancer Genome Consortium 
(ICGC) (Hudson et al., 2010), which led to the identification of recurrent somatic mutations 
 70 
 
that drive oncogenesis in selected cancer types, through the comparative sequencing of 
tumour tissue and the constitutional genome. The Catalogue Of Somatic Mutations In Cancer 
(COSMIC) is the world's largest and most comprehensive resource for exploring the impact of 
somatic mutations in human cancer (Forbes et al., 2015) and also provides the Cancer Gene 
Census, a continuously updated comprehensive catalogue of curated genes that are causally 
implicated in cancer. 
The evolution of the genomics sector brings with it the requirement to have 
scientific and technical staff at the frontline, with the necessary skills and expertise to deliver 
the transformation. The necessity to support a modern workforce is recognised in the 5 Year 
Forward View (NHS England, 2014). The importance of genomics is recognised and  the need 
to invest in relevant training of the current and future workforce is supported by the Health 
Education England (HEE) long term strategy (Health Education England, 2015) to support the 
successful integration of genomics into mainstream care pathway.  
The shortage of genomic scientific and bioinformatic skills is recognised (Monitor 
Deloitte, 2015). Bioinformatics expertise is a key constraint for development of the discipline 
and is desperately needed to underpin genomic and genetic testing. To meet this challenge 
for data analysis and interpretation, new education programmes have been commissioned 
and are under development including: new scientist training programmes (STP) in molecular 
pathology, genomics and bioinformatics; higher specialist scientist training (HSST) posts in 
genetics and molecular pathology with an approved curriculum in molecular pathology 
leading to Fellowship of the RCPath, in order to develop the future consultant clinical 
scientist workforce, and the introduction of a modular MSc in genomic medicine (Delon & 
Scott, 2016). There will be additional opportunities for translational research stemming from 
the 100,000 Genomes Project research fellowships for PhD students and post-doctoral 
scientists, thus further enhancing the skills base and developing future research leaders in 
pathology and increasing capacity in data analysis (Medical Research Council, 2013). The UK 
Government has agreed to support genomics education and the workforce transformation 
project with an allocation of £25 million (Delon & Scott, 2016). 
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Whilst some traditional assays will be transferrable immediately to new platforms, 
the utility and cost efficiency of some new assays may take years to emerge with the 
persistence of traditional testing methods. One technology will not dominate for many years, 
and, most likely, a hybrid approach to address practical, clinical, and financial pressures will 
prevail (Schnepp et al., 2015). The integration of genomics in cancer diagnosis practice will 
take time and will require a phased adaptation of the technology, gradually transferring 
single gene tests to panels, validating multi-gene profiles by NGS and introducing WGS when 
interpretation is deemed feasible and cost efficient.  
Changes in practice need to be closely aligned with a health economic assessment of 
their impact on patient pathways. Cancer care is costly: genomic testing can be used in 
decision making to rule out chemotherapy or other treatment options that would not be 
effective for the care of an individual patient. The benefits of increasing personalisation of 
medicine will be to use genomic testing to help eliminate ineffective or possible harmful 
treatment options and determine appropriate care will benefit the patient while reducing 
healthcare utilisation and costs. The effect of personalised medicine on NHS costs is still a 
matter of debate, but there is no question that for advanced cancer, most individualised 
treatment will add to costs and the prolongation of life will add to the overall cost of 
healthcare. Such developments therefore need to be introduced in concert with strategies to 
improve early diagnosis of cancer and other disorders, when the chance of cure is high and 
less expensive (Cree, 2016). Deep uncertainty in a time of unpredictability and uncertainty at 
a time when the NHS is suffering its “worst financial crisis in history” and according to the 
Forward View the NHS will need to make efficiency savings of £22bn by 2020/21 to live 
within the planned budget (Royal College of Physicians, 2016; Murray et al., 2014; Lafond et 
al., 2016). 
Genome sequencing also requires a ‘big data’ approach to analysis and 
interpretation which is already apparent in many research facilities; presenting a challenge to 
storage capacity and transfer of this data across networks. Computer facilities will require to 
be upgraded, coordinated and delivered effectively, which the NHS is not renowned for. That 
this will be patient identifiable data through linked demographics and personal DNA 
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sequence data, including whole genome sequences for use with outputs from central 
facilities, local pathology labs or even point of care diagnostic devices, data security will be a 
significant issue. The project will test the serious practical challenges of integrating and 
safeguarding genomic data within an expansive but under-resourced health service and this 
requires the further development of the medico-legal and ethical framework for the use of 
genomic data. 
Finally, it may be necessary to exercise caution and reframe our expectations and 
acknowledge that translational rather than transformational change is required; this is not so 
much a “revolution as an evolution”. 
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1.6 Project aims and what it adds to scientific field  
The project was a Proof of Principle (POP) study to demonstrate the feasibility of 
performing targeted NGS to detect a range of types of genetic abnormalities in AML, for the 
detection of all known, clinically relevant mutations in a single experiment. This examined 
the practicality of merging multiple existing diagnostic tests and newly discovered mutation 
profiles into a single assay, thereby being able to replace existing tests and unifying diverse 
workflows. In particular, a number of studies have demonstrated the utility of exome 
sequencing for the detection of single nucleotide variants (SNVs) and small indels, which 
have been transferred to the diagnostic laboratory environment. WGS can reveal large indels 
and gene fusions but the combination of target selection and the analytical pipelines 
required to detect large scale structural variation is underdeveloped. The project entailed the 
design of a novel NGS assay and used a custom-designed selection of targets for sequencing 
genomic DNA, including for the detection of gene fusions and other structural variants, which 
represented a unique aspect of this project in AML. The project compared the performance 
of the new assay for detection of genomic abnormalities with standard methods of 
cytogenetics, FISH and molecular testing and with an orthogonal NGS assay using a 
commercial kit for SNV detection, based on different target capture technology and 
sequencing chemistry. 
 
The main aims of the project were; 
 
1. To demonstrate the principle that a novel genome sequencing assay for the diagnosis 
of AML was feasible combining key features; 
 Use target enrichment for genes of clinical relevance, to optimise use of capacity of 
currently available sequencers and facilitate the management of costs. 
 Use genomic DNA as the sole test material, to streamline the assay and provide a 
stable nucleic acid as the analyte, facilitating universal accessibility and reproducible 
performance. Investigate the potential for using gDNA for the detection of different 
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variant types, including large duplications and gene fusions, which was considered 
technically demanding. 
 Perform NGS without use of control, to reflect the typical diagnostic workflow. A 
sample of normal cells would not be readily available from an AML patient at 
diagnosis and therefore, there would be no option to use constitutional germline DNA 
as normal control, to distinguish somatic mutations from germline variants. 
 Target genomic variation of different types to detect recurrent genetic changes in 
AML that are clinically relevant and abnormalities that are likely to be actionable in 
the near future. In particular, detect structural variation, including gene fusions from 
translocations and inversions, to reproduce the output of different conventional 
technologies, including cytogenetics. 
 
2. Evaluate the feasibility of translation of the NGS assay to a routine diagnostic genetics 
laboratory. 
 Examine the principle that this could be transferrable to the diagnostic laboratory. 
 Reproduce the diagnostic and prognostic findings from existing methods, to 
accurately detect the types of genetic abnormalities encountered in conventional 
AML diagnosis.  
 Consider how the stringent principles required in a diagnostic laboratory and rigorous 
accreditation standards can be met. 
 Demonstrate how the conventional workflow can be improved and, by extending the 
range of conventional testing to the highest, single nucleotide resolution, it should be 
possible to increase the sensitivity of the tests by sequencing to an appropriate depth. 
 
A key objective for the project was to not only take into account the technical aspects of the 
test but to understand the challenges of the technique and the practicality for mainstream 
adoption of the technology in a specialised pathology laboratory, such as the one at The 
Christie. This will provide evidence of incorporating NGS in routine practice and the problems 
of adopting complex technology into routine diagnostic environments and developing the 
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infrastructure for NGS in mainstream healthcare systems, with particular emphasis on 
challenges presented by bioinformatics, data generation and storage. Commentary will be 
provided on the prospects of transformational change to the diagnostic laboratory 
infrastructure and how this can be managed.  
 
3. Enhancement of the Patient pathway 
 To evaluate the potential of the new targeted genome sequencing assay in a clinical 
context and how this may improve AML management.  
 In particular, how the successful genomic screen of a wider range of genetic targets, 
not part of the standard workflow, could facilitate reclassification of patients by their 
mutational and cytogenetic profile. Demonstrate how the incorporation of new 
markers and combination thereof may lead to better disease classification; improve 
prognostication to emerging standards; provide targets for personalisation of 
treatments. 
 Evaluate the potential clinical utility by comparing the new NGS assay with standard 
testing regime, from samples from the test cohort of clinical cases.  
 
The hypothesis is that within 35 representative cases, it should be possible to demonstrate 
that there is a change in diagnostic classification or prognostic stratification as a result of the 
additional findings. Therefore, from experimentation, it will be possible to understand the 
performance of the new assay in terms of technical validity, clinical validity and its potential 
clinical utility, prior to refinement and formal validation for use in the clinical setting, 
consistent with protocols for validation and professional guidance. Whilst focussing on AML, 
the adoption of a similar strategy applicable to all cancer types will be considered. 
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2.0 Methods 
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2.1 Sample selection and processing  
Bone marrow aspirate specimens are routinely referred to the Oncology Cytogenetics 
department of The Christie NHS Foundation Trust for cytogenetic analysis to aid the 
diagnosis of AML. Cytogenetic samples are sent in a Universal container in transport medium 
(RPMI-1640 Culture Medium, 10% Foetal Bovine Serum (FBS), sodium heparin solution 
40IU/ml, penicillin-streptomycin 50U/ml; (Gibco™, ThermoFisher Scientific, Waltham, 
Massachusetts, USA). Separate specimens in potassium EDTA were sent to different 
departments for molecular genetics studies. Following a manual cell count using a 
haemocytometer, a volume of sample containing 107 mononuclear cells (MNCs) were 
removed for each of two cytogenetic cultures (see below).  For next generation sequencing, 
samples strictly surplus to diagnostic requirements were collected over a period of eight 
months (March 2013 to October 2013). 35 bone marrow samples and one peripheral blood 
sample were selected for the project. MNCs were separated by density gradient 
centrifugation within 24 hours, using Ficoll-Paque Plus™ (GE Healthcare UK Limited, Little 
Chalfont, Buckinghamshire) and cryopreserved at -80oC. Once a diagnosis of AML was 
confirmed by morphology, immunophenotyping and/or by identification of a clonal, 
diagnostic cytogenetic marker, and ratified at Multi-Disciplinary Team meeting, DNA was 
extracted with QIAamp DNA Blood Mini Kit™ (Qiagen, Hilden, Germany) using the standard 
protocol. Extracted DNA was stored at -20oC until sequencing. DNA quality was initially 
estimated using a NanoDrop Lite spectrophotometer (Thermo Scientific™, ThermoFisher 
Scientific, Waltham, MA, USA) and re-quantified using a Qubit® 3.0 fluorometer with Qubit® 
dsDNA BR Assay Kit (Invitrogen™, ThermoFisher Scientific),  immediately prior to next 
generation sequencing. 
2.2 Ethical Approval 
Samples were received in the Oncology Cytogenetics department following informed 
consent for genetic testing. Advice from National Research Ethics Service (Ref 04/26/57) 
(NRES; now part of the Health Research Authority) suggested that the project was a genetic 
service evaluation and development, not considered to be research requiring review by an 
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NHS Research Ethics Committee. Management permission was obtained from Research & 
Development Division of the Christie NHS Foundation Trust (“R&D approval”) and the project 
registered with the Trust as Method Development under protocol (HT014). The Academic 
Ethics Committee of the Faculty of Health, Psychology and Social Care of Manchester 
Metropolitan University approved formal ethics application for study (Ethics Application 
1186). Despite not requiring formal review by an NHS Research Ethics Committee, 
experiments were conducted in accordance with core ethical principles and strictly 
conforming to Information Governance policies of the Pathology department and the Christie 
NHS Foundation Trust. Informed consent was obtained for genetic testing for diagnostic 
purposes. The confidentiality of participants was respected and samples were anonymised, 
meeting requirements in processing identifiable data under the Data Protection Act 2000. 
2.3 Routine genetic testing 
2.3.1 Cytogenetics 
Samples for conventional cytogenetic analysis were processed and analysed 
according to standard protocols of the Oncology Cytogenetics laboratory, which are based on 
universal methods (Czepulkowski, 2001) with the following amendments. Two overnight 10 
ml suspension cell cultures using unselected MNCs (106 cells/ml) were set up in complete 
culture medium containing RPMI 1640 supplemented with 20% fetal bovine serum and 
reagents to final concentrations; L-Glutamine (2mM) and Penicillin-Streptomycin 50 U/ml 
(Gibco™, ThermoFisher Scientific). One of the cultures has Colcemid® (KaryoMAX™, 
ThermoFisher Scientific) added for the final 45 minutes of culture (0.1 µg/ml) and the other 
has a cocktail of 5-bromo-2-deoxyuridine (BrDU) (Sigma-Aldrich, Dorset, UK) (16mg/ml) and 
1/10th concentration Colcemid® added overnight. Both cultures are treated with 75 mM 
hypotonic solution of potassium chloride and are fixed in 3:1 methanol/glacial acetic acid, as 
per protocol. Chromosome preparations are made using GTL banding method (pg 14 ISCN 
2016; An International System for Human Cytogenomic Nomenclature 2016). A minimum of 
20 cells were analysed and reported using standard nomenclature (ISCN 2016; An 
International System for Human Cytogenomic Nomenclature 2016).  
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2.3.2 FISH 
Fluorescence in situ Hybridisation (FISH) was used to supplement conventional 
cytogenetic testing to investigate the molecular involvement of genes indicated by disease 
subtype (cell morphology and immunophenotype) or to confirm presence of a specific 
chromosomal abnormality detected by conventional cytogenetic analysis. FISH was 
performed on fixed cells from cytogenetic cultures following manufacturers’ protocols 
(Cytocell, Oxford Gene Technology, Begbroke, Oxfordshire), with the exception that the pre-
treatment stages were eliminated. 
2.3.3 PCR for NPM1 and FLT3-ITD mutations 
Routine diagnostic molecular genetic testing for NPM1 and FLT3 was performed at 
the Molecular Diagnostics Centre, Manchester Royal Infirmary using standard protocols, as 
follows. A number of cases were not tested at diagnosis and were tested retrospectively at 
the time of the project. Screening for NPM1 gene mutations was performed using a melting 
curve PCR assay with primers and fluorescent probes hybridising to the mutated region, as 
previously reported (Schnittger et al., 2005). All cases that showed an abnormal melting 
curve were analysed by Sanger sequencing, as described. Detection of FLT3-ITD mutation was 
performed with fragment analysis by PCR amplification of DNA with primers flanking the 
juxtamembrane coding sequence at exons 11 and 12 and the intervening intron. A 328bp 
fragment is produced from wild-type (WT) alleles and an additional band indicated FLT3-ITD.  
These cases were retested using semi-quantitative PCR and the level of mutant FLT3 
expressed as a percentage of the total signal (Kottaridis et al., 2001).  
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2.4 Next Generation Sequencing 
2.4.1 Target Selection 
42 target genes were selected for the project (see Section 1.3 ‘Genetic, cytogenetic 
and genomic influences in AML’), including all exons from the set of 30 genes known to be 
frequently recurrently mutated in AML for detection of SNV only (Figure 1.7), the positions of 
typical junctions of FLT3 internal tandem duplications and KMT2A partial tandem 
duplications, and exons and introns covering known breakpoints in genes of recurrent gene 
fusions in AML, including the breakpoint cluster regions in both partner genes of 
CBFB/MYH11, PML/RARA, DEK/NUP214, RUNX1/RUNX1T1, two genes with multiple fusion 
partners, KMT2A and NUP98, as well as two common partners of KMT2A (MLLT1 and MLLT3). 
All exons of RUNX1, as well as breakpoint cluster regions of the RUNX1-RUNX1T1 gene fusion 
were included (see Table 2.2 below). Genomic coordinates were extracted for HGP19 
locations from the Genome Browser tool suite (http://genome.ucsc.edu/cgi-bin/hgTables) 
(Kent et al., 2002) using Table Browser (Karolchik et al., 2004), with the following criteria; 
Clade = Mammal, Genome = Human, Assembly = GRCh37/hg19 (Feb. 2009), Group = Genes 
and Gene Prediction Tracks, track = RefSeq Genes (NCBI RefSeq release 45) and Table = 
refGene (see Figure 2.1). 
Under the “Region” header, using the “Define Regions” button, the list of target 
genes was uploaded and submitted. Filters were not applied. Output was selected in browser 
extensible data (BED) format. On the following screen ‘Output refGene as BED’ page, the 
desired features were selected as either ‘coding exons’ or ‘whole gene’, depending on 
whether exons only or exons and introns were required for specific genes (Figure 2.2). The 
exon coordinates for all possible splice variants were selected, to ensure capture of all coding 
regions. To limit the number of required baits and eliminate unnecessary sequencing, introns 
outside of the expected breakpoint regions were manually deleted from the resulting BED 
files. The ‘Merge BED files (mergeBed)’ function in Galaxy (Galaxy Version 2.22.1) was used 
to merge overlapping regions. The data was loaded as a track back into the UCSC genome 
browser as a visual check that the correct regions were selected. 
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Figure 2.1. UCSC Table Browser (http://genome.ucsc.edu/cgi-bin/hgTables) 
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Figure 2.2; UCSC Output refGene as BED (http://genome.ucsc.edu/cgi-bin/hgTables) 
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The BED file of the custom gene coordinates for the target regions was used to create the 
Agilent SureSelect custom, cRNA biotinylated oligonucleotide bait library (Agilent 
Technologies, Santa Clara, CA, USA) to capture relevant sequences. This was designed using 
Agilent SureDesign software (release version 3.5.2), Agilent’s proprietary algorithm to design 
optimal 120bp bait coverage and synthesise the custom capture reagents for the gene panel. 
The masking option used was “least stringent”, to avoid removal of repetitive regions in 
introns. To compensate, “Boosting” was set to “Maximise Performance” (see Table 2.1). To 
utilise the capacity of the library kit, the tiling density was set to 5x so that five different baits 
covered each base and allowed baits to overlap by 100bp to optimise DNA capture of 
repetitive, GC-rich regions. In the design, target regions were extended by 10 bases at 3' end 
and 10 bases at 5' end, to ensure adequate coverage at exon and target boundaries, as the 
majority of intronic single nucleotide variants listed as disease-causing mutations are within 
this distance and is the recommended minimal region of interest for the design of new 
targeted assays (Association for Clinical Genetic Science, 2015). 
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Table 2.1. Summary of SureSelect DNA design for custom AML sequencing panel 
 
 
Species H. sapiens (H. sapiens, hg19, GRCh37, February 2009) 
Target 
Summary 
490 Target IDs resolved to 490 targets comprising 490 
regions. 
0 Target IDs were not found. 
Region Size: 591.402 kbp 
Probe 
Summary 
Total Probes: 36572 
Total Probes Size: 591.579 kbp 
Coverage: 98.84292% 
Target 
Parameters 
Databases: RefSeq, Ensembl, CCDS, Gencode, VEGA, 
SNP, CytoBand 
Region: Entire Transcribed Region 
Region Extension: 10 bases from 3' end and 10 bases 
from 5' end. 
Allow Synonyms: No 
Probe Tiling 
Parameters 
Tiling density: 5x 
Masking: Least Stringent 
Boosting: MaximizePerformance 
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Table 2.2.  Genes selected for AML NGS sequencing project  
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      Start End       
ASXL1 chr20 all exons 30946137 31027132 13 7685 100.00 
BCOR chrX all exons 39910489 40036592 17 7329 100.00 
CBFB chr16 intron 5 67116243 67132612 1 16370 97.61 
CBL chr11 exons 1 - 15 119076976 119169260 15 2876 100.00 
CBL chr11 exon 16 119170195 119178869 1 8675 99.53 
CEBPA chr19 exon 1 33790830 33793480 1 2651 100.00 
CUX1 chr7 all exons 101459174 101927260 36 16576 100.00 
DEK chr6 intron 2 - intron 3 inc 18258294 18264073 1 5780 97.68 
DNMT3A chr2 all exons 25455820 25565469 27 6475 100.00 
EGR1 chr5 all exons 137801171 137805014 2 3176 100.00 
EZH2 chr7 all exons 148504454 148581451 23 3762 100.00 
FAM5C chr1 all exons 190066787 190446769 9 3097 100.00 
FLT3 chr13 exon 20 28592604 28592726 1 123 100.00 
FLT3 chr13 exon 14 - exon 15 inc 28608024 28608351 1 328 100.00 
GATA2 chr3 all exons 128198255 128369729 19 6569 100.00 
IDH1 chr2 all exons 209100941 209119877 12 3021 100.00 
IDH2 chr15 all exons 90627201 90645796 12 2096 100.00 
KIT chr4 all exons 55524085 55606891 22 5798 100.00 
KMT2A chr11 intron 2 - exon 13 inc 118339490 118360844 1 21355 99.11 
KRAS chr12 all exons 25357713 25403875 6 6009 100.00 
MLLT1 chr19 exon 1 - intron 6 inc 6218053 6304958 1 86906 97.22 
MLLT3 chr9 intron 4 - intron 8 inc 20354879 20448120 1 93242 99.45 
MYH11 chr16 intron 28 - intron 34 inc 15814170 15826565 1 12396 96.10 
NPM1 chr5 all exons 170814698 170837898 12 2020 100.00 
NRAS chr1 all exons 115247075 115259525 7 4594 100.00 
NUP214 chr9 exon 4 134006224 134007982 1 1759 100.00 
NUP98  chr11 intron 8 - intron 14 inc 3746450 3789810 1 43361 96.97 
PHF6 chrX all exons 133507332 133562832 14 8750 100.00 
PML chr15 intron 3 74315751 74317197 1 1447 100.00 
PML chr15 exon 6 - intron 6 inc 74325497 74326818 1 1322 100.00 
PTPN11 chr12 all exons 112856526 112947727 17 7072 100.00 
RAD21 chr8 all exons 117858163 117887115 14 4030 100.00 
RARA chr17 intron 2 38487649 38504567 1 16919 97.09 
RPS14 chr5 all exons 149823782 149829329 7 1245 100.00 
RUNX1 chr21 exons 6 - exon 9 inc 36160088 36206908 4 5664 100.00 
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RUNX1 chr21 intron 6 36206899 36231770 1 24872 99.42 
RUNX1 chr21 exons 1 - 5 36421455 36421605 7 2701 100.00 
RUNX1T1 chr8 intron 1 93029592 93115084 1 85493 99.16 
SETBP1 chr18 all exons 42260128 42648485 8 11132 100.00 
SF3B1 chr2 all exons 198256688 198299827 27 6779 100.00 
SMC1A chrX all exons 53401060 53449687 26 10540 100.00 
SMC3 chr10 all exons 112327439 112364402 29 4692 100.00 
STAG2 chrX all exons 123094400 123236515 38 7440 100.00 
TET2 chr4 all exons 106067022 106200970 13 19127 100.00 
TP53 chr17 exons 5 - 11 7571710 7578564 9 2387 100.00 
TP53 chr17 intron 4 - exon 5 7578361 7578821 1 461 98.26 
TP53 chr17 exons 1 -4 7579302 7590878 6 1037 100.00 
U2AF1 chr21 all exons 44513056 44527698 9 1200 100.00 
WT1 chr11 all exons 32409312 32457091 12 3638 100.00 
  * inc denotes inclusive. All interval is targeted    
 
Table 2.2 shows the gene targets selected for the project, including gene name, chromosome 
location and the start and end positions of the DNA sequence (according to Human Genome 
Assembly (GRCh37/hg19). ‘Regions’ denotes the number of separate regions that were 
included in the design and the size of the genomic target in base pairs. Coverage denotes the 
proportion of the region covered by target baits.  ‘inc’ in the Target column indicates 
‘inclusive,’ that all intervening sequences are targeted not isolated exons. 
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2.4.2 DNA Library Construction and Hybrid Capture 
1 µg of genomic DNA was sheared in a Covaris S2 ultrasonicator (Covaris, Woburn, 
MA, USA) to an average size of 150-200 bp. The resulting DNA was then end repaired and 
ligated to Illumina adapters (Illumina, San Diego, CA, USA) using the manufacturer’s protocol. 
Multiplexed libraries were prepared using the SureSelectXT Target Enrichment System for 
Illumina Paired-End Sequencing Library kit and a custom 42 gene panel SureSelect Target 
enrichment Library kit (Agilent). Molecular barcode index sequences were ligated to sample’s 
DNA to permit multiplexing of all thirty six specimens and sequencing in the same flow cells. 
Libraries were purified to remove small fragments of DNA and unligated adapters from the 
mix using AMPure magnetic beads (Agencourt, Brea, CA, USA). DNA targets were pulled 
down by solution phase hybridisation capture using the custom biotinylated RNA oligo pools 
in the custom kit designed in SureDesign, which was performed according to manufacturer’s 
instructions for the kit SureSelectXT Target Enrichment System for Illumina Paired-End 
Sequencing Library (Agilent Technologies). Streptavidin-coated paramagnetic beads were 
added and allowed to bind the biotinylated capture probes (see Figure 2.3). An external 
magnetic field was then applied and unbound DNA removed. The bound, captured DNA was 
eluted from the magnetic beads by digestion of the cRNA capture probes and purified. 
Successful capture was confirmed and library quality was checked on a high sensitivity DNA 
chip using the Agilent 2100 Bioanalyzer (Agilent Technologies, CA, USA). Libraries were 
quantified by qPCR using the KAPA Library Quantification Kit for Illumina (Kapa Biosystems, 
Wilmington, MA, USA). 
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Figure 2.3: Diagram of target enrichment workflow using SureSelect technology. 1. Library 
preparation and hybridisation set up. 2. Hybridisation. 3. Target capture. 4. Wash, elution 
and amplification. (Adapted from manufacturer’s diagram, reproduced with permission).  
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2.4.3 DNA Sequencing 
Libraries were pooled (5 µL per library) and quantified by PCR to determine molarity 
for loading onto the NextSeq flow cell to achieve optimal cluster density (170~220 k/m2). 1.8 
pM pooled libraries were denatured, diluted and loaded onto a reagent cartridge according 
to standard Illumina protocol. The enriched target DNA was then amplified using universal 
primers targeting the paired-end adapters and clusters generated. 2x 150bp paired end 
sequencing was performed on the NextSeq 500 desktop sequencer (Illumina, San Diego, CA, 
USA) with the 36 samples multiplexed on a single NextSeq 500 High Output setting (300 
cycles), using a NextSeq 500/550 High Output v2 kit (Illumina). The sample sequencing was 
run across multiple lanes to reduce the possibility of lane and position bias.  Eight FASTQ files 
(Cock et al., 2010) were generated for each specimen; two for each paired reads across four 
lanes of the flow cell. The FASTQ files were automatically uploaded to BaseSpace® (Illumina) 
cloud for storage of genomics data. 
2.5 Data Analysis 
2.5.1 Run Parameters and Quality Control 
The sequencing metrics variables were recorded and used as evidence of run quality 
to inform confidence in data interpretation. This included; 
 The number of reads before and after trimming, including the numbers of trimmed 
and untrimmed reads and the resulting mean read length. 
 The number of reads discarded as being below the Quality threshold and number of 
duplicates identified 
 Error rate 
 The number of remaining unique reads used to calculate the proportion of reads 
aligned to target regions and reads mapping to multiple regions 
 Proportion of target regions captured and covered in the sequencing reads 
 Number of reads mapped and the percentage of target covered at the minimum 
coverage required 
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 Average and median read depth was calculated for target regions. The number of 
bases and regions covered at various read depths was recorded, as an indication of 
the average depth and uniformity of coverage. This is an estimate of the quality of 
sequencing to sample the complexity of data across the target regions. 
 Range of insert size 
 Average base call Quality scores for each position as a Phred-based value on a log 
scale related to the base calling error probabilities (P)2 
The alignment algorithm and alignment settings (seed length, mismatch tolerance, mismatch 
penalties, gap penalties and gap extension penalties) were recorded 
Initial data analysis was performed within the Illumina online BaseSpace genomics analysis 
platform, BaseSpace®, which provides a computing environment with common analytical 
tools within its suite of software to integrate sequencing, data storage and analytical 
workflow. Initial quality metrics were assessed by running FASTQC analysis (v1.0.0) for each 
sample in the sequencing run using BaseSpace® Apps. 
2.5.2 Analysis of data for SNVs and short indels 
2.5.2.1 SureCall Pre-alignment Settings 
Pre-alignment filters were adjusted in configurable Settings in SureCall and saved as a 
specific workflow for the analyses, for the exclusion of reads or bases from downstream 
analysis. The threshold for end trimming was set to 5 bp and reads between 30%~100% of 
original read length were retained (default setting). FASTQ files were enabled with a 
minimum read depth of 20. The variant score threshold was 0.3 and minimum Q Score 
(Quality Score) was set to 30, which is considered the standard in NGS, equivalent to the 
probability of an incorrect base call 1 in 1000 times or that the probability of a correct base 
call is 99.9%. The minimum variant call quality score used was 100. The SNPPET parameters 
Minimum Mutant allele frequency adjusted to 0.01 (from 0.10) for inclusion of greater 
number of high quality reads at low frequency, to be inclusive and subject low frequency 
reads to downstream analysis to assess the performance of the assay to detect subclonal 
variants. A minimum of 10 reads were required to  support the variant call. 
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2.5.2.2 SureCall Method 
Data was analysed using Agilent SureCall software (v3.5.1.46) (Agilent Technologies), 
which includes widely accepted, open source algorithms, augmented with tools specific to 
Agilent assays for optimisation for use with Agilent target selection products. SureCall was 
used for quality control (QC) metric calculation, assembly, visualisation and contextualisation 
of sequencing results. The multiple raw FASTQ files from the Illumina Next Seq for each 
sample were downloaded from Basespace and each set of 8 FASTQ files uploaded to Surecall 
as a Single Sample analysis, to detect insertions and deletions in the individual samples. 
Residual adaptor sequences were removed from each read using cutadapt (Martin, 2011). 
Sequence reads were aligned to (GRCh37/hg19 Feb. 2009 assembly) using the Burrows-
Wheeler Aligner (BWA-MEM) (Li, 2013) and a BAM file was produced for each sample.(Li, 
2013) and a BAM file was produced for each sample. SNPPET, an algorithm designed by 
Agilent to enhance detection of low allele frequency variants, was preferred as an alternative 
to SAMtools for variant calling and alignment viewing as well as sorting, indexing, data 
extraction and format conversion within SureCall for the mosaic leukaemia cancer samples, 
with a range of VAF. Incorporating regions from the BED file of the SureSelect analysis design, 
SNPPET used information from the coordinate sorted BAM file with additional Region 
Padding to extend the ends of the analysable covered region (the sequencable region with 
first bases removed) in the sequencing data by 100bp. Duplicate reads were removed and 
the quality of reads was recalibrated. 
2.5.2.3 Annotation and Filtering of Variants to diagnostic reporting standards  
The practice of variant calling is developing in the UK and guidelines are available for 
general practice (Association for Clinical Genetic Science, 2013) and general guidelines for 
NGS (Association for Clinical Genetic Science, 2015; Rehm et al., 2013). Oncology samples 
present additional challenges and this area of practice is emerging (Dienstmann et al., 2014; 
Lee et al., 2015; Sukhai et al., 2015; Strom, 2016). These sources were used to devise the 
following strategy for variant calling for the AML project. It was necessary to use various 
variant calling algorithms, with different functionality, to display and annotate sample 
mutations (see Table 2.3). Text files of all variant calls for SNV and short indel analysis were 
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downloaded from SureCall and were imported into Microsoft Excel™ for manual examination 
and interpretation. The analysis of variant call files from other software is described below. 
Attempt was made to eliminate the false positive calls inherent in most NGS data (Clark et 
al., 2011; Wall et al., 2014) (see Technical Validation below). Having established that the data 
calls are likely to represent true variants in a patient’s DNA sample, it was then necessary to 
detect clinically relevant changes from background passenger changes and germline 
polymorphisms (see Clinical Validation below). The variants that neither cannot be 
eliminated as insignificant nor confirmed as clinically significant remain as Variants of 
Uncertain Significance (VUS). The following strategy for Variant Selection was devised a 
priori, as a standardised approach to interrogate exons for nucleotide substitutions and short 
insertion-deletion variants using SureCall. Examination of regions for structural variation, 
including introns for gene fusions and complex rearrangements, by specific software is 
described in other sections below.  
2.6 Rationale for Variant Selection 
A number of features of data quality were reported in SureCall and recorded as part 
of the sequencing audit trail, which were taken into account in technical validation of variant 
calls. This included the following (Association for Clinical Genetic Science, 2015); 
2.6.1 Base call quality score (Q Score) 
A base Quality score (Q Score) is a measure of the reliability of each base call and it is 
generated during sequencing and is assigned to each base call for every sequencing cycle 
during a sequencing run. Illumina Q Scores are computed measures of quality predictor 
values, such as intensity profiles and signal-to-noise ratios, compared to an empirically pre-
calibrated quality model (Q table) (Illumina, 2011; Illumina, 2014b).(Illumina, 2011; Illumina, 
2014b). A Q Score of less than 20 (equivalent to a P-value of 0.01) is considered low quality 
and will be removed from consideration (Strom, 2016) and generally scores less than 30 were 
filtered from downstream analysis. 
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2.6.2 P-value 
Variant calls with a P-value of >0.01, as calculated within SureCall, were eliminated 
from further consideration. 
2.6.3 Read Depth 
The minimum depth of coverage was established for ‘true’ read depth as a measure 
of the number of independent, overlapping sequence alignments at a locus of interest. 
Coverage was determined for unique reads only, following removal of any duplicate reads 
which probably represented copies generated by amplification during the library 
preparation. A minimum read depth of 100x was considered desirable for single nucleotide 
detection, to avoid missing low level variants and to filter sequencing artefacts. However, this 
was reduced for multiple reads confirming the same complex variant and the target was 
adjusted. Where a definite pathogenic mutation was identified and confirmed, regions of 
sequence not meeting the required read depth were accepted and described as low coverage 
(Association for Clinical Genetic Science, 2015; Strom, 2016; Rehm et al., 2013). 
2.6.4 Variant read number and Variant Allele Frequency (VAF) 
10 independent reads supporting the presence of a single base variant was 
considered the number below which would indicate a false positive signal, to accommodate a 
higher number of false reads expected with increasing read depth (Strom, 2016; Wall et al., 
2014). Variant allele frequency was calculated as the proportion of mutated reads versus 
total number of reads covering that base. It was decided to be permissive with variant read 
proportion and to allow the a VAF threshold of 1%, providing higher specificity (and reduced 
sensitivity) and submit these variants for scrutiny of their clinical significance, as a measure of 
test sensitivity (see below), to test the assay in its intended use as routine testing without 
confirmatory control sample or parallel testing. 
2.6.5 Variant Quality Scores (QUAL) 
Variant quality scores (QUAL) are similar to base quality score and are transformed 
log scale Phred-like scores generated during the variant calling step and are included in the 
Variant Call File (VCF) for an analysis (Strom, 2016). QUAL is an estimate of the confidence 
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that the variant caller correctly identified that a given genome position displays variation in 
at least one sample; a score of 90 is equivalent to P value of 1x10-9. The threshold for the 
project was set at 100. 
2.6.6 Strand Bias 
Strand bias is a measure of likelihood that variant reads are detected equally on + and 
– DNA strands and deviation from equivalence indicates that that the variant is an alignment 
artefact. Forward and reverse read data was manually examined and considered in variant 
calling. 
2.7 Clinical Validation of Variants 
Having excluded technical artefacts which would be likely false positive variants with 
insubstantial credentials to be considered as genuine sequence changes, it was then 
necessary to attempt to filter non-pathogenic variation non-pathogenic in AML, including 
germline single nucleotide polymorphisms (SNPs) and more challengingly, somatic passenger 
mutations of no clinical effect. Some variants will be common and immediately recognisable 
as recurrent driver mutations and clearly pathogenic. It was necessary to apply certain 
criteria to reduce subjectivity for downstream filtering and provide high confidence variants 
in clinically relevant information leading to annotation (from RefSeq database), leading to 
simulation of diagnostic standard reports. For those variants that are not clearly pathogenic, 
several means were used of interpreting clinical significance, to provide high confidence. 
2.7.1 Filtering benign germline polymorphisms (SNPs) 
The presence of a variant in an unaffected individual at population risk was used as 
evidence of non-pathogenicity. Benign germline polymorphisms were defined as variants 
with a population frequency of ≥1% (in dbSNP, a large normal population screening 
databases) were excluded as probable germline SNPs. All variants passing initial filtering were 
manually interrogated and those suspicious for germline polymorphisms were excluded (with 
VAF of 50% or 100%, reflecting germline heterozygous or homozygous state respectively). To 
screen for lower frequency germline variants, all those detected at <1% frequency were 
manually interrogated and retained for further analysis, if they had a corresponding COSMIC 
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database entry with multiple reports in malignancy, particularly in haematopoietic tissue of a 
confirmed somatic variant. 
2.7.2 Filtering non-pathogenic variation  
Variant calls were further assessed to eliminate variants of no significance in AML. The 
association of the variant and its frequency in AML (and possibly or other tumours) was 
assessed by examination of the COSMIC database and multiple entries in haematopoietic and 
lymphoid tissue showed co-segregation with AML and were considered evidence as evidence 
of pathogenicity. Apparent somatic variants not found in haematological neoplasia but with 
apparent functionality in other cancer subtypes were scrutinised further. Other cancer 
databases and online tools for these variant annotation tasks were consulted as necessary, 
such as:  
 ClinVar - https://www.ncbi.nlm.nih.gov/clinvar/ 
 My Cancer Genome (https://www.mycancergenome.org/ 
 cBioPortal - http://www.cbioportal.org/ 
 HGMD - http://www.hgmd.cf.ac.uk/ac/index.php 
 OMIM -https://www.ncbi.nlm.nih.gov/omim 
 
The use of locus specific databases (LSDB) was limited for this study but TP53 database would 
be consulted if necessary. Manual curation of primary PubMed citations, professional 
guidelines; and comprehensive clinical, genetic, biochemical, and functional database 
searches, and clinical trials of possible targeted therapies were checked as appropriate. 
Although the main aim of the project is not to mine for novel variants of ambiguous clinical 
significance, in silico prediction of oncogenicity using tools for predicting the biochemical 
dysfunction of the variant were considered such as SIFT (and as necessary others such as 
Provean, PolyPhen-2, MutationTaster, CADD) to substantiate evidence for 
damaging/deleterious or potentially driver mutations. Variants were described in accordance 
with the Human Genome Variation Society (HGVS) recommendations (Human Genome 
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Variation Society (HGVS), 2016) or the coding sequence derived from Reference Sequence 
(RefSeq) (National Center for Biotechnology Information (NCBI), 2016). 
2.7.3 Identification of actionable cancer-associated somatic mutations 
Once benign or likely benign variants were excluded, three categories of actionability 
were used although for clinical purposes this could be refined (as defined by a new 
classification system – see Table 3.5) (Lin et al., 2017): 
1. Known actionable (direct impact on patient care) 
2. Potentially actionable (somatic mutation with biological relevance not previously 
reported) 
3. Variant of unknown significance (VUS) (likely somatic mutation with uncertain effect).  
2.8 Variant Annotation using SureCall 
SureCall used several tools to provide input for the mutation classification. SureCall 
also identified additional information, including the chromosomal location of the mutation 
with Human Genome Variation Society (HGVS) nomenclature. Each mutation was evaluated 
by the software based on its location, amino acid change, and effect on protein function 
(SIFT) (Hu & Ng, 2013) and impact on structure and function of the protein using the 
Polymorphism Phenotyping v2 (PolyPhen-2) tool. Further information regarding the mutation 
was then aggregated from various public sources, including National Center for 
Biotechnology Information (NCBI) Database of Genomics Structure Variation (dbVar), 
COSMIC (Catalogue of Somatic Mutations in Cancer), PubMed, and Locus-Specific Databases. 
After collecting the various inputs for classification, the proprietary mutation classifier 
evaluated the significance of the mutation following default guidelines. Each variant was 
then independently examined by triaging each mutation and reviewing supporting evidence. 
Mutation calls were examined in the built-in Integrative Genomics Viewer (IGV) 
(Thorvaldsdottir et al., 2013) to confirm regional coverage, visualize read alignments and 
confirm variant calls.  
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2.8.1 Analysis of data for SNVs and short indels using GATK HaplotypeCaller 
FASTQ reads from each sample were aligned to the GRCh37 human genome using 
Burrows-Wheeler Aligner (BWA) (Li & Durbin, 2009). SAM alignment files were then 
converted to sorted, indexed BAM format using Picard tools from the Broad Institute (Broad 
Institute, 2017).  BAM files for each sample from four lanes were merged using Picard into a 
single unified BAM file, so that full depth of coverage could be estimated and that duplicates 
for the whole sample could be removed. Indel-realignment and Base Quality Score 
Recalibration (BQSR) were performed using GATK 3.6 (McKenna et al., 2010), as 
recommended in guidance (DePristo et al., 2011; Van der Auwera et al., 2013). Extra effort 
realignment was performed in order to take advantage of high depth. Variants were called 
using the joint genotyping procedure which allows low frequency variation in one sample to 
be rescued statically by evidence from another. Following alignment and variant calling, hard 
filtering was performed, which used a set of pre-defined hard cut-offs for variation to be 
included, producing filtered VCF files for all samples containing the variants passing the 
filters. Following filtration procedures, filtered VCF files were used as the input to Ensembl 
Variant Effect Predictor (VEP) (McLaren et al., 2016). 
2.8.2 Indel and Structural Variations Calling using Pindel 
Pindel (version 0.2.5b9) (Ye et al., 2009) was used to detect breakpoints of large 
deletions, medium sized insertions, inversions, tandem duplications and other structural 
variants at single-base resolution, within the targeted regions from the merged BAM files 
from. The event finding algorithm was set to maximum size, to detect the largest possible 
events. Of the Parameters which affect which structural variants are reported, the ‘--
report_interchromosomal_events’ option was activated in attempt to detect gene fusions. 
The output from Pindel was in the form of a text file for each type of structural event, in a 
specific format, including in many cases a text-drawn diagram of how the reads are stacked 
up as evidence for particular events (User Manual from The Genome Institute at Washington 
University School of Medicine, 2014).   
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2.8.3 Gene fusions and Structural Variation Calling using LUMPY 
LUMPY (version 0.2.13) (Layer et al., 2014) was used to detect gene fusions and other 
structural variation (SV). LUMPY provides a mechanism based upon probability distributions 
of an SV breakpoint that allows evidence from multiple alignment signals to be 
simultaneously integrated into a single detection algorithm, which includes discordant read-
pairs and split reads, as well as other signals such as read depth and prior knowledge of the 
SV breakpoint. LUMPY aligns the discordant read-pairs and determines a pair of intervals 
upstream or downstream of the mapped reads as possible breakpoint positions; the 
evidence from the alignment signals is mapped to the breakpoint intervals and the 
probabilities of overlapping intervals and clustered breakpoints are integrated. Any clustered 
breakpoint region that contains sufficient evidence is returned as a predicted SV. LUMPY was 
downloaded from (https://github.com/arq5x/lumpy-sv) and lumpyexpress was run on the 
BWA / Picard produced BAM files. The individual BAM files from each of four sequencing 
where ran separately in order for lumpyexpress to accurately detect split and discordant 
reads. The output from LUMPY is in the form of a VCF file v.4.2 (Samtools, 2015) which were 
converted to text files and imported into Microsoft Excel. The number of reads was encoded 
into the genotype field as ‘SU,’ ‘PE.’ and ‘SR’ in the final column of the VCF output. The 
minimum number of supporting reads for an event to be reported in LUMPY was 4. Different 
types of events with multiple supporting reads were examined and particularly, the presence 
of gene fusions were examined as represented in the INFO field as SVTYPE=BND (a break 
end), which were also present as paired events with pairs of IDs on adjacent lines. 
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Table 2.3. List of Analysis Software accessed for project 
 
Pipeline step Software Software 
Suite 
Function 
Adapter 
trimming 
FASTQ Toolkit 
2.0.0 
Basespace Removal of residual adapter sequences from 
reads 
Cutadapt Surecall Removal of residual adapter sequences from 
reads 
Quality control FastQC Basespace Quality metrics for sequencing 
Highlight sequencing errors 
Mapping/Read 
Alignment 
BWA-MEM SureCall Aligns FASTQ files from samples to the 
reference genome. Create index. Read 
alignment generate alignment metrics. 
Duplicate removal 
Haplotype 
Caller 
GATK Read alignment generate alignment metrics. 
Duplicate removal. 
Pre-processing Picard In BWA, 
Basespace 
Mark duplicates 
Samtools In BWA, 
Basespace 
Convert SAM to BAM, fix read pairing 
information and flags, sort BAM by 
coordinates. Merge and index BAM files, 
Calculate alignment statistics. 
Post-alignment 
QC 
FastQC Basespace QC info on alignments on merged BAM files 
BamQC  QC info on alignments on merged BAM files 
Variant calling BWA-MEM SureCall Detection of SNV and small indels 
Variant 
Quality Score 
Recalibration 
(VQSR) 
GATK Variant filter 
SNV calling 
Pindel - Detection of large scale indels 
Lumpy - Identification of discordant paired end reads 
or split end reads to detect gene fusions 
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Quality Control e.g. FastQC 
Sequence Alignment (BWA-MEM) 
Pre-processing (SNPPET) 
Mark duplicates 
Base quality score recalibration 
Add/replace read groups 
Local realignment 
Variant Calling 
Calling SNVs and short indels (SNPPET, Surecall) 
 
Sample and run level quality control 
Variant filtering, annotation and validation (IGV) 
Adapter trimming (cutadapt) 
Sequence Alignment (GATK HaplotypeCaller) 
Pre-processing (GATK) 
Mark duplicates 
Base quality score recalibration 
Add/replace read groups 
Local realignment 
Variant Calling 
Calling SNVs and short indels (Haplotype Caller, 
GATK) 
 
Calling long indels (Pindel) 
 
Calling gene fusions (Lumpy) 
 
Figure 2.4. Analysis Pipeline of Software used for the project and data flow 
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2.9 Orthogonal sequencing using Ion Torrent 
AML project samples with sufficient DNA and expected to be most informative were 
selected for sequencing using Ion Personal Genome Machine™ (PGM™) System (Thermo 
Fisher Scientific Inc.), for comparison of the somatic mutations detected by the main project. 
10ng of DNA (see Table 2.4 and Table 3.7 in Results) was used to create a targeted 
sequencing library using Ion AmpliSeq™primers for the AML Community Panel (Ion 
AmpliSeq™ AML Research Panel), targeting the coding regions of known mutations in 21 
commonly mutated genes involved in AML. A modified protocol, AmpliSeq™ AML Protocol 
Modifications for 4-Pool Panel (https://ioncommunity.thermofisher.com/docs/DOC-8939 
accessed 30/03/2016), was used to enhance GC rich regions that are difficult to amplify 
consistently. The library was prepared from resulting amplicons using Ion AmpliSeq™ 
Library Kit 2.0.  Automated template preparation for 200 base-read libraries was 
performed using an automated Ion OneTouch™ 2 System with Ion PGM™ Template OT2 200 
reagent kit, yielding barcoded libraries using Ion Xpress™Barcode Adapters 1-96 Kits. Six 
barcoded samples were loaded on to each of five Ion 318™ Chips (kit v2.0), the 
recommended, optimal capacity to detect enabling 4~5.5 million reads per chip at target 
>95% 500x base coverage. Sequencing was performed in April and May 2015 on an Ion 
Personal Genome Machine™ (PGM™) System semiconductor-based sequencer, which uses 
digital reads of polymerase-driven base incorporation. Standard Ion PGM™ Hi-Q™ 
Sequencing Kit reagents were used. 
Sequencing data was uploaded to Ion Reporter™ Software v5.0 
(https://ionreporter.thermofisher.com/ir/ last accessed 29/09/2015), which comprises a 
suite of bioinformatics tools to provide a workflow from data import, detection of SNPs, 
indels, and annotation of variants. BAM files were generated by use of the standard pipeline. 
Detects and annotates low frequency variants (SNPs, Indels) from targeted DNA libraries 
from the Ion AmpliSeq™AML Cancer Research Panel. Target regions AML hg19,  Custom 
filters COSMIC (v67), 0.0 <= PValue <= 0.01, Filtered Coverage >= 250, 100 <= Allele Read-
Count <= 100000, dbSNP. 
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Table 2.4. Genes covered in the Ion AmpliSeq™ AML Cancer Research Panel. 
 
This utilises 237 amplicons to analyse 19 genes implicated in AML 
 
*Hotspot regions  
 
 
 
 
ASXL1* FLT3* KIT* RUNX1* 
BRAF* GATA2 KRAS* TET2 
CBL* IDH1* NPM1* TP53 
CEBPA IDH2* NRAS* WT1* 
DNMT3A JAK2* PTPN11*   
*Hotspot regions 
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3.0 Results 
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3.1 Patient population 
Samples were collected from patients referred with a possible diagnosis of AML, and 
that also had sufficient surplus cells after diagnostic testing. After the diagnosis of AML had 
been confirmed, DNA was extracted and thirty-six samples with DNA of adequate quality and 
quantity for the range of sequencing studies were used. Five samples were rejected for 
having a poor yield of DNA. Two samples were later confirmed to be pre-treatment, 
diagnostic bone marrow aspirate samples from the same patient (13.1141 and 13.1485). 
There were 20 male and 15 female patients. The cases were representative of the typical age 
range in AML; the median age of the patient cohort was 64 (range 14-84). There were two 
adolescent patients (ages 14 and 16) and 20 patients were aged 60 or over (see Figure 3.1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Age distribution of participants in the AML sequencing project 
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3.2 Cytogenetic and standard molecular testing 
Thirty-five out of thirty-six samples were successfully cytogenetically analysed; one 
sample failed to yield sufficient analysable metaphases. The majority of patients (68%) 
showed intermediate risk cytogenetics; 18 showed a normal karyotype (CN-AML) and 5 
patients with intermediate risk abnormalities, including various non-specific abnormalities 
common to myeloid neoplasia. Sample 23 was found to have t(11;19)(q23;p13.3) with 
KMT2A-KMT2AT1 by FISH. Sample 13 showed a NUP98 gene rearrangement by FISH, 
apparently resulting from a large pericentric inversion of chromosome 11, inv(11)(p15q22).  
Six patients had favourable cytogenetics, two had acute promyelocytic leukaemia 
with t(15;17) and PML-RARA gene fusion. CBF-AML was diagnosed in four patients, three 
with inv(16)/t(16;16) and CBFB gene rearrangement and one with t(8;21) with RUNX1-
RUNX1T1. Specific gene fusions were confirmed by FISH. The remaining 6 samples showed 
karyotypes with adverse prognostic features, two of which were from the same patient and 
showed karyotypes which were both complex (≥4 abnormalities) and monosomal. As would 
be expected, the APL and CBF-AML patients were of lower median age (27.5 years) compared 
to remaining patients (NK-AML and other abnormal) (67 years). The remaining 6 samples 
showed karyotypes with adverse prognosis, two of which were from the same patient and 
showed karyotypes which were both complex (≥4 abnormalities) and monosomal karyotypes.  
Thirteen NPM1 exon 12 mutations (36%) and eleven FLT3-ITD (31%) were detected by 
conventional molecular genetic studies. Six patients were NPM1 mutated alone 
(NPM1+/FLT3wt) (17%), four patients FLT3-ITD alone (NPM1wt/FLT3-ITD+) (11%), and seven 
were double mutated (NPM1+/FLT3-ITD+) (19%). All showed normal karyotypes with the 
exception of Sample 18 who was NPM1+/FLT3wt with a non-specific abnormal karyotype, 
apparently involving rearrangement of chromosome 5. In Patient 5, who showed double 
mutation, NPM1+/FLT3-ITD+, the conventional cytogenetics failed and negative results were 
obtained with the panel of FISH tests. Of the four cases with NPM1wt/FLT3-ITD genotype, 
two also showed translocations by cytogenetics; t(8;21) and t(15;17) (summarised in Table 
3.1 and details in Table 3.2). 
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Table 3.1. Summary of clinicopathologic characteristics of 35 patients with AML 
 
Features Number (%) 
Gender 
Male 
Female 
 
20 (57%) 
15 (43%) 
Age years (median/range) 62.5 (14-84) 
Cytogenetics 
Favourable 
APML/t(15;17) 
CBF-AML / inv(16)/t(16;16) 
CBF-AML / t(8;21) 
Intermediate 
Normal karyotype 
Other abnormalities 
Adverse 
Complex 
 
 
2 (5.5%) 
3 (8.3%) 
1 (2.7%) 
23 (63.9%)  
18 (50%) 
5 (13.9%) 
5 (13.9%) 
1 (2.7%) 
Molecular Genetics 
NPM1+/FLT3wt 
NPM1wt/FLT3-ITD 
NPM1+/FLT3-ITD 
 
6 (16.7%) 
4 (11.1%) 
7 (19.4%) 
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Table 3.2 - Patient samples and routine cytogenetic and molecular genetic profiles 
Samples 10 and 14 are pre-treatment diagnostic samples from the same patient 
Sample No. Sex Age Karyotype FISH positive results (%) Other FISH tested (negative results) NPM1 FLT3 
1 F 75 46,XX,del(5)(q15q33)[4]/46,XX[6] Deletion of EGR1 at 5q31 (56%)   neg neg 
2 F 67 46,XX,idic(7)(q11.2)[4]/46,XY[6] Deletion 7q detected (55%)   neg neg 
3 M 83 46,XY[20]   KMT2A neg neg 
4 F 70 46,XX[20]   BCR-ABL1 neg pos 
5 F 74 Failed   5q31, 7q31, TP53, KMT2A pos pos 
6 F 84 46,XX[20]     neg neg 
7 F 53 46,XX[20]   PML/RARA, KMT2A pos neg 
8 M 79 46,XY[20]     pos neg 
9 M 42 46,XY,t(15;17)(q24.1;q21.1)[9]/46,XY[1] PML-RARA gene rearrangement 
(94%). 
  neg neg 
10 M 60 41~47,XY,del(1)(q41q42),add(2)(p13),-5,-7,+8,+11,add(13)(q14), 
der(13;21)(q11;q11),add(17)(p11.2),-18,-20,-
21,+22,+1~5mar[cp9]/46,XY[1] 
  CBFB, RUNX1/RUNX1T1 neg neg 
11 M 65 46,XY[20]     neg neg 
12 M 58 46,XY[20]   PML-RARA, RARA pos neg 
13 M 64 47,XX,+inv(11)(p15q22)[10] NUP98 gene rearrangement (77%)   neg neg 
14 M 60 41~46,XY,del(1)(q41q42),-5,-7,+8,add(13)(q14),add(17)(p11.2),-18,-
20,-21,+1~2mar[cp5]/46,XY[5] 
    neg neg 
15 M 61 46,XY[20]     pos neg 
16 M 25 46,XY,inv(16)(p13q22)[10] CBFB gene rearrangement (80%) PML/RARA neg neg 
17 F 47 46,XX[20]   PML/RARA, RARA, BCR/ABL1 pos pos 
18 M 37 48,XY,+del(5)(q?12q?33),+8,der(20)t(1;20)(q12;q13.3)[8]/46,XY[2]     pos neg 
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Table 3.2 (continued) 
Sample No. Sex Age Karyotype FISH positive results (%) Other FISH tested (negative results) NPM1 FLT3 
19 F 16 46,XX,t(15;17)(q24.1;q21.1)[10] PML-RARA gene rearrangement 
(91%) 
  neg pos 
20 M 73 46,XY[20]     pos pos 
21 F 66 46,XX[20]   KMT2A pos pos 
22 M 77 46,XX[20]   CBFB pos neg 
23 F 69 46,XX,t(11;19)(q23;p13.3),del(12)(p11p13)[10] KMT2A-KMT2AT1 gene 
rearrangement (82%), deletion of 
ETV6 (94%). 
  neg neg 
24 M 25 45,X,-Y,t(8;21)(q22;q22.3)[10] RUNX1-RUNX1T1 gene 
rearrangement (95%) 
  neg pos 
35% 
25 M 74 46,XY,der(9)t(9;11)(q34;q13)[4]/46,XY,der(9)del(9)(q13q34)t(9;11)
(q34;q13)[6] 
Gain of KMT2A (70%) KMT2A, BCR-ABL1 neg neg 
26 F 54 49,XX,+6,+7,+8[9]/46,XX[1]   PML/RARA, RARA, BCR-ABL1, 
KMT2A 
neg neg 
27 M 42 46,XY,del(9)(q?13q?22)[3]/46,XY[28]   MECOM, KMT2A, RUNX1/RUNX1T1 neg neg 
28 M 75 46,XY[20]     neg pos 
29 M 53 46,XY[20]   KMT2A pos pos 
30 F 30 46,XX,t(16;16)(p13;q22)[17]/46,XX[3] CBFB-MYH11 gene rearrangement 
(48%) 
  neg neg 
31 M 68 46,XY[20]     pos pos 
32 M 46 46,XY[20]   KMT2A pos pos 
33 M 40 46,XY,inv(16)(p13q22),i(22)(q10)[5]/47,XY,inv(16)(p13q22),+22[5] CBFB gene rearrangement (66%)   neg neg 
34 F 71 46,XX[20]     neg neg 
35 F 79 45,XX,-7[6]/47,XX,+8[4]     neg neg 
36 F 14 46,XX[20]   KMT2A, NUP98 neg neg 
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3.3 Illumina sequencing of the custom NGS panel 
3.3.1 Run level performance of custom panel sequencing 
The libraries from 36 DNA samples were sequenced as described in the Methods 
(section 2.3 and 2.4) to produce paired end reads with a single index tag (8bp). 150 
informative cycles for each read cluster were obtained and the yield (Gbp) is shown in Table 
3.3. The percentage of the sample that aligned to the control PhiX genome was used to 
calculate the error rate, including at specific cycle points during the sequencing run (Illumina, 
2014a). The signal intensity at cycle 20 (as a proportion of intensity at cycle 1) and the 
percentage of reads with Q Score ≥ 30) is shown in Table 3.3. Overall, 83.7% of base calls 
achieved a Q Score of ≥ 30 (87.1% of Read 1 and 79.7% of Read 2) (see Figure 3.2), with an 
estimated error rate of 1.39% (1.08% of Read 1 and 1.69% of Read 2). 
 
Table 3.3. Run Metrics Summary 
  Cycles Yield 
(Gbp) 
Aligned to PhiX 
genome control 
(%) 
Error Rate  
(%) 
Intensity 
Cycle 
20/1*100 
≥Q30 
(%) 
Read 1 151 69.49 0.89 1.08 4,292 87.42 
Read 2 151 69.45 0.85 1.69 4,847 80.00 
Non-Index Reads 
Total 
302 138.93 0.87 1.39 4,569 83.71 
Totals 310 142.18 0.87 1.39 4.055 83.95 
 
The total number of reads for the 36 sample runs was 512,880,334, with 463,258,793 of the 
indexed read clusters passing quality filtering. The indexing QC results for the run showed 
that there were no unexpected results for a sample and that all indexed samples were 
properly represented. The mean number of reads per sample was 12.39 million (standard 
deviation 1.04 million, range 10.46~14.87m). Indicating that there was even coverage across 
different lanes of the flow cell and good representation of reads from each sample 
(maximum and minimum % reads per sample per lane = 3.2241 and 2.2495 respectively) (see 
Table 3.4). The run metrics from Ion Torrent sequencing are presented in Appendix 3 (see 
section 7.3).  
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Figure 3.2. Histogram showing distribution of Quality Scores (total read 1 and 2) showing 
proportion of reads ≥ 30 (green) 
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Table 3.4. Index Performance Summary 
Flow 
Cell 
Lane 
Total 
Reads 
Reads 
Passing Filter 
Identified 
Reads 
Passing 
Filter (%) 
Coefficient 
of Variation 
Reads per 
sample  
Identified 
Minimum% 
Reads per 
sample 
Identified 
Maximum% 
1 131999850 120908797 96.4733 0.0847 2.2513 3.2241 
2 130027750 119339052 96.3578 0.0842 2.2495 3.2057 
3 126349863 112689372 96.2354 0.0836 2.2676 3.2099 
4 124502871 110321572 95.9765 0.0836 2.2688 3.2011 
 
 
3.3.2 Sample level post-alignment quality statistics from SureCall BWA-MEM 
Quality Control (QC) reports for each sequence alignment were generated from 
SureCall, downloaded and assimilated into an Excel spreadsheet. A mean of 22,909,567 reads 
(SD 1,169,853) were present in untrimmed FASTQ files and 22,900,409 (SD 1,169,321) after 
trimming. The resulting average read length was 143 (SD 0.41). A mean of 10,667,341 reads 
were trimmed and 12,233,068 remained untrimmed. 9,158 reads were discarded. 3,443,288 
(SD 275,847) were duplicate reads, ranging from 13.81% and 16.27% of the total trimmed 
reads. This is expected and acceptable for this sequencing run.  
36.97~38.79% mapped to target regions, which was expected due to capturing 
multiple regions with repetitive elements. 4.95-5.37% of reads mapped to multiple locations 
and 0.10% of reads of covered regions had no coverage. The mean number of analysable 
reads in covered regions was 6,816,275 (SD 295,846) (36.29~38.08%). The overall average of 
and median read depths in analysable target regions was 1,650 (SD 70.64) and 1,805 (SD 
74.03) respectively. 99.9% of analysable target bases had at least 10 reads, 98.96% at least 
100 reads, 93.39% at least 500 reads and 82.22% at least 1,000 reads. All analysable target 
regions had at least 10 reads, 98.85% at least 100 reads, 94.66% at least 500 reads and 
88.84% at least 1,000 reads. These figures suggested a run of good quality, as demonstrated 
by Average Target-Coverage plot and Covered Region-Coverage plot from SureCall QC 
reports. 
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3.3.3 Sample level quality statistics from FASTQC and BAM QC reports 
FASTQ files were analysed using FastQC and BAMQC using analysis modules in 
Illumina Basespace, to provide further quality control checks on raw sequence data from the 
NGS pipeline. Sample level, post-alignment quality control reports were generated 
automatically by SureCall. These contain a modular set of analyses, based on different 
parameters, to highlight issues with the data prior to further analysis. Formal reports are 
presented with summary graphs and tables. There were no problems or biases detected in 
the sequencer or in the starting library material. 
3.3.4 SureCall suite of software for sequence alignment and variant annotation 
A mean of 855 variants per sample (range 725~989) were identified using the SureCall 
settings described in Methods (see Sections 2.7 and 2.8). Using the filtration criteria 
described in section 2.6, all variant calls showed extremely low P-values, indicating high 
confidence in the validity of the reads. All reads met the criteria for Variant Quality Score 
(mean 229.5, SD 51.4, range 103~255) outlined in section 2.5. A number of SNVs with small 
variant read number and low VAF showed reads of dubious significance. In particular, a series 
of 12 U2AF1 homozygous SNV calls (at 21:44513243 G>A) (VAF 0.0205-0.0532) were 
removed despite having a COSMIC reference. Also, nine homozygous SETBP1 exon 4 
tetranucleotide insertions (all at 18:42456664) and three SMC1A exon 2 substitutions with 
significant strand bias, particularly at low read depth or VAF, were eliminated from further 
consideration. The strategy detected a number of reads of VAF of less than 5%. These were 
not detected by Ion Torrent PGM sequencing, and are therefore not validated and remain 
classified as Variants of Uncertain Significance. It is possible that they are subclonal variants 
that may emerge as significant disease clones later in disease course, but it is likely they are 
artefacts of sequencing and will not be considered as clinically significant at this time. NPM1 
and CEPBA indels showed multiple low VAF variants at similar loci and were assumed to be 
misreads of the same source sequence and the apparently aberrant reads were removed 
(see Indel section below). Low level variants were retained if they had a COSMIC annotation 
suggesting recurrence as a potentially pathogenic variant in a haematological tumour. 
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3.3.5 Variant Annotation from SureCall, Pindel and Lumpy alignments 
Table 3.6 shows all variants that are classified as pathogenic or likely to be of clinical 
significance. These variants had not been detected previously from conventional testing at 
diagnosis. The indels and gene fusions are also included in Table 3.6, some of which were 
detected previously, if specifically tested or identified in the karyotype. 
A total of 196 variants were retained after the initial filtering process. Each variant 
was then reviewed in detail and characterised using COSMIC, published literature and other 
on line resources as necessary. Variants were annotated according to recently published 
guidelines (Li et al., 2017) and were curated as Tier I or Tier II variants based on Levels of 
evidence A – D (see Table 3.5; Categories of Evidence for Somatic Variant Interpretation). Variants 
of Uncertain Significance (VUS) and Benign variants were excluded from further 
consideration and not included in the variant Table (see Table 3.6). Variant passing 
assessment filters and annotated as strong or potential clinical significance (Tier I or Tier II) 
from the three sets of data from the analytical pipeline were assimilated (Table 3.6). 143 
genetic abnormalities were retained after variant annotation described in section 2.5.2.3. 
This included 46 Level A variants (Tier 1 Variants of Strong Clinical Significance). 7 IDH1/2 
known mutations (2x IDH1 R132, 4x IDH2 R140Q and 1x IDH2 R172K) were interpreted as 
Level C evidence for diagnostic significance and putative therapeutic targets. The remaining 
90 variants were assigned as Level D markers that may assist diagnosis, alone or with other 
mutations (Li et al., 2017). All seven gene fusions found by standard techniques were also 
detected by the experimental NGS. Other recurrent abnormalities included thirteen NPM1 
exon 11 tetranucleotide insertions, ten FLT3-ITD, four FLT3-TKD and fifteen CEBPA mutations, 
five were heterozygous single mutations, two were homozygous mutation and six were 
double mutation in three patients. The two samples from the same patient (samples 10 & 14) 
showed the same TP53 exon 8 mutation. 
 Eleven variants were called at a VAF of less than 10%. Three variants were not 
covered in the Ion Torrent panel and so could not be confirmed. 4 mutations were identified 
by both NGS methods, with the smallest VAF of 2.4%; however, the level detected by Ion 
Torrent was reported as 7.5%. An ASXL1 SNV at VAF 0.1% could not be confirmed by Ion 
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Torrent. Double KIT mutations (in patient 13.1760) at 1.8% and 1.5% were also not confirmed 
by Ion Torrent, but were found in a typical setting, secondary to CBFB-MYH11 fusion.  
Overall, 105 out of 112 variants (93.8%) that were sequenced by both NGS systems 
were in agreement. Two mutations (1x DNMT3A at VAF 0.18 and 1x RUNX1 at VAF 0.15) 
could not be confirmed by Ion Torrent. The DNMT3A was an insertion of 22 nucleotides in 
exon 14 and RUNX1 a single base pair in exon 6. Two CEBPA variants were not called by Ion 
Torrent, in sample 27, who was also showed to have a 6bp insertion. The sequencing 
anomalies and CEPBA sequencing will be discussed.  The Variant allele Frequency (VAF) of 
selected variants ranged from 0.0105 – 0.969, with a median of 0.444 and mode 0.45 – 49 
(see Figure 3.4). 
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Table 3.5. Categories of clinical and/or experimental evidence for Somatic Variant Interpretation (adapted from Li et al., 2017) 
Tier Category Therapeutic Diagnosis Prognosis 
I Level A 1. Biomarkers that predict response or resistance 
to FDA-approved therapies for a specific type of 
tumour                                                 2. Biomarkers 
included in professional guidelines that predict 
response or resistance to therapies for a specific 
type of tumour 
Biomarkers included in professional 
guidelines as diagnostic for a specific 
type of tumour 
Biomarkers included in professional 
guidelines as prognostic for a specific type 
of tumour 
Level B Biomarkers that predict response or resistance to 
therapies for a specific type of tumour based on 
well-powered studies with consensus from 
experts in the field 
Biomarkers of diagnostic significance 
for a specific type of tumour based 
on well-powered studies with 
consensus from experts in the field 
Biomarkers of prognostic significance for a 
specific type of tumour based on well-
powered studies with consensus from 
experts in the field 
II Level C 1. Biomarkers that predict response or resistance 
to therapies approved by the FDA or professional 
societies for a different type of tumour                                                                                 
2. Biomarkers that serve as inclusion criteria for 
clinical trials 
Biomarkers of diagnostic significance 
based on the results of multiple 
small studies
Biomarkers of prognostic significance based 
on the results of multiple small studies 
Level D Biomarkers that show plausible therapeutic 
significance based on preclinical studies 
Biomarkers that may assist disease 
diagnosis themselves or along with 
other biomarkers based on small 
studies or a few case reports 
Biomarkers that may assist disease 
prognosis themselves or along with other 
biomarkers based on small studies or a few 
case reports 
III Variants of 
Unknown 
Significance 
Not observed at a significant allele frequency in the general or specific subpopulation databases, or pan-cancer or tumour specific 
variant databases No convincing published evidence of cancer association 
IV Benign or 
Likely 
Benign 
Variants 
Observed at significant allele frequency in the general or specific subpopulation databases. No existing published evidence of cancer 
association 
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Table 3.6. Mutations, indels and gene fusions called by the analysis pipeline 
Sample No. Impacted Gene HGVS(Genomic)  H
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1 NRAS NC_000001.10:g.115256529T>G HOM 115256529 0.152 197 1299 Q61P 1 3 D II 
2 DNMT3A NC_000002.11:g.25466797C>T HET 25466797 0.603 620 1028 V636M 2 16 D II 
  IDH2 NC_000015.9:g.90631838C>T HET 90631838 0.461 428 929 R172K 15 4 C II 
3 CEBPA (smx2)   HOM 33793252 0.799 295 369   19 1 A I  
  TET2 NC_000004.11:g.106193748C>T HET 106193748 0.443 430 970 R1404* 4 10 D II 
  TET2   HET 106156042 0.465 862 1853 S315 4 3 D II 
4 FLT3-ITD ins 57 HET 28608248   108     13 14 A I n/a 
  DNMT3A NC_000002.11:g.25457242C>T HET 25457242 0.429 471 1097 R882H 2 23 D II 
  TET2 NC_000004.11:g.106180777A>T HET 106180777 0.444 575 1295 R1269* 4 7 D II 
  BCOR   HET 39932538 0.443 537 1212   X 4 D II n/a 
5 NPM1 TCTG (Type A) insertion HET 170837543 0.51 241 473   5 11 A I 
  FLT3-ITD ins 54 HET 28608220   895     13 14 A I n/a 
  TET2   HET 106155748 0.486 858 1766 S217 4 3 D II 
  TET2 NC_000004.11:g.106180795G>T HET 106180795 0.469 549 1171 G1275W 4 7 D II 
6 CEBPA (dm)   HET 33792981 0.514 89 173   19 1 A I 
  CEBPA   HET 33792731 0.405 30 74 -183TR 19 1 A I 
  IDH2 NC_000015.9:g.90631934C>T HET 90631934 0.418 410 981 R140Q 15 4 C II 
  ASXL1   HET 31022441 0.272 237 872 G641 20 12 D II 
  STAG2   HET 123210249 0.376 600 1595 A867 X 26 D II 
7 NPM1 TGTG insertion HET 170837543 0.504 288 571   5 11 A I 
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  NRAS NC_000001.10:g.115258744C>T HET 115258744 0.261 568 2180 G13D 1 2 D II 
  SMC3 NC_000010.10:g.112356176G>T HOM 112356176 0.0656 131 1998 G662C 10 19 D II n/a 
  CEBPA sm NC_000019.9:g.33793394C>T HET 33792731 0.294 75 255 G11D 19 1 D II 
  DNMT3A   HOM 25467472 0.166 268 1614 -346TTTTATC 2 14 D II X 
  FLT3 NC_000013.10:g.28592612T>C HOM 28592612 0.0959 175 1824 R845G 13 20 D II 
8 NPM1 TGCA insertion HET 170837545 0.522 275 527   5 11 A I 
  IDH2 NC_000015.9:g.90631934C>T HET 90631934 0.47 471 1003 R140Q 15 4 C II 
  CEBPA sm   HET 33792731 0.296 45 152 -183TR 19 1 D II 
9 PML-RARA t(15;17)(q24.1;q21.1)   74326159::38493875   759         A I n/a 
  KRAS NC_000012.11:g.25380276T>C HET 25380276 0.439 849 1936 Q61R 12 3 D II 
10 TP53 NC_000017.10:g.7577108C>A HET 7577108 0.614 583 949 C238F 17 8 A I 
11 DNMT3A NC_000002.11:g.25469528A>C HET 25469528 0.533 602 1129 F414V 2 10 D II 
  DNMT3A NC_000002.11:g.25457249T>C HET 25457249 0.47 555 1181 M880V 2 23 D II 
  IDH2 NC_000015.9:g.90631934C>T HET 90631934 0.444 477 1075 R140Q 15 4 C III 
  PTPN11 NC_000012.11:g.112888165G>C HET 112888165 0.426 831 1952 D61H 12 3 D II 
  SMC1A   HOM 53432200 0.855 796 931 E679- X 12 D II n/a 
  CEBPA sm   HET 33792555 0.422 588 1394   19 1 D II 
12 NPM1 TATT insertion HET 170837543 0.502 298 594   5 11 A II 
  IDH1 NC_000002.11:g.209113113G>A HET 209113113 0.476 503 1056 R132C 2 4 C II 
  NRAS NC_000001.10:g.115258748C>T HET 115258748 0.444 1014 2286 G12S 1 2 D II 
  CEBPA sm   HET 33792357 0.444 1096 2466   19 1 D II 
  ASXL1   HOM 31022441 0.0105 11 1051 G641 20 12 D II X 
13 NUP98-DDX10 inv(11)(p15q22)   3758130::108549638   230         D II n/a 
  NRAS NC_000001.10:g.115258744C>T HET 115258744 0.292 626 2147 G13D 1 2 D II 
  TET2   HET 106197269 0.435 705 1622 H1868 4 11 D II 
14 TP53 NC_000017.10:g.7577108C>A HET 7577108 0.375 637 1700 C238F 17 8 A I 
15 NPM1 TCTG (Type A) insertion HET 170837543 0.52 263 506   5 11 A I 
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  TET2   HET 106196829 0.464 896 1932 L1721W 4 11 D II 
  IDH1   HET 209108317 0.46 858 1864 V178I 2 6 Benign IV 
  DNMT3A   HET 25457242 0.414 439 1060 R882H 2 23 D II 
  PTPN11   HET 112888189 0.343 651 1896 E69K 12 3 D II 
  TET2   HET 106156187 0.487 931 1911 P363L 4 3 D II 
  TET2   HET 106180852 0.473 696 1473   4 7 D II 
16 CBFB-MYH11 inv(16)(p13q22)   15814603::67116255   541         A I n/a 
  NRAS NC_000001.10:g.115256529T>C HOM 115256529 0.108 134 1243 Q61R 1 3 D II 
  KRAS   HOM 25398287 0.034 59 1735 -11E 12 2 D II 
  KIT   HOM 55589778 0.0158 27 1714 R420 4 8 VUS III X 
  KIT   HOM 55589765 0.0181 27 1494 R420 4 8 VUS III X 
17 NPM1 TCTG (Type A) insertion HET 170837543 0.574 303 528   5 11 A I 
  ASXL1 NC_000020.10:g.31023821G>T HET 31023821 0.485 847 1746 E1101D 20 12 D II 
  IDH2 NC_000015.9:g.90631934C>T HET 90631934 0.459 428 933 R140Q 15 4 C II 
  FLT3-ITD ins 30 HOM 28608235 0.0464 73 1573 K634NEYDLKWEVPR 13 14 A II n/a 
  TET2 NC_000004.11:g.106155199C>T HET 106155199 0.496 877 1768 L34F 4 3 VUS III 
18 NPM1 GTAG insertion HOM 170837546 0.232 139 599   5 11 A I 
19 PML-RARA t(15;17)(q24.1;q21.1)   74315996::38488278   1097         A I n/a 
  FLT3-ITD ins 24 – 72   28608237-80   133     13 14 A I n/a 
20 NPM1 TCTG (Type A) insertion HET 170837543 0.471 252 535   5 11 A I 
  DNMT3A NC_000002.11:g.25457242C>T HET 25457242 0.389 461 1186 R882H 2 23 D II 
  FLT3-ITD ins 36 – 87   28608231/52         13 14 A I 
21 NPM1 ACTG  insertion HET 170837543 0.473 288 609   5 11 A I 
  FLT3-ITD ins 51~57   28608261         13 14 A I 
  TET2 NC_000004.11:g.106196819G>T HET 106196819 0.457 1085 2376 V1718L 4 11 D II 
  DNMT3A NC_000002.11:g.25467449C>A HET 25467449 0.438 698 1592 G543C 2 14 D II 
22 NPM1 TCTG (Type A) insertion HOM 170837543 0.128 72 563   5 11 A I 
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  DNMT3A NC_000002.11:g.25457242C>T HET 25457242 0.378 453 1197 R882H 2 23 D II 
  TET2 NC_000004.11:g.106155620C>A HET 106155620 0.505 1074 2125 P174H 4 3 D II 
  TET2   HET 106162500 0.368 778 2116 Q1138 4 4 D II 
  TET2 NC_000004.11:g.106156180C>T HOM 106156180 0.213 489 2294 Q361* 4 3 D II 
  TET2   HOM 106157162 0.195 424 2174 D688 4 3 D II 
23 KMT2A-MLLT1 t(11;19)(q23;p13.3)   118359297::6277438   642         A II n/a 
  PTPN11 NC_000012.11:g.112888168T>G HET 112888168 0.352 782 2219 Y62D 12 3 D II 
  SMC1A NC_000023.10:g.53432008C>T HOM 53432008 0.107 98 917 R711Q X 13 D II 
24 RUNX1-RUNX1T1 t(8;21)(q22;q22.3)   93076976::36213332   897         A I n/a 
  FLT3-ITD ins 12 HET 28608260 0.296 461 1555   13 14 A I n/a 
25  JAK2 g.5073770V>F HET 5073770 0.111 114 1290   9 14 A I 
  TET2   HET 106164895 0.517 391 756   4 6 D II 
  TET2   HET 106158438 0.53 1011 1907   4 3 D II 
  KRAS NC_000012.11:g.25378562C>G HET 25378562 0.289 594 2052 A146P 12 4 D II 
26 DNMT3A NC_000002.11:g.25505372G>A HET 25505372 0.41 335 818 S129L 2 4 D II 
  NRAS NC_000001.10:g.115258748C>A HOM 115258748 0.161 306 1900 G12C 1 2 D II 
27 CEBPA dm   HET 33793002 0.528 149 282   19 1 A I X 
  CEBPA NC_000019.9:g.33793004A>C HET 33793004 0.438 135 308 F106C 19 1 A I X 
  CEBPA   HET 33792731 0.261 29 111 -183TR 19 1 A I 
  WT1 NC_000011.9:g.32417947G>A HOM 32417947 0.968 1124 1161 R639* 11 7 D II 
  ASXL1   HOM 31022908 0.461 613 1329   20 12 D II 
28 TET2 NC_000004.11:g.106158509G>C HET 106158509 0.488 959 1966 G1137A 4 3 D II 
  TET2 NC_000004.11:g.106156776T>A HET 106156776 0.466 996 2138 Y559* 4 3 D II 
  RUNX1 NC_000021.8:g.36259161C>A HET 36259161 0.453 266 587 K110N 21 4 A I 
  RUNX1   HOM 36252939 0.246 489 1990 S114LIGVA 21 2 A I 
  RUNX1 NC_000021.8:g.36164601G>A HOM 36164601 0.175 88 503 P398L 21 6 A I X 
  DNMT3A NC_000002.11:g.25457242C>A HET 25457242 0.443 461 1040 R882L 2 23 D II 
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  ASXL1   HET 31022441 0.378 345 913   20 12 D II 
  FLT3 NC_000013.10:g.28592629T>C HOM 28592629 0.201 385 1911 D839W 13 14 D II 
  PHF6 NC_000023.10:g.133549137G>A HET 133549137 0.636 589 926 R274Q X 8 D II n/a 
  SETBP1 NC_000018.9:g.42643337C>T HET 42643337 0.428 360 842 P1489S 18 6 D II n/a 
  KMT2A-PTD  29.619 kbp   118326943::118356561         11   D II n/a 
  FLT3-ITD ins 69   28608227         13 14 A I n/a 
29 NPM1 TCTG (Type A) insertion HET 170837543 0.603 334 554   5 11 A I 
  FLT3-ITD ins 36   28608266         13 14 A I n/a 
  DNMT3A NC_000002.11:g.25457243G>A HET 25457243 0.463 537 1160 R693C 2 23 D II 
  FLT3 NC_000013.10:g.28592642C>A HOM 28592642 0.151 317 2097 D835Y 13 20 D II 
  PTPN11 NC_000012.11:g.112926887G>A HOM 112926887 0.0369 76 2059 G503R 12 13 D II 
  SMC1A NC_000023.10:g.53436051C>T HOM 53436051 0.949 391 412 R496H X 9 D II n/a 
  FAM5C NC_000001.10:g.190068080G>T HET 190068080 0.455 679 1492 R457S 1 8 D II n/a 
  KRAS NC_000012.11:g.25398284C>A HOM 25398284 0.0242 43 1780 G12 12 2 D II 
30 CBFB-MYH11 t(16;16)(p13;q22)   15815105::67127201     1588       A I 
31 NPM1 TGCA insertion HET 170837545 0.494 344 697   5 11 A I 
  FLT3-ITD Ins 24 HOM 28608259 0.107 180 1683 I626IVDFREYEE 13 14 A I n/a 
  IDH1 NC_000002.11:g.209113112C>T HOM 209113112 0.0554 71 1281 R132H 2 4 C II 
32 NPM1 GCCA insertion HET 170837546 0.505 380 753   5 11 A II 
  DNMT3A NC_000002.11:g.25457242C>T HET 25457242 0.487 538 1105 R882H 2 23 D II 
  CEBPA sm   HET 33792731 0.304 38 125 -183TR 19 1 D II 
  FLT3-ITD ins 42   28608263   152     13 14 A I n/a 
33 CBFB-MYH11 inv(16)(p13q22)   15814942::67118135   1114         A I n/a 
  RUNX1 NC_000021.8:g.36164646G>A HET 36164646 0.436 246 564 S410L 21 9 D II 
34 CEBPA smx2   HOM 33793252 0.778 309 397   1 1 A I 
  RUNX1   HET 36252855 0.512 662 1294   21 9 D II 
  TET2   HET 106197114 0.512 701 1369   4 11 D II 
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  ASXL1   HET 31022419 0.51 469 920   20 12 D II 
  SETBP1 NC_000018.9:g.42643142A>G HET 42643142 0.476 728 1531 K1424E 18 6 D II n/a 
  ASXL1 NC_000020.10:g.31022422C>A HET 31022422 0.435 327 752 A635E 20 12 D II 
35 TET2   HET 106190836 0.49 689 1407   4 9 D II 
  TET2 NC_000004.11:g.106164913C>T HET 106164913 0.447 257 575 R1261C 4 6 D II 
  DNMT3A NC_000002.11:g.25463511T>C HET 25463511 0.488 440 901 Y724C 2 18 D II 
  DNMT3A NC_000002.11:g.25463287G>A HET 25463287 0.466 428 918 R736C 2 19 D II 
  U2AF1 NC_000021.8:g.44524456G>A HET 44524456 0.456 718 1576 S34F 21 2 D II n/a 
  KMT2A-PTD 9.827 kbp   118341773::118351603             D II n/a 
36 CEBPA dm   HET 33792381 0.472 1135 2403 K194- 19 1 A I 
  CEBPA   HET 33793227 0.458 330 720   19 1 A I 
  EZH2 NC_000007.13:g.148526829C>T HOM 148526829 0.0551 90 1633 G159R 7 5 D II n/a 
  EZH2 NC_000007.13:g.148512610G>A HET 148512610 0.55 560 1018 Q512* 7 13 D II n/a 
  GATA2 NC_000003.11:g.128202732G>C HET 128202732 0.462 425 919 R330G 3 4 D II n/a 
  SMC3 NC_000010.10:g.112333474A>G HET 112333474 0.44 606 1377 N34S 10 3 D II n/a 
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Figure 3.3. The frequency of mutated genes and gene fusions detected by the variant calling pipeline and the number of 
samples with each mutation. 
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Figure 3.4. Distribution of Variant Allele Fraction (VAF) of Single Nucleotide Variants called by SureCall   
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3.3.6 Comparison of SureCall to GATK Haplotyper and Ion Torrent AML Ampliseq 
There was broad but not complete agreement between the alternative bioinformatic 
pipelines used for SNV and short indel detection, BWA-MEM (used in SureCall for the 
experiment) and GATK Haplotyper hard-filtered data. The most significant anomaly was an 
NRAS variant in sample 13.0816 (NC_000001.10:g.115256529T>G @VAF 0.152) identified by 
SureCall but not GATK. This was confirmed to be present by Ion Torrent and is therefore a 
result of misalignment or inappropriate filtering by GATK.  Generally, the low level variants at 
<3%, allowed by SureCall, were not detected by GATK, in its default setting to avoid 
sequencing errors being called as variants. 
 Sequencing of the samples was also performed on an Ion Torrent PGM (PGM), using 
the AML Ampliseq panel, as a comparison of the experimental method to alternative 
(amplicon) DNA library preparation and sequencing (semi-conductor) technology, to aid 
validation of the results. The AML Ampliseq panel covers mutation hotspots or entire coding 
regions in 19 disease-associated genes, limiting the comparison to the most clinically relevant 
variants and excludes FLT3-ITD (see Table 3.7). The PGM detected a JAK2 V617F mutation 
(chr9:5073770) in sample 25, which was not part of our panel but would be included in a 
more comprehensive diagnostic panel. This mutation was confirmed by PCR testing in a 
separate diagnostic work-up and will be included in further analysis. A median of 26 variants 
per sample were detected by the PGM pipeline pre-filtering (range 21-27). 
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Table 3.7 Gene locations covered by the Ion Torrent AML Ampliseq panel 
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     Start End         
ASXL1 chr20 exon 12 31022215 31025161 2947 0 100 28 
BRAF chr7 exon 15 140453131 140453141 11 0 100 1 
CBL chr11 exon 8 119148856 119149027 172 0 100 2 
    exon 9 119149200 119149443 244 0 100 3 
CEBPA chr19 all coding 33792224 33793340 1117 0 100 9 
DNMT3A chr2 all coding 25457128 25536873 3,619 0 100 42 
FLT3 chr13 exon 21 28589830 28589838 9 0 100 1 
    exon 20 28592604 28592657 54 0 100 1 
    exon 16 28602340 28602342 3 0 100 1 
GATA2 chr3 all coding 128199842 128205894 1,643 0 100 20 
IDH1 chr2 exon 4 209113073 209113404 332 0 100 3 
IDH2 chr15 exon 4 90631799 90631999 201 0 100 2 
JAK2 chr9 exon 14 5073678 5073805 128 0 100 1 
KIT chr4 exon 8 55589730 55589884 155 0 100 1 
    exon 10 55593364 55593510 147 0 100 3 
    exon 11 55593562 55593728 167 0 100 3 
    exon 17 55599216 55599378 163 0 100 2 
KRAS chr12 exon 3 25380148 25380366 219 0 100 2 
    exon 2 25398188 25398338 151 0 100 2 
NPM1 chr5 exon 11 170837511 170837589 79 0 100 1 
NRAS chr1 exon 3 115256401 115256619 219 0 100 2 
    exon 2 115258651 115258801 151 0 100 1 
PTPN11 chr12 exon 3 112888102 112888336 235 0 100 3 
    exon 13 112926808 112926999 192 0 100 2 
RUNX1 chr21 exon 8 36171578 36171779 202 0 100 3 
    exon 7 36206687 36206918 232 0 100 3 
    exon 6 36231751 36231895 145 0 100 3 
    exon 5 36252834 36253030 197 0 100 2 
    exon 4 36259120 36259413 294 0 100 3 
    exon 3 36265202 36265280 79 0 100 1 
TET2 chr4 all coding 106155080 106197696 6,369 0 100 59 
TP53 chr17 exon 12 7572907 7573028 122 7 94.26 2 
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    all coding 7573907 7578574 1146 0 100 19 
    exon 4 7579282 7579610 329 15 95.44 4 
    exon 3 7579680 7579741 62 18 70.97 1 
    exon 2 7579819 7579932 114 18 84.21 1 
WT1 chr11 exon 9 32413498 32413630 133 0 100 2 
    exon 7 32417783 32417973 191 0 100 2 
 
The different bioinformatics pipelines yielded different variant calls and a number from Ion 
Torrent sequencing, selected by Ion Reporter software, were filtered by the custom protocol 
as normal variation. Of the most significant genes that passed filtering by Sure Call, CEBPA, 
and FLT3-ITD are discussed below. 
3.3.7 Pindel for ITD classification 
Pindel (Ye et al., 2009) was used for the detection of large indels and showed no false 
positive calls, compared to standard testing. 13 NPM1 exon 11 mutants were included in the 
dataset and all were identified by next generation sequencing by both SureCall and Pindel 
programmes and Ion Torrent sequencing (see Table 3.8). The different alignment algorithms 
and platforms identified mutations at the same breakpoints but there was a difference in the 
tetranucleotide sequences; the Pindel alignment and Ion Torrent sequencer agreeing on all 
sequences which were discordant with SureCall in 3 samples. 9 out of 13 NPM1+ cases were 
of the common Type A TCTG insertion and therefore the subtype was misclassified in three 
cases by SureCall. 
CEBPA indels were detected in 9 patients There was general agreement between the 
methodologies for detection of CEBPA indels, with 6 producing identical mutations and two 
samples with heterozygous single mutations (3 and 34) yielding a 2 base pair difference in 
insertion position. Sample 37 showed different mutations with different methods, a GCGGGT 
insertion detected by SureCall and Ion Torrent (but not Pindel) and a 39bp insertion which 
was detected by Pindel and no others. A single bp insertion and base substitution was 
detected only by SureCall. These appear to be a double mutation which shows the limitation 
of different methodologies to detect variants of different sizes (see also FLT3-ITD below). 
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All eleven FLT3-ITD mutations were correctly identified by Pindel but only three of the 
smaller ones (between 12-30bp) were detected by SureCall and the larger ones (30-87bp) 
were not. Multiple reads were generated for three samples (19, 20 and 21) which overlapped 
and probably represent sequencing misrepresentation of the same large insertions or actual 
subclonal variation. This cannot be resolved by this study and an alternative technique such 
as Sanger sequencing would be required. Pindel detected two KMT2A-PTD in sample 28 
between introns 1 and 10, resulting in a 29.619 kbp duplication of exons 2-10 and in sample 
35 between introns 2 and 6, resulting in a 9.827 kbp duplication of exons 3-6 (see Table 
3.11). This was also detected by Lumpy (with slightly different intron 6 breakpoint 
(11:118351603). The fusion breakpoint could be retrospectively detected in the SureCall data 
and visualisable in IGV (see Figures 3.3a and 3.3b). 
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Table 3.8. NPM1 exon 11 tetranucleotide insertions (NM_002520.ex.11) 
             No. Supporting Reads 
Sample 
no.  
Pindel 
sequence 
SureCall 
sequence 
Ion 
Torrent  
Insertion 
type 
Zygosity Breakpoint Pindel SureCall Ion 
Torrent 
5 TCTG TCTG TCTG Type A HET 170837543 107 241 866 
7 TCTG TGTG TCTG Type A HET 170837543 137 288 957 
8 TGCA TGCA TGCA   HET 170837545 122 275 907 
12 TCTG TATT TCTG Type A HET 170837543 151 298 838 
15 TCTG TCTG TCTG Type A HET 170837543 113 263   
17 TCTG TCTG TCTG Type A HET 170837543 147 303   
18 GTAG GTAG GTAG   HOM 170837546 44 139 406 
20 TCTG TCTG TCTG Type A HET 170837543 105 252   
21 TCTG ACTG TCTG Type A HET 170837543 150 288   
22 TCTG TCTG TCTG Type A HOM 170837543 37 72   
29 TCTG TCTG TCTG Type A HET 170837543 160 334   
31 TGCA TGCA TGCA   HET 170837545 140 344 848 
32 GCCA GCCA GCCA   HET 170837546 179 380 968 
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Table 3.9. CEBPA variants 
Sample 
No.  
No. 
Nucleotid
es 
Insertion Zygosity Pindel 
Breakpoint 
SureCall 
Breakpoint 
Ion 
Torrent 
SureCall 
No. 
Alleles 
Pindel No. 
Alleles 
3 ins 1 G HOM 33793252 33793252 33793252 295 145 
6 ins 6 GCGGGT HET 33792731 33792731 n/a 30 28 
6 del 8 CGCGGGCG HET 33792981 33792981 n/a 89   
7 ins 6 GCGGGT HET 33792731 33792731 33792729 45 36 
11 ins 1 C HET 33792555 33792555 33792555 588 400 
12 ins 1 A HET 33792357 33792357 33792355 1096 650 
27 Ins 39 GTCACTGGTCAGC
TCCAGCACCTTCT
GCTGCGTCTCCAC 
n/a  33792360 - - - 519 
27 ins 6  GCGGGT HET - 33792731 33792729 29 - 
27 ins 2 AG HET - 33793002 - 149 - 
27 SNP A>C HET - 33793004 - 135 - 
32 ins 6 GCGGGT HET 33792731 33792731 33792731 38 24 
34 ins 1 G HOM 33793252 33793252 33793252 309 162 
36 del 3 CTT HET - 33792381 33792381 1135 - 
36 del 1 G HET - 33793227 33793227 330 - 
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Table 3.10. FLT3-ITD variants 
Sample 
No.  
Nucleotides 
inserted 
Sequence inserted Breakpoint Detected 
SureCall  
SureCall bp Pindel Supporting 
Reads  
4 ins 57 ATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTA
TCTGAGG 
28608248 X   108 
5 ins 54 AACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCT
CTG 
28608220 X   183 
17 ins 30 CTTGGAAACTCCCATTTGAGATCATATTCA 28608235  28608235 226 
19 ins 66 CTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACT
CATTATCTGAGGAGCC 
28608243 X   57 
  ins 72 TGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGA
AGTACTCATTATCTGAGGAGCC 
28608237 X   40 
  ins 30 ACGTAGAAGTACTCATTATCTGAGGAGCCG 28608280 X   24 
  ins 24 TCTCTGAAATCAACGTAGAAGGGG 28608268 X   12 
20 ins 36 TTCTCTTGGAAACTCCCATTTGAGATCATATTCATA 28608231 X   161 
  ins 87 GAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTG
AGGAGCCGGTCACCTGTACCATCTGTAGCTGGCTTTC 
28608252 X   14 
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Table 3.10. FLT3-ITD variants (cont.) 
Sample 
No.  
Nucleotid
es 
inserted 
Sequence inserted Breakpoin
t 
Detected 
SureCall  
SureCall 
bp 
Pindel 
Supporting 
Reads  
21 ins 57 TTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGA
GGAGCCGGTCACCTG 
28608261 X   185 
  ins 51 GAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTC
ATTATCTGA 
28608252 X   33 
24 ins 12 ATTCATATTCTA 28608260  28608260 385 
28 ins 69 AATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTC
TCTGAAATCAACGTAGAAGTACTCGG 
28608227 X   12 
29 ins 36 ATTCTCTGAAATCAACGTAGAAGTACTCATTATCTG 28608266 X   6 
31 ins 24 TATTCATATTCTCTGAAATCAACG 28608259  28608259 389 
32 ins 42 CATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGG 28608263 X   152 
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Figure 3.3a Integrated Genome Viewer screenshot of region of chromosome 11 (chr11:118,351,560-118,351,645) showing track 
of read alignments in “squished” view, centred at 11:118,351,603. The read alignments are coloured by insert size and show the 
reads with discordant pairs due to KMT2A-PTD coloured brown, with duplication junction at 11: 11:118,351,603. 
Position on chromosome 11 of KMT2A at 11q23.3 
Human Genome Reference location 
Nucleotide sequence with  
87bp  section in view  
KMT2A intron 1  Selected region covered by  NGS  experiment  
from project BED files   
Split reads at the duplication junction breakpoint  
Coloured reads are discordant  
with their paired read 
 
Dense stack of sequencing  
reads aligned to genome  
reference  
 135 
 
 
 
 
Figure 3.3b Integrated Genome Viewer screenshot of region of chromosome 11 (chr11:118,351,560-118,351,645) showing 
partial track of read alignments in “expanded” view, centred at 11:118,351,603. The read alignments are coloured by insert size 
and show the reads with discordant pairs due to KMT2A-PTD coloured brown, with duplication junction at 11: 11:118,351,603. 
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Table 3.11. KMT2A partial tandem duplications detected by Lumpy alignment of targeted Next Generation Sequencing 
 
Sample No. Conventional Result Gene Exons 
duplicated 
Position Position Supporting Reads  
28 Normal KMT2A 2~10 118326943 (/49)* 118356561 111 
35 -7,+8 KMT2A  3~6 118341773 (/72)* 118351603 175 
 
*Numbers in brackets in breakpoint Position column represent last two digits difference in breakpoint designation in a smaller 
proportion of reads. 
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3.3.8 LUMPY for detection of gene fusions 
The bioinformatics algorithm Lumpy was used to detect structural variation, using 
points of evidence from DNA sequence, including read pair and split reads (Layer et al., 
2014). Seven gene fusions were identified by conventional testing (see section 3.2 and Table 
3.2 above) and all were detected by this next generation sequencing approach of targeting 
each partner gene in the translocations. This included two PML-RARA fusions, three CBFB-
MYH11 fusions, one RUNX1-RUNX1T1, and a KMT2A-KMT2AT1 (see Table 3.12). The fusion 
breakpoint could be retrospectively detected in both chromosomal breakpoints in the 
SureCall data and visualisable in IGV (see Figures 3.4 a and b).  Slight variation in breakpoint 
designation was apparent between Lumpy alignments from different lanes of the sequencer 
that were not merged before alignment. Two alternative sets of molecular breakpoints are 
offered for inv(16) in Sample 16 and t(8;21) in Sample 24. Nevertheless, it was possible to 
define chromosomal rearrangements, with close to base pair accuracy, in the majority of 
cases or to identify the breakpoints to a narrow range. A deletion of chromosome 11 is also 
apparent in 13.3005, in addition to inv(16). No gene fusions were detected in any other 
genes tested for gene fusion in the panel.  
Case 13.1420 was known to have a NUP98 gene rearrangement by FISH, apparently 
resulting from a large pericentric inversion of chromosome 11, a rare but recognised 
abnormality in AML. The partner gene of NUP98 could be inferred from this rearrangement 
but had not been identified.  A strategy to target all possible partner genes is costly and 
impractical, particularly for promiscuous genes like NUP98.  NUP98 was targeted as part of 
the panel and chimaeric reads resulting from gene fusion were captured and sequencing 
extended into the unidentified sequences. DDX10 at 11q22.3 was identified as the fusion 
partner and the stack of reads can be shown in IGV (see Figures 3.5a and b and 3.6 a and b). 
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Table 3.12. Gene fusions detected by Lumpy alignment of targeted Next Generation Sequencing 
Sample 
No. 
Conventional Result Genes Chr #1 Position Chr #2 Position Supporting 
Reads  
9 t(15;17)(q24.1;q21.1) PML-RARA 15 74326159 17 38493875 759 
16 inv(16)(p13q22) CBFB-MYH11 16 15814603 16 67116255 541 
      16 15814963 16 67116382 (/79)* 374 
19 t(15;17)(q24.1;q21.1) PML-RARA 15 74315996 (/95)* 17 38488278 (/73)* 1097 
23 t(11;19)(q23;p13.3) KMT2A-MLLT1 11 118359297 19 6277438 640 
24 t(8;21)(q22;q22.3) RUNX1-RUNX1T1 8 93076976 21 36213332 897 
   8 93077238 21 36183258 385 
30 t(16;16)(p13;q22) CBFB-MYH11 16 15815105 (/03)* 16 67127201 1588 
33 inv(16)(p13q22) CBFB-MYH11 16 15814942 16 67118135 1114 
   11 119148585 11 119149432 565 
13 inv(11)(p15q22) NUP98-DDX10 11 3758130 (/29)* 11 108549638 230 
 
Two alternative set of molecular breakpoints are offered for inv(16) in 13.1760 and t(8;21) in 13.2412. A deletion of chromosome 
11 is also apparent in 13.3005, in addition to inv(16). 
*Numbers in brackets in breakpoint Position column represent last two digits difference in breakpoint designation in a smaller 
proportion of reads.  
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Figures 3.4a. Integrated Genome Viewer screenshots of regions of (a) chromosome 15 (chr15:74,326,139-74,326,179) and (b) 
chromosome 17 (chr17:38,493,855-38,493,895) showing partial track of read alignments in “expanded” view, centred at 
breakpoints in intron 6 in PML (15: 74326159) and intron 2 in RARA (17:38493875) respectively. The read alignments are coloured 
by insert size and show the reads with discordant pairs due to PML-RARA gene fusion in case no. 13.1050. 
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Figures 3.4b. Integrated Genome Viewer screenshots of regions of (a) chromosome 15 (chr15:74,326,139-74,326,179) and (b) 
chromosome 17 (chr17:38,493,855-38,493,895) showing partial track of read alignments in “expanded” view, centred at 
breakpoints in intron 6 in PML (15: 74326159) and intron 2 in RARA (17:38493875) respectively. The read alignments are coloured 
by insert size and show the reads with discordant pairs due to PML-RARA gene fusion in case no. 13.1050. 
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Figures 3.5a. Integrated Genome Viewer screenshots from case no. 13.1420 of regions at (a) chromosome 11 (from 
chr11:3,757,956-3,758,301) centred at breakpoint in NUP98 in intron 12 at 11:3758130 and (b) view of chromosome 11 
(chr11:108,549,618-108,549,658) centred at the second breakpoint in chromosome 11 in intron 5 in DDX10 (at 11:108549638). 
Diagram shows partial stack of reads in “expanded” view, with reads enriched in DDX10 due to preferential selection. The read 
alignments are coloured by insert size and show the reads with discordant pairs due to NUP98-DDX10 gene fusion. 
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Figures 3.5b. Integrated Genome Viewer screenshots from case no. 13.1420 of regions at (a) chromosome 11 (from 
chr11:3,757,956-3,758,301) centred at breakpoint in NUP98 in intron 12 at 11:3758130 and (b) view of chromosome 11 
(chr11:108,549,618-108,549,658) centred at the second breakpoint in chromosome 11 in intron 5 in DDX10 (at 11:108549638). 
Diagram shows partial stack of reads in “expanded” view, with reads enriched in DDX10 due to preferential selection. The read 
alignments are coloured by insert size and show the reads with discordant pairs due to NUP98-DDX10 gene fusion. 
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Figure 3.6a. chr11:3,758,110-3,758,150) centred at breakpoint of NUP98 in intron 12 at 11:3758130 and (b) view of chromosome 
11 (chr11:108,549,465-108,549,810) centred at the second breakpoint of chromosome 11 in intron 5 in DDX10 (at 11:108549638, 
also showing C>A base substitution at 11:3758129 in green). Diagram shows partial stack of reads in “squished” view, with reads 
enriched in DDX10 due to preferential selection. The read alignments are coloured by insert size and show the reads with 
discordant pairs due to NUP98-DDX10 gene fusion. 
Split reads at the gene fusion junction 
breakpoint  
Coincidental base pair difference to the reference 
sequence   
(C>A) at he fusion breakpoint  (green) 
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Figure 3.6b. Integrated Genome Viewer screenshots from case no. 13.1420 of regions in (a) chromosome 11 (from 
chr11:3,758,110-3,758,150) centred at breakpoint of NUP98 in intron 12 at 11:3758130 and (b) view of chromosome 11 
(chr11:108,549,465-108,549,810) centred at the second breakpoint of chromosome 11 in intron 5 in DDX10 (at 11:108549638, 
also showing C>A base substitution at 11:3758129 in green). Diagram shows partial stack of reads in “squished” view, with reads 
enriched in DDX10 due to preferential selection. The read alignments are coloured by insert size and show the reads with 
discordant pairs due to NUP98-DDX10 gene fusion. 
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3.4 Functional classification of diseases, complementation groups and mutual exclusivity 
The mutations, indels and gene fusions that were newly found from the variant 
annotation protocol that were classified as pathogenic or likely pathogenic were examined to 
assess their value for more accurate prognostication, and potential for better treatment 
stratification. The prominent genetic class or cytogenetic profile were collated in Table 3.13 
and grouped according to conventional ELN prognostic criteria, colour-coded according to 
disease risk (Döhner et al., 2016). The additional genomic information was added and used to 
calculate the new prognostic group from a recent genomic-based classification and 
prognostic stratification (Papaemmanuil et al., 2016). The a priori ELN grouping was 
compared to the new grouping and the change recorded (see Table 3.13).  
The cohort of 35 AML cases is representative of the range of disease subtypes (see 
Tables 3.1 and 3.2) and incidence of mutations is as expected (see Figure 3.3). All patients 
presented with detectable recognisable driver gene fusions or mutations. Four patients had 
no class-defining mutations and two patients qualified in more than one group (Table 3.13). 
The largest distinct diagnostic subgroup diagnostic were NPM1 mutated group (13 patients; 
37%), one of whom also qualified as a second diagnostic category by having del(5q) by 
cytogenetics. Seven of these patients also harboured FLT3-ITD, 7 with DNMT3A, 3 IDH1 and 2 
IDH2. The other main mutational profiles were represented in approximately equal numbers; 
CEBPA double mutation (3), TP53/aneuploidy (4), and the Chromatin modifier/Spliceosome 
group (3). Of the patients defined by chromosomal rearrangements leading to gene fusions, 
there were two PML-RARA, four CBF-AML (3 with MYH11-CBFB and 1 RUNX1-RUNX1T1), and 
one each of KMT2A-MLLT1 and NUP98-DDX10 (see Table 3.12). 
It is predicted from the additional information with emerging clinical significance of 
mutational profiling that 8 out of 35 patients’ prognostic would be modified. Three patients 
with CEBPA double mutation were reclassified as favourable as these mutations were not 
part of routine testing prior to this study. Three patients with chromatin 
modifier/spliceosome mutations were reclassified as unfavourable (Papaemmanuil et al., 
2016). The KMT2A-MLLT1 fusion was reclassified as Intermediate. Therefore, 7 patients 
moved from Intermediate to Favourable (3) or Adverse (4). Two NPM1 patients could be 
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reclassified to Intermediate as in one study, the favourable prognosis of NPM1 is not 
retained in elderly patients (> 60 years) (Metzeler et al., 2016). Patient 7 is the single case 
where mutation profiling has the most powerful impact, changing the complexion of the 
disease from a favourable outlook (due to NPM1 prognosis) to a high risk disease associated 
with NPM1/NRAS/DNMT3A mutation combination (Metzeler et al., 2016). 
Multi-gene mutational profiling is starting to create a picture of cooperating 
mutations in CBF-AML and explain the outcome heterogeneity in this group (Duployez et al., 
2016). The adverse effect of KIT mutation on CBFB-MYH11 rearranged leukaemia has been 
previously reported. It is suggested that the NRAS and KRAS mutations detected in case 
Sample 16, in the absence of KIT or FLT3 mutations are associated with a favourable 
prognosis. 
 
3.5 Influence of genomic profiling on the outcomes of the AML patients 
Crude outcome data were collected from death statistics only and therefore Overall 
Survival (OS) could be calculated (see Table 3.14 below). This was compared to genomic 
profile alone, without access to additional clinical information and therefore with no 
knowledge of confounding factors, such as comorbidities, treatment related mortality, or the 
decisions to treat and treatment modalities. There are insufficient data for rigorous statistical 
analysis or to draw any definite conclusions; they are included for indicative purposes only.   
However, the data is interesting and shows distinct trends and improved prediction 
from genomic profile data and independently from other clinical and laboratory data, 
demonstrated the potential of genomic profiling. 24 out of 35 outcomes were as expected 
based on genomic profile. 10 out of 13 patients with favourable genomics were alive at the 
time of analysis. 3 patients with favourable genomics died very early, possibly for reasons 
unrelated to genomic risk factors. 7 out of 8 patients with adverse genomics died within 12 
months, however, probably also including uncorrelated to prognostic influence. 1 patient 
was an unexpected long term survivor. Of 8 patients who changed prognosis due to 
additional genomic information, 6 outcomes appeared to reflect the expected outcome more 
accurately. Two patients with favourable outcome were alive at the time of data collection. 
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Three patients with an adverse genomics profile (change from Intermediate) died rapidly (20, 
84 and 258). 
A one-way Analysis of Variance (ANOVA) with Tukey's multiple comparisons test was 
performed to test the performance of ELN and genomic prognostic systems to stratify patient 
risk (see Figure 3.7). The genomic profiling showed a significant difference between (1) 
favourable and intermediate and (2) favourable and adverse. However, by ELN criteria only 
the favourable and intermediate groups were statistically different. This appears mainly 
attributable to the reclassification of ELN Intermediate risk patients to favourable and 
adverse in the genomic data. 
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Figure 3.7. Scatter plot showing the median overall survival of patients in the study with 
interquartile range. (A) Overall survival of patients stratified using ELN criteria. (B) Overall 
survival of patients stratified using sequencing data from current study. Groups were 
compared using one way ANOVA with Tukey's multiple comparisons test **p<0.01.  
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Table 3.13. Main genomic features in 35 patients in the project, prior ELN risk status and 
new genomic classification  
Sa
m
p
le
 
Prior Main Genetic 
Features 
P
ri
o
r 
EL
N
 R
is
k 
G
ro
u
p
* 
Genes with Variants of 
Clinical Significance  
Papaemmanuil (2016) 
group** 
R
is
k 
C
h
an
ge
 
1 del(5q) Adv NRAS TP53/aneuploidy  
2 7q abn, NPM1-/FLT3- Int DNMT3A, IDH2
R172K
 TP53/aneuploidy  
3 CN-AML NPM1-/FLT3- Int CEBPA(smx2), TET2 biallelic CEBPA  
4 CN-AML NPM1-/FLT3-ITD Int DNMT3A, TET2, BCOR, 
FLT3-ITD 
Chromatin/Spliceosome  
5 Failed cytogenetics 
NPM1+/FLT3-ITD 
Int NPM1, FLT3-ITD, TET2 NPM1+ (FLT3+)  
6 CN-AML NPM1-/FLT3- Int CEBPA(dm), IDH2
R140Q
, 
ASXL1, STAG2 
Chromatin/Spliceosome  
7 CN-AML NPM1+/FLT3- Fav NPM1, DNMT3A, NRAS, 
SMC3, CEBPA(sm), FLT3-
TKD 
NPM1 (NRAS/DNMT3A)  
8 CN-AML NPM1+/FLT3- Fav NPM1, IDH2
R140Q
, 
CEBPA(sm) 
NPM1 (IDH)  
9 t(15;17)/PML-RARA Fav KRAS t(15;17) PML-RARA  
10 & 14 Complex karyotype Adv TP53 TP53/aneuploidy  
11 CN-AML NPM1-/FLT3- Int DNMT3A(x2), IDH2
R140Q
, 
PTPN11, SMC1A, 
CEBPA(sm) 
No class-defining lesions  
12 CN-AML NPM1+/FLT3- Fav NPM1, IDH1
R132C
, NRAS, 
CEBPA (sm), ASXL1  
NPM1 (IDH)  
13 inv(11) with NUP98 
rearranged 
Int NRAS, TET2 No class-defining lesions  
15 CN-AML NPM1+/FLT3- Fav NPM1, DNMT3A, TET2, 
PTPN11 
NPM1  
16 CBF-AML with 
inv(16)/CBFB-MYH11 
Fav NRAS, KRAS, (KIT) CBF-AML with 
inv(16)/CBFB-MYH11 
 
17 CN-AML NPM1+/FLT3-ITD Int NPM1, FLT3-ITD, TET2,  
IDH2
R140L
, ASXL1 
NPM1 (FLT3-ITD)  
18 del(5q) NPM1+/FLT3- Adv NPM1 NPM1/aneuploidy  
19 PML-RARA, FLT3-ITD Fav FLT3-ITD PML-RARA (FLT3-ITD)  
20 CN-AML NPM1+/FLT3-ITD Int NPM1, DNMT3A, FLT3-ITD NPM1 (FLT3-ITD)  
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21 CN-AML NPM1+/FLT3-ITD Int-I NPM1, TET2, DNMT3A, 
FLT3-ITD 
NPM1 (FLT3-ITD)  
22 CN-AML NPM1+/FLT3- Fav NPM1, DNMT3A, TET2 (x2) NPM1  
23 t(11;19) KMT2A-MLLT1 Adv PTPN11, SMC1A KMT2A-KMT2AT1  
24 CBF-AML with 
t(8;21)/RUNX1-RUNX1T1 
FLT3-ITD 
Fav FLT3-ITD CBF-AML with RUNX1-
RUNX1T1 
 
25 Other cyto Int JAK2
V617F
, TET2x2, KRAS No class-defining lesions  
26 Other cyto Int DNMT3A, NRAS No class-defining lesions  
27 Other cyto Int CEBPA(dm), WT1, ASXL1 biallelic CEBPA  
28 CN-AML NPM1-/FLT3-ITD Int TET2x2, RUNX1x2, 
DNMT3A, ASXL1x2, FLT3-
TKD, FLT3-ITD, KMT2A-
PTD, PHF6, SETBP1 
Chromatin/Spliceosome  
29 CN-AML NPM1+/FLT3-ITD Int NPM1, FLT3-ITD, DNMT3A, 
FLT3-TKD, PTPN11, 
SMC1A, FAM5C, KRAS 
NPM1 (FLT3-ITD)  
30 CBF-AML with 
inv(16)/CBFB-MYH11 
Fav No variants detected CBF-AML with 
inv(16)/CBFB-MYH11 
 
31 CN-AML NPM1+/FLT3+ Int NPM1,  IDH1
R132H
, FLT3-ITD NPM1 (FLT3-ITD)  
32 CN-AML NPM1+/FLT3-ITD Int NPM1, DNMT3A, FLT3-ITD, 
CEBPA(sm) 
NPM1 (DNMT3A & FLT3-
ITD) 
 
33 CBF-AML with 
inv(16)/CBFB-MYH11 
Fav RUNX1 CBF-AML with 
inv(16)/CBFB-MYH11 
 
34 CN-AML NPM1-/FLT3- Int CEBPA(smx2), RUNX1, 
TET2, ASXL1, SETBP1  
Meeting criteria for ≥2 
genomic subgroups 
 
35 Monosomy 7 Adv TET2, DNMT3A, U2AF1, 
KMT2A-PTD 
TP53/aneuploidy  
36 CN-AML NPM1-/FLT3- Int CEBPA(dm), EZH2x2, 
GATA2, SMC3 
biallelic CEBPA  
 
Key to abbreviations 
NPM1- (NPM1 wild type), NPM1+ (NPM1 tetranucleotide insertion), FLT3- (FLT3 wild type), FLT3-ITD (FLT3 
internal tandem duplication), FLT3-TKD (FLT3 Tyrosine kinase domain mutation), KMT2A-PTD (KMT2A partial 
tandem duplication),  CEBPA(dm) (CEBPA double heterozygote mutation), CEBPA(smx2) (CEBPA homozygous 
mutation), CEBPA(sm) (CEPPA single mutation), CBF-AML (Core Binding Factor AML), CN-AML (Cytogenetically 
Normal AML) 
*ELN Risk Group derived from (Döhner et al., 2016) 
**Papaemmanuil (2016) group from (Papaemmanuil et al., 2016) 
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Table 3.14 Survival and change of risk status in 35 patients used from the project. 
Sa
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p
le
 
P
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r 
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k 
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R
is
k 
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ge
 
Su
rv
iv
a
l (
O
S 
d
ay
s)
 (
d
ay
s)
 Actual O vs E 
1 Adv  1596 F X 
2 Int-II  1135 I  
3 Int-I  40 A X 
4 Int-I  33 A  
5 Int-I  6 A X 
6 Int-I  258 A  
7 Fav  1576 F  
8 Fav  59 A X 
9 Fav  1570 F  
10 & 14 Adv  111 A  
11 Int-I  374 I  
12 Fav  40 A X 
13 Int-II  629 I  
15 Fav  1522 F  
16 Fav  1500 F  
17 Int-I  745 I  
18 Adv  81 A  
19 Fav  1480 F  
20 Int-I  211 A X 
21 Int-I  461 i  
22 Fav  1050 I X 
23 Adv  170 A X 
24 Fav  842 F  
25 Int-II  56 A X 
26 Int-II  6 A X 
27 Int-II  1431 F  
28 Int-I  20 A  
29 Int-I  843 F  
30 Fav  1488 F  
31 Int-I  366 I  
32 Int-I  84 A  
33 Fav  1393 F  
34 Int-I  223 A X 
35 Adv  355 A  
36 Int-I  1441 F  
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4.0 Discussion 
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4.1 Introduction; the potential for routine use of NGS in AML diagnosis 
Next-generation sequencing facilitated an era of intense study in cancer genomics 
by providing the technology for genome-wide examination of the acquired and germline 
abnormalities in cancer. This provided new insight into how these changes initiate the 
disease, contribute to phenotypes and influence clinical behaviour. Rapid evolution of the 
technology in the last decade has resulted in improved speed and better resolution of 
DNA sequencing, at dramatically lower costs. The technology is now being used in a 
routine diagnostic setting for many applications. AML is the most intensively studied type 
of cancer and its somatic genome has been defined in detail (The Cancer Genome Atlas 
Research Network, 2013; Mazzarella et al., 2014; Metzeler et al., 2016; Papaemmanuil et 
al., 2016). The genomic heterogeneity of AML has been shown to reflect the diversity in 
haematological and clinical features. Genetic studies are the basis for conventional risk-
adapted therapy (Döhner et al., 2016) but the newfound variety of underlying genetic 
defects adds to the determination of clinical outcome; recently, AML has been 
categorised into 11 molecularly-defined subgroups that correlate with pathogenesis and 
disease prognosis (Figure 1.4) (Papaemmanuil et al., 2016). AML is an aggressive cancer 
and is particularly difficult to treat. It typically occurs in the elderly and most patients 
relapse after initial remission. It is widely predicted that the detailed understanding of the 
mutational landscape will be used to modernise treatment, to more accurately stratify 
the disease risk, direct conventional treatment, and offer the prospect to personalise 
therapy (Ofran & Rowe, 2013; Meyer & Levine, 2014; Roug et al., 2014). 
  The aim of the project was to develop a streamlined NGS assay for the genomic 
diagnosis of AML, to demonstrate the principle that this could be transferrable to the 
diagnostic laboratory and to evaluate its potential to improve AML management. The 
project used a novel design to detect all clinically relevant genetic changes in AML and 
recurrent abnormalities that are likely to be actionable in the near future. It investigated 
the potential for using genomic DNA for the detection of variants, including duplications 
and gene fusions, which was previously considered technically demanding. AML is 
currently sub-classified using several disparate laboratory methods with limited 
resolution. Key objectives were to reproduce the diagnostic and prognostic findings from 
existing methods, to accurately detect the types of genetic abnormalities encountered in 
conventional AML diagnosis. Additional molecular abnormalities of growing importance 
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to AML diagnosis were identified and the sensitivity of testing was increased. The project 
demonstrated how a single, specific NGS assay could achieve these objectives and replace 
multiple techniques, with the potential to rationalise laboratory workflows. The genome-
wide screen of 42 genes, including genetic targets not part of the standard workflow, 
permitted reclassification of patients to the genomic classification of Papaemmanuil et al 
(2016) and it was possible to demonstrate how a benefit to patient management can be 
derived from its implementation. 
The new assay would need to achieve a speed of turnaround appropriate to 
clinical demands and provide reliability and reproducibility for the upmost confidence in 
diagnostic results. In practice, it would need to meet the stringent principles required in a 
diagnostic laboratory and rigorous accreditation standards (Jennings et al., 2009; 
Mattocks et al., 2010). To reflect the typical diagnostic workflow, a sample of normal cells 
would not be readily available and there would be no option to use constitutional DNA as 
normal control from the same individual, to distinguish somatic mutations from germline 
variants. By detecting all types of genomic rearrangements to the highest, single 
nucleotide resolution, it should be possible to increase the sensitivity of the tests by 
sequencing to an appropriate depth. To provide this capacity on currently available 
sequencers, it is necessary to be selective about the sequencing of genomic targets, 
which also facilitates management of costs. The feasibility of the implementation of the 
technique will be discussed. 
4.2 Improved detection of clinically relevant genomic profiles 
The project shows that this targeted sequencing strategy and analytical pipeline 
can efficiently identify all major categories of somatic mutations found in AML. 
Recognisable driver mutations, indels and/or gene fusions were detected in all patients by 
the new genomic profile. The sequencing panel detected disease-defining lesions, 
conventionally detected by cytogenetics and FISH; two PML-RARA, three CBFB-MYH11, 
one RUNX1-RUNX1T1, and one KMT2A-MLLT1 gene fusions resulting from chromosomal 
translocations or inversions. A NUP98-DDX10 fusion, resulting from inv(11)(p15q22), was 
correctly identified by the targeting of NUP98 only; its partner gene, DDX10, was not 
selected directly, but was identified and characterised by virtue of the sequencing of 
chimaeric DNA fragments containing NUP98. The analytical pipeline correctly detected 
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thirteen NPM1 exon 11 tetranucleotide insertions and ten FLT3-ITDs which were part of 
normal molecular genetics work-up for the cases. JAK2 was not included in the panel 
design at this time and so one patient with JAK2 V617F was not detected but was 
identified using the parallel sequencing method and confirmed during routine molecular 
genetic testing. A total of 112 other variants from 36 samples were annotated and passed 
filtering as known or likely pathogenicity. Many of these were specific with known 
hotspots, including CEBPA, IDH1/2 mutations and FLT3-TKD. The remaining genes were 
recurrent in myeloid disease, the majority of which showed relevant annotations in the 
COSMIC database (Wellcome Trust Sanger Institute, 2016). Some variants were included 
without a specific COSMIC reference but passed filtering as having a suggestive 
functionality and likely pathogenicity. Often these were supported by studies where any 
coding location was sequenced and therefore no sublocation of the SNV defined, but 
were considered to contribute to AML development. Functionality studies are required to 
delineate their clinical significance further.  
The sole case of complex karyotype showed TP53 exon 8 mutation, consistent 
with the genomic instability conferred by lack of functional p53. TP53 mutation has been 
used as a surrogate marker for these high risk patients previously, in a molecular genetic 
classification of AML (Grossmann et al., 2012). However, 30% of AML patients with 
complex karyotype do not have TP53 mutations and it needs to be confirmed that other 
genes may account for this observation. Whilst TP53 is an essential molecular marker for 
disease stratification, the significance of other mutations in this important prognostic 
group needs to be identified for a relevant molecular classification to be devised. Of the 
nucleotide substitutions and indels in 19 genes that were also sequenced by the Ion 
Torrent semi-conductor NGS method, there was broad agreement; the majority of point 
mutations were detected by both NGS protocols. Discrepancies were detected between 
systems and were thought to be products of sequencing and alignment errors, which are 
still common and expected with any NGS platform. The significance of these is discussed 
below. 
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4.3 Clinical significance of genomic evidence on AML management 
The new genomic profile not only identified significant lesions previously detected 
by cytogenetics and molecular genetics, at an increased resolution and sensitivity, but 
also was able to redefine prognostic categories in a significant proportion of patients, 
according to a proposed genomic prognostic system (Papaemmanuil et al., 2016). This 
offers the prospect of improved disease stratification and better options of standard 
treatment. Previously, eighteen out of thirty-five patients were CN-AML, five of which 
showed no evidence of NPM1 or FLT3-ITD mutations and so could not be resolved further 
by standard molecular testing. Nineteen patients were of Intermediate ELN risk. Under 
the new system, four patients had no class-defining mutations and two patients qualified 
in more than one group (Table 3.13). In total, 8 patients were reclassified. Four patients 
changed from Intermediate to Adverse, three of which entered the new 
‘Chromatin/Spliceosome’ category. If eligible for intensive treatment, this high risk group 
would indicate allogeneic SCT as post remission therapy, and affect the decision-to-treat 
in the elderly, although age alone is not the sole predictor of treatment-related mortality, 
due to better health status and improved supportive care (Döhner et al., 2016). Three 
patients changed from Intermediate to Favourable, all three by detection of biallelic 
CEBPA mutations (two compound heterozygotes and 1 homozygote). Two patients were 
long term survivors (the other died very rapidly, presumably unrelated to genetic 
prognostic factors). This emphasises the need for routine CEBPA mutation screening, 
which was not part of routine diagnostic testing. Favourable patients typically receive 
single cytotoxic agent as consolidation (e.g. intermediate dose Ara-C, IDAC) and would 
avoid allogeneic SCT and high dose cytarabine, under typical circumstances. One patient 
changed from High Risk to Intermediate, due to redesignation of their KMT2A 
translocation in the new scheme.  
The crude survival data from the project, based on 35 patients only without access 
to any other modifying factors, can only be considered for indicative purposes but it was 
interesting by showing better discrimination of patient outcome by genomic profiling, 
mainly by redesignation of seven patients from the Intermediate category. It should be 
noted that the genomic classification used an extended panel of 111 genes for screening, 
of which only the common 30 genes were tested in this study. By inclusion of more 
infrequently mutated genes, only rarely will positive results add to the diagnostic profile 
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but occasionally better distinction of prognostic groups would be possible. The predictive 
power of the new genomic classification requires validation in independent clinical trials. 
Other well-powered studies take a different perspective and could add to this evidence; 
e.g. patients with DNMT3A mutations, well-represented in this study, have been reported 
to have a poor prognosis in other studies, particularly in younger patients (Metzeler et al., 
2016). 
AML is an active field of new drug investigation in early-phase, experimental trials, 
usually in refractory patients, and in clinical studies (Döhner et al., 2016). Genomic targets 
provide an important indication of possible efficacy of novel therapies to oncogenic 
proteins or broader spectrum agents, such as protein kinase inhibitors and epigenetic 
modulators.  Patients already screened as part of routine genetic testing could access 
FLT3 inhibitors which have been under trial and may not only impede the FLT3-ITD but 
also FLT3-TKD, of which there were 4 in this patient group, two concurrently with FLT3-
ITD (Grunwald & Levis, 2015; Stein & Tallman, 2016). There is early understanding of the 
KMT2A gene fusions as a possible target for epigenetic therapies (Placke et al., 2014; 
Chen & Armstrong, 2015). Whilst effective inhibitors of the common NPM1 mutations are 
elusive, alternative therapies may emerge that use the disease hallmark as a predictive 
marker (El Hajj et al., 2015; Martelli et al., 2015). The IDH1/2 mutations, of which there 
were eight in this cohort that would not have been detected previously, are also under 
investigation in early phase trials (Wang et al., 2013; Stein & Tallman, 2016; Dombret & 
Gardin, 2016). The subclonal (but unconfirmed) KIT mutation, which was found secondary 
to CBFB-MYH11 in case 16, could be a target for dasatinib (or other TKI) if this clone 
progressed (Paschka et al., 2013). The knowledge that AML is comprised of subclones that 
harbour mutations which may be differently susceptible to existing and novel therapies 
suggests that their accurate identification at first presentation is increasingly important. 
4.4 Clonal heterogeneity and cooperating mutations 
This NGS experiment demonstrates the remarkable genetic heterogeneity in AML 
even with a limited panel of genes and in only thirty-six samples. Such multi-gene 
mutational profiling is able to depict patterns of cooperating mutations and mutual 
exclusivity (Figure 1.5) (The Cancer Genome Atlas Research Network, 2013; 
Papaemmanuil et al., 2016; Metzeler et al., 2016). AML is clonal and has been shown to 
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evolve in both linear and branching patterns, with mutations occurring in non-random 
temporal order, often leading to a complex network of subclones and forming an intricate 
subclonal architecture (Anderson et al., 2011; Welch, 2014).  
Genetic defects can be considered to be ‘initiation’ or ‘progression’ events; 
initiators occur at an early stage and will therefore be present in the founding clone and 
in all descendants of the leukaemic cells. Balanced translocations involving transcription 
factor gene fusions, e.g. t(15;17), t(8;21), and inv(16), such as  cases 9, 16, 19, 24 & 33 in 
this study, are primary, initiating events found in the founding clone (Grimwade et al., 
2016). Mutations in genes affecting the epigenome, such as DNMT3A and TET2 are also 
more likely to occur earlier in leukaemogenesis (Corces-Zimmerman et al., 2014; Shlush et 
al., 2014) and have also been found in pre-leukaemic clones of haematopoietic stem cells 
that provide a selective growth advantage but are insufficient alone to initiate leukaemic 
transformation (Corces-Zimmerman & Majeti, 2014; Grove & Vassiliou, 2014). These 
mutations in the study can all be shown to have high VAF, consistent with being initiating 
mutations (Table 3.6 and Figure 3.4).  
Progression mutations are secondary events that enhance the proliferative 
capacity of the cell and may occur in distinct subclones and only be present in a 
proportion of the leukaemic cells. NPM1 mutations were considered early events (Jan et 
al., 2012; The Cancer Genome Atlas Research Network, 2013), however, they have been 
shown to often occur with DNMT3A mutations, are not always present in all cells, and can 
be lost in clonal development in some studies (Kronke et al., 2013; Corces-Zimmerman & 
Majeti, 2014). Chromosome abnormalities such as trisomy 8 and nucleotide variants in 
genes involved in activated signalling, such as FLT3, RAS, KIT and WT1, are also found 
exclusively as late events and frequently occur in subclones. They are observed either to 
emerge or to be lost at relapse (Corces-Zimmerman et al., 2014; Welch, 2014). These are 
often found with lower VAF consistent with emerging subclones in many cases in these 
samples. Primary abnormalities account for mutations with VAF around 0.5, consistent 
with heterozygous mutations present in the majority of cells in the sample (Fig. 3.4). In 
contrast, mutations in genes with lower VAF allele frequencies, indicate they are present 
only in a subpopulation of the cells. Therefore multiple genetic events are required to 
promote development of AML and they act in cooperation in leukaemogenesis and have 
complementary modes of action (The Cancer Genome Atlas Research Network, 2013; 
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Papaemmanuil et al., 2016; Metzeler et al., 2016). The recognition of clonal heterogeneity 
within AML will become important in our understanding of the efficacy of therapeutic 
interventions. Apparent clonal diversity and subclonal resistance to chemotherapy and 
the choice of appropriate single biomarkers as therapeutic targets and MRD monitoring, 
will all be significant considerations. We are moving into an age whereby further insight 
into AML will be obtained by an understanding of functional synergism and complex 
interrelations between gene mutations, with an increasing importance of genome-wide 
cancer studies rather than testing for single genes in isolation.  
4.5 Performance of the NGS assay for AML diagnosis 
4.5.1 Detection of Somatic Mutations 
NGS technology has now progressed sufficiently that multiple studies have now 
been performed and many diagnostic laboratories are experimenting with allele-specific 
assays to identify hotspot mutations in genes. For validation, it is impractical to have 
positive controls for mutations in each region or to confirm all alterations detected 
independently. Diagnostically, this would not be required. However, to demonstrate 
confidence in a new assay, the conventional approach is to assess the overall 
performance of the sequencing platform using different samples with a range of mutation 
types (Singh et al., 2013). In this study, the experimental custom panel using Illumina 
NextSeq and SureSelect analysis was compared to a different sequencing technology and 
mutation hotspot panel; Ion Torrent PGM/Ion AML Ampliseq. A proportion of genes in 
the experimental panel were not covered by the standard AML Ampliseq but evidence 
from the covered genes offered a direct comparison and provided an understanding of 
the performance of the approach and would inform future work.  
Somatic mutations in the dominant leukaemic clone were identified in all cases 
studied using sequence alignment/configuration with SureCall corroborated by other 
methods. The discrepancies were two lower VAF calls (of 0.18 and 0.15) that were not 
detected by Ion Torrent, and discordance between sequencing the CEBPA mutations in 
sample 27. There were no abnormalities found by Ion Torrent that were not detected by 
the study, suggesting 100% sensitivity and false positive calls appear unlikely. Despite the 
rapid advances in NGS development to clinical standards, anomalies in sequencing are 
still apparent in all studies. Standard NGS analysis software typically makes insertion calls 
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based on data obtained during the initial read mapping and alignment process, which is 
thought to be the source of the errors observed in these data, because of the difficulty 
associated with always aligning short reads consistently. 
In line with the developing nature of this technology, improvements are still to be 
gained in bioinformatics and there is need for standardisation of practice. In a recent Pre-
Pilot external quality assurance round for AML mutation detection, variability in all 
aspects of the process was observed including gene panel composition, variants detected, 
variant nomenclature and pathogenicity classification (UKNEQAS, 2017). In particular, 
nineteen out of twenty-three participants detected an IDH2R172K variant, five out of 
twenty participants detected a KRASG12R variant of low VAF and only nine out of twenty 
three participants detected an FLT3-ITD, due to attempting to use inappropriate variant 
calling software. This was a trial assessment but shows the current stage of development 
of NGS for mutational screening. By applying relevant bioinformatic software for variant 
detection, this assay performed well and appears would perform favourably compared to 
other systems. It is understood that NGS is still at an early phase of its development for 
AML diagnosis but this will improve with further use and refinement of the sequencing 
technology, improvement in bioinformatics approaches and with more personal 
experience in variant calling, to permit expert review and to recognise nonsensical calls. 
4.5.2 Detection of FLT3 and CEBPA insertions 
The inclusion of regions of genomic insertions is essential for a comprehensive 
mutation profile in AML, due to the prognostic significance of NPM1, FLT3-ITD and 
KMT2A-PTD. This analytical pipeline was not used to detect CNV; detection of ITD/PTD 
was achieved in this experiment by targeted sequencing of the entire span of the known 
regions to look for signature junction fragments. This avoided reliance on copy number 
estimates of duplicated regions and  extending sequencing into normal regions as normal 
controls to validate duplications, which is complex and bioinformatically demanding 
(Conte et al., 2013).  
The favourable NPM1 exon 11 insertions are typically of uniform size and, 
generally, do not present a challenge for sequencing; most sequence alignment software 
is designed to detect small indels as well as SNV and short reads containing small 
insertions retain sufficient homology in the regions flanking the insertion to permit 
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alignment whereas large insertions do not. NPM1 is detected reliably in most AML NGS 
studies, without using special procedures (e.g. Luthra et al., 2014) and is sufficiently 
sensitive to be used to detect MRD (Salipante et al., 2014). All thirteen NPM1 mutations 
in our samples, that were detected by standard PCR, were also identified by the two NGS 
platforms and multiple sequence mapping programmes. The software used in SureCall for 
sequence alignment miscalled the tetranucleotide sequence in three out of eleven cases; 
the reason for accurate detection of the duplicate but wrong assignment of the sequence 
is unclear but is probably an issue of reporting by the software and will be investigated 
further. Whilst not currently of significance, allelic heterogeneity is a known feature in 
NPM1 mutation which may prove to be important and needs to be accurately 
represented (Falini et al., 2007; Alpermann et al., 2016). 
FLT3-ITD and CEBPA present different challenges and are notorious for being 
difficult to detect by NGS. FLT3-ITD, in particular, has highly variable length (up to 300bp) 
and allelic burden. SureCall performed poorly for detection of FLT3-ITD but this was 
expected as it is designed for detecting SNVs and short insertions only. Pindel was chosen 
for FLT3-ITD detection and eleven mutations, ranging from 12 – 87bp, were detected by 
this NGS approach, which was in complete concordance with the results from standard 
molecular tests (Spencer et al., 2013). Other reports suggest that Pindel is limited for 
determining large FLT3-ITD, which were not detected in our patients (Bolli et al., 2015; Au 
et al., 2016). Alternative detection methods (Schnittger et al., 2014; Kim et al., 2016) and 
special bioinformatics approaches for ITDs (Kadri et al., 2015; Rustagi et al., 2016) are 
being tested. Allelic fraction was not calculated by our conventional testing and so could 
not be compared. The nine samples with CEBPA appeared to be reliably called, with the 
exception of case 27 with the largest insertion (39 bp by this method) which showed 
multiple variant alleles but only one (heterozygous) call by Ion Torrent, which is assumed 
to have been a false by this method. Platforms such as Ion Torrent relying on Single 
Nucleotide Addition (SNA) strategies suffer predominantly indel errors (Dohm et al., 
2008; Schirmer et al., 2015) and homopolymer read errors occur with homopolymers 
longer than 6~8bp (Goodwin et al., 2016). 
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4.5.3 Detection of gene fusions and structural variation 
A novel feature of this project was to evaluate the use of a highly targeted assay 
to detect known, clinically relevant, structural alterations by combining testing genomic 
DNA with hybrid capture of genomic features, thereby detecting multiple types of 
genomic abnormalities in AML, in a single workflow. NGS of structural variation 
breakpoints is feasible and has shown to work with WGS, however, this was only recently 
demonstrated in combination with target enrichment (Abel et al., 2014). The strategy 
required coverage of known genomic breakpoints within exons and introns in genes of 
recurrent gene fusions and tandem duplications. By definition this necessitated selection 
and sequencing of repetitive intronic regions where breakpoints typically reside, which 
favoured a hybrid capture approach, as opposed to target enrichment by amplification. 
Solution-phase hybrid capture can capture larger regions, has fewer PCR-introduced 
artefacts and has better within run and inter-run reproducibility.  
Chromosomal breakpoints involved in structural variation arise from DNA double-
strand breaks (DSBs) and ineffective DNA repair. The genomic distribution is non-random 
and typically occurs in repetitive regions and may be facilitated by repeat elements 
(Bacolla et al., 2016). However, the relative contribution of different mechanisms to the 
generation of chromosomal translocations and other types of structural variants is 
unclear (Yang et al., 2013; Ghezraoui et al., 2014; Ottaviani et al., 2014). The low 
complexity of regions involved in chromosomal rearrangements presents an issue for 
target enrichment and sequencing of these regions. The breakpoint cluster regions in 
both partner genes of CBFB/MYH11, PML/RARA, DEK/NUP214, RUNX1/RUNX1T1, two 
genes with multiple fusion partners, KMT2A and NUP98, as well as two common partners 
of KMT2A (MLLT1 and MLLT3) were included. All exons of RUNX1, as well as breakpoint 
cluster regions of the RUNX1-RUNX1T1 gene fusion were included. This was successful 
and sufficed to demonstrate the feasibility of sequencing translocation breakpoints for 
this Proof-of-Principle experiment.  
The method of target enrichment for DNA selection used a custom designed 
hybrid capture Agilent SureSelect panel (Gnirke et al., 2009) prior to deep sequencing. 
This enabled the simultaneous identification of specific mutations and structural variants 
in genes described above (section 4.2 and 4.3). Target coordinates needed to be 
thoroughly checked to ensure all regions are adequately covered, before uploading the 
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BED file into the Agilent Sure Design project design tool (Bolli et al., 2015). A reagent kit is 
then provided which contains the custom set of biotinylated RNA 120mer 
oligonucleotides which is used to isolate the specific DNA fragments of interest to form 
the library of genomic DNA for sequencing. 
To optimise target enrichment for the type of library required, different 
adjustments were applied to the design in SureDesign.  Repeat masking was set to the 
lowest stringency (at most 20 bp overlap) to include a standard set of repetitive genomic 
regions in the Bait Tiling process. Masking of repeat sequences was not applied. Different 
iterations of the design were performed, reducing the stringency (to moderate then least 
stringent) in an attempt to optimise coverage. By including regions of low complexity 
within non-coding regions, there is a risk that a larger number of poor quality, non-
specific baits were generated and so ‘Boosting’ was set to ‘maximum performance’ to 
make genomic fragment pull-down consistent and balanced; to increase the number of 
replicate copies of both orphan baits and GC-rich baits.  
5x Bait Tiling was chosen to obtain better coverage and offer the best opportunity 
of capturing the breakpoints of rearrangements when tiling across intronic regions where 
the exact breakpoints are not known. Increased tiling of baits increases the cost of kit but 
in this experiment, the size capacity of the library was not reached in the design tool and 
increasing the frequency was not cost prohibitive. Theoretically, baits are staggered and 
overlap starting every 24bp so that five baits cover each base in each interval, however, 
the exact density of tiling may be less particularly at the extreme 5' and 3' ends of each 
interval. Generally, the higher level of tiling means that a target sequence that is 
represented at the end of one bait is represented in different positions of alternate baits 
that cover the same region. 
Overall coverage of the design by baits was 98.84% with all exonic regions 
showing 100% coverage (see Table 2.2). However, the coverage of targets which included 
introns varied from 96.10% for MYH11 and 99.53% for KMT2A although the design report 
classed all regions with >90% as high coverage. The ‘Regions not covered’ were reported 
by the design software and were found in the alltracks.bed file under missed regions. 
These regions were viewed in USCS Genome Browser and it was noticeable that coverage 
was not evenly distributed and that gaps were present in bait coverage, for example CBFB 
intron 5 was sequenced for inv(16); 16 regions missed with a size of up to 304 base pairs 
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(chr16:67129543 – 67129846). A region of 490 bp within RARA intron 2 had no probe 
coverage (see Figure 4.1). This creates the potential for some genomic sequences to miss 
selection by bait pull-down and therefore miss representation in the sequencing. To 
mitigate this, where possible, the breakpoint cluster regions of both partner genes in a 
known gene fusion were targeted. Also, as DNA sequencing potential is driven by DNA 
fragment shear size and not by bait size or proximity, sequences can be obtained from 
regions without baits by sequencing into these areas with overhanging DNA fragments, 
e.g. a 500bp DNA fragment will not all be covered by the 120mer bait that pulls it down, 
but the entire fragment will be available for sequencing. A core principle of the project 
was that coverage would extend into adjacent regions. This principle also supports the 
sequencing of split reads from chimaeric gene fusions with unknown partners (see 
below). Fragment length was part of a standard workflow and not quantified for this 
experiment prior to sequencing but 500bp fragments are typical. It is possible to enhance 
coverage beyond the bait site by increasing fragment size. Anecdotally, it might be 
possible to pull down fragments of 800 ~ 1,200bp to enhance the sensitivity of the assay, 
which would be a modification for future tests. Theoretically, a randomly sheared 500 bp 
fragment, anchored by a 120mer bait could extend into 380 bp of region that is not 
covered by baits, as could a fragment pulled down by an adjacent bait on the other side 
of the coverage gap. Therefore, regions of several hundred bases could be salvaged, with 
an issue being their alignment and recognition. This might rely on sufficient complexity of 
sequence being present in the paired read from the DNA fragment extending into the 
uncharted regions. The sensitivity of this strategy would need to be tested on more 
samples. 
By capturing non-coding sequences, repetitive areas become the majority of 
sequencing, which could reduce representation of other targeted regions and limit the 
depth of sequencing. The project achieved good read depth achieved for translocation 
detection. Another consequence was that reads with repeat sequences were aligned to 
multiple areas of the genome; 61-63% of off-target alignment resulted. This did not 
appear to affect the variant prediction of gene fusions for the project. It is possible, 
however, that breakpoints may not be recognised amidst regions of low DNA specificity 
and a high degree of redundant sequencing was observed and which reduced efficiency. 
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Figure 4.1. USCC Genome Browser view tracks of RARA intron 2. The diagram shows genome position with coordinates (Window Position in 
black, top track). The ‘Target Regions’ track (green) is the selected region from the design BED file to cover the known breakpoints in RARA 
gene fusions. The lower green track, ‘Covered Probes’ are the probes available from Agilent bait library to cover the target region. The red 
‘Missed Regions’ track are the gaps in probe coverage. The RARA and RefSeq Genes tracks show the RARA gene structure. RepeatMasker is a 
program that screens DNA sequences for interspersed repeats and low complexity DNA sequences; this track shows the repeat elements that 
would be screen by the programme. Bait design was optimised to allow repeat sequences by having no masking (see text). 
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4.6 Bioinformatics 
The project was performed in a diagnostic environment with no prior experience of 
use of NGS and therefore relied entirely on access to external software for bioinformatic 
analysis. Diagnostic bioinformatic pipelines usually contain a mix of software that has been 
developed in-house and externally (Association for Clinical Genetic Science, 2016). A 
bioinformatic pipeline was planned for the project and multiple options were examined 
before arriving at the version that was accessible and worked, as described in Table 2.3 and  
Figure 2.4. Open source, external, non-commercial software that has been published 
following peer review (with detailed documentation, support network and version control) is 
readily available on line. However, the download, installation and implementation of the 
software required specialist expertise and knowledge of computer language coding to run 
the programmes. Without the skill set of a trained bioinformatician, setting up a diagnostic 
pipeline was particularly challenging, at this stage of the technology’s development. Highly 
developed and tested software with a graphical user interface is highly desirable in this 
context. Furthermore, a software package, with settings different to those recommended or 
the default, and the bioinformatics pipeline would need to be validated before introduction 
into clinical service, by comparison with the validation dataset (Association for Clinical 
Genetic Science, 2016). Validation of a bioinformatics pipeline was not possible for the 
project and is the main restriction from widespread dissemination of routine sequencing. 
Sequencing technology providers have belatedly understood this critical need for diagnostic 
grade workflow and commercial software is being developed. 
Different aspects of the analysis required different analytical software and no single 
analytical framework can be used in all cases. Agilent SureSelect, a leading hybrid capture 
system (Hedges et al., 2011; Chilamakuri et al., 2014; Rykalina et al., 2014), was chosen for 
selection of genomic targets. Agilent SureCall suite of software was therefore accessible for 
data analysis and was optimised for use with Agilent reagents. SureCall provided a user-
friendly analysis tool that incorporated the widely accepted, open source libraries and 
algorithms, augmented with tools specific to Agilent assays. Sequence read pre-processing, 
quality control, and read alignment to the reference the genome (BWA-MEM, BWA) were 
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performed using the SureCall package. Single Sample analysis was used to detect mutations 
and insertions or deletions (indels) in individual samples, using SNPPET, an in-house Agilent 
algorithm developed specifically for the detection of low allele frequency variants. The 
software suite provided accurate detection of variants with supporting features to aid the 
annotation. This software was perfectly adequate to access data processing software for 
preparation sequence data and was useful for use by a novice. The graphical user interface 
and incorporation of IGV was particularly helpful. Other software was tried, such as the suite 
of tools provided in Illumina Basespace but was less intuitive for the novice user and because 
Agilent reagents were used, access was not available to Illumina’s BaseSpace Variant 
Studio™. SureCall is available for research use only and would need to be extensively, 
independently validated for diagnostic purposes. SureCall adequately provided initial data 
alignment, using publicly accessible BWA-MEM (Li, 2013). 
4.6.1 Single versus Paired analysis 
The project attempted to analyse the samples without the requirement for a matched 
normal sample, to match the typical diagnostic work-up, whereby normal tissue is not readily 
available at diagnosis from leukaemia patients. The differentiation of germline and somatic 
variants is potentially a significant challenge and the approach employed for the project in 
the filtration of SNVs and indels was designed to minimise the likelihood of misreporting 
inherited variants. This was successful although it introduces more subjectivity into variant 
determination than if germline DNA was co-analysed, with a risk that more variants are 
discarded with uncertain significance and rare (uncurated) pathogenic mutations are missed. 
This process is helped by a structured protocol for variant annotation and the recent 
publication of guidelines for the Assignment of variant significance in cancer (Li et al., 2017). 
The value of paired normal germline DNA as comparator (pre-treatment or remission 
samples) was demonstrated by the GATA2 germline data, where paired analysis was used 
and the controls simplified the distinction between germline and somatic variants. However, 
erroneous calls are still possible with normal control samples and all variants were 
scrutinised manually for significance, to reduce the possibility that clinically important 
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mutations could be missed due to mutations persisting in the remission sample, or pre-
leukaemic sample in the case of our study (McKerrell et al., 2016). 
4.7 Variant annotation and the most useful determinants of pathogenicity 
SureCall provide several tools for mutation classification and interpreted the 
chromosomal location of the mutation with Human Genome Variation Society (HGVS) 
nomenclature. Each variant was examined for quality and confidence measures, as described 
in Methods (section 2.6 and Table 3.5), before using links to external databases for further in 
silico analysis. Each variant was evaluated by the software based on its location, amino acid 
change, and effect on protein function; Sorting Intolerant From Tolerant (SIFT) (Hu & Ng, 
2013), was particularly informative, and impact on structure and function of the protein 
using the Polymorphism Phenotyping v2 (PolyPhen-2) tool. Further information regarding the 
mutation was then aggregated from various public sources, including Catalogue of Somatic 
Mutations in Cancer (COSMIC), PubMed, and Locus-Specific Databases. After collecting the 
various inputs for classification, the proprietary mutation classifier evaluated the significance 
of the mutation following default guidelines. Each mutation was triaged to categorise the 
predicted mutations by reviewing supporting evidence. Variant calls passing filtering were 
examined in the built-in Integrative Genomics Viewer (IGV) (Thorvaldsdottir et al., 2013) to 
confirm regional coverage, visualize read alignments and confirm variant calls. 
Typically, no single criterion was used to exclude pathogenicity but some were more 
useful determinants of pathogenicity than others. Generally, the sequencer generated 
performance scores were adequate and quality scores generated upon alignment were 
satisfactory. Filtering did not eliminate variants on these criteria alone. A small number of 
reads with low VAF and/or low coverage were excluded by strand bias; the surviving variants 
with low VAF are described above. It was very difficult to filter variants by VAF alone as VAF 
nearing 1.0 or 0.5 resembled germline homozygous or heterozygous fraction allele fraction 
and caution was exerted in the use of VAF to define a somatic variant due to the 
mononuclear cells enriched prior to DNA extraction. 
Single Nucleotide Polymorphism Database (dbSNP) was consulted for all variants, to 
exclude previously reported variants that occur naturally in the human population. It is 
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known that such repositories include somatic mutations, and indiscriminate filtering can 
often remove variants with known pathogenicity (e.g. IDH2 R140Q) (Jung et al., 2013; Kenna et 
al., 2013). Benign germline polymorphisms were defined as variants which are common in 
the human population, with a population frequency of ≥1% (in dbSNP, a large normal 
population screening databases) were excluded as probable inherited polymorphisms 
germline SNPs; this approach eliminated variants which otherwise looked to be convincing 
cancer genes. All related information was scrutinised in ambiguous annotations and were 
examined in multiple sources. 
An entry in the COSMIC database, with reports in haematopoietic tissue of a 
confirmed somatic variant but caution was exerted with more ambiguous records. All 
COSMIC annotations were examined in detail for their relevance. An entry as a somatic 
variant in an unrelated tumour was considered poor quality evidence for pathogenicity and 
cross-reference with other information was necessary. Caution that germline SNPs are also 
present in COSMIC, derived from unpaired data analysis and it is possible that acquired 
mutants may be present in dbSNP (Kenna et al., 2013; Jung et al., 2013). All related 
information was scrutinised in ambiguous annotations and multiple points of evidence 
considered.  
4.8 Experimental design and future considerations 
4.8.1 Patient cohort 
The Oncology Cytogenetics service offers a regional service to all DGHs, specialised 
tertiary hospitals and paediatric services for leukaemia genetic diagnosis. The case mix is 
considered representative of the range of patient demographic and AML subtypes. Cells were 
collected from samples with cells that were surplus to diagnostic requirements. This may 
introduce limited bias from preferential selection of patients with cellular bone marrows. 
However, hypercellularity of the involved bone marrow sample is a typical feature of the 
disease when testing the involved tissue and this is not thought to be an issue. Five samples 
were rejected for having poor yield of DNA but this was partly due to training issues in DNA 
extraction. The cases were representative of the typical age range in AML; the median age of 
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the patient cohort was 64 (range 14~84). AML with recurrent genetic abnormalities were 
included in the group, including 4 CBF-AML (11%), 2 APML (5.5%) and 1 11q23/KMT2A (3%). 
Approximately, the expected numbers of NPM1 mutated (%) and FLT3-ITD (%) were included 
for this small sample and so random occurrence will explain deviation from expected. 50% of 
cases were NK-AML and 64% of cases overall were of intermediate prognosis. Morphological 
subtypes were inconsistently reported from multiple diagnostic centres; in the absence of 
recurrent genetic abnormalities, most reports made the diagnosis of ‘AML’ only or ‘AML, not 
otherwise specified’ without specifying the morphological subtype. This probably reflects the 
questionable significance of morphological subtype alone (Swerdlow et al., 2008).  Multiple 
different morphological types were present but without re-interpretation of flow cytometry 
immunophenotyping, disease subtype could not be analysed further. Similarly, disease 
history was not commented on in morphology reports and so background of myelodysplasia 
to identify ‘AML with myelodysplasia-related changes’ and prior disease history to diagnose 
‘therapy-related myeloid neoplasm’ was unreliable although the cohort contained each of 
these categories; this final diagnosis would be made at MDT, with full facts from the case 
presentation. Crude survival data (date of diagnostic marrow - date deceased) was obtained 
from the NHS Summary Care Record (where not obtainable from local database) to inform 
the influence of genetic testing within the remit of the ethical approval. These records were 
not scrutinised further and therefore detailed cause of death is not known and will confound 
some data. 
4.8.2 Choice of target genes 
It was necessary to define a narrow range of diagnostically relevant and actionable 
mutations which a comprehensive genomic assay would need to identify. Genetic targets 
were selected for the assay based on known current clinical utility and likelihood that genes 
would have future applications, based on current impact on disease classification, efficacy for 
risk-stratification and potential as biomarkers for emerging clinical applications in the 
individualisation of treatment (Grimwade et al., 2010; Döhner et al., 2010). To capture 
sufficient genes with recurrent single nucleotide variation, a list was generated of known 
genes and revised, taking into account emerging evidence from a range of multiple sources, 
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particularly the 23 ‘significantly mutated’ genes from The Cancer Genome Atlas (The Cancer 
Genome Atlas Research Network, 2013) and a larger cohort of AML cases with genes listed by 
frequency and mutation type with an applied false discovery rate calculations to rank them 
by significance (Broad Institute, 2011). Other sources where mutation profiling of AML has 
inferred clinical significance in specific genes were also considered (Grossmann et al., 2012; 
Patel et al., 2012; Conte et al., 2013; Rinke et al., 2013; Hou et al., 2014; Kihara et al., 2014). 
A panel of 30 genes, generally of the highest frequency resulted, including the 10 most 
frequently mutated in CN-AML. Many lacked obvious clinical validity at the time of design but 
were recurrent and sufficiently common in multiple datasets that they may achieve 
significance by their frequency in future, independently or as part of an informative 
mutational profile. The least common abnormalities were present in the ‘long tail’ of genes 
of low frequency and an arbitrary cut-off was finally made for practicality and involved 
subjective assessment but was satisfactory for this POP study. All exons from these 30 genes, 
for detection of SNV only, were sequenced. The selection of specific exons of regions to 
capture was a particular challenge due to varying nomenclature of genetic sub-regions, from 
different sources in the literature, changes over time, with different version of the Human 
Genome reference and with exons based on nomenclature of different expressed transcripts. 
All exons were sequenced from these genes as a result, to ensure that all relevant exons 
were targeted and for simplicity of defining gene coordinates. A small amount of redundant 
sequencing resulted, without significantly increasing the sequencing burden (compared to 
sequencing intervening introns),  e.g. the exonic sequencing of 30 genes for SNV only 
represented 405kbp whereas, the 15 genes with introns was 439kbp. The sequencing 
showed excellent detection and sequencing depth of all regions selected. The main 
implication of capturing repetitive sequences was that there was additional sequencing 
necessary to cover the large intronic regions of structural variant breakpoints. A 
disproportionate amount of sequencing was necessary to detect translocation breakpoints, 
particular as both partner genes are also sequenced. With the addition of more genes to the 
panel for structural variant detection, these then become the bulk of the sequencing, 
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including sequencing a lot of repeats and proportionately little of other targeted regions, or 
needing to sequence more to get the depth of coverage on the targets.  
The benefits of sequencing both genes in a translocation, including the non-oncogenic 
partner (e.g. MLLT3, MLLT1 and RUNX1T1), was thought to increase the likelihood of 
capturing the relevant breakpoint. Introns and exons were sequenced encompassing the 
positions of typical junctions of FLT3 internal tandem duplications and KMT2A partial tandem 
duplications were sequenced. This worked successfully. Targeting NUP98 only in the panel 
also detected DDX10 as its partner gene. However, by sequencing the oncogenic partner 
within a pair of fused genes, there is an option to reduce costs with no loss of sensitivity. 
Sensitivity performance would need to be assessed with more cases. 
Several genes were not included in the original panel to restrict costs and because 
they would be unlikely to be detected for the study but they would need to be included for a 
comprehensive gene set for diagnosis. This includes BCR-ABL1 now that this is a provisional 
diagnostic entity, and is a prognostic marker that also indicates alternative therapy (Arber et 
al., 2016; Döhner et al., 2016).  RBM15-MKL1 is a rare gene fusion resulting from t(1;22) but 
might be considered necessary if paediatric disease is to be included. RPN1-EVI1/MECOM 
presents a particularly difficult challenge in this regard; EVI1/MECOM translocations are 
important diagnostic and prognostic subgroups. However, EVI1/MECOM is activated from 
distance with breakpoints spanning a large region upstream and downstream of the EVI1 
gene (Chapter 5, AML pg 56 from Heim & Mitelman, 2009). The cost of sequencing extensive 
genomic regions was prohibitive for this research, particularly by the price structure of the 
bait design kit. This will remain lest the production of the targeted panel is reduced or parts 
of the assay are replaced by standard technique such as FISH. 
A number of genes that are uncommonly mutated but achieve significance for other 
reasons would probably now need be included in a revised set for contemporary diagnosis of 
AML. Due to our understanding advancing as the result of some landmark reports into the 
significance of AML genomics, to organised patients into functionally relevant categories, 
more class-defining genetic abnormalities would need to be included (Metzeler et al., 2016; 
Papaemmanuil et al., 2016). (Metzeler tested 68 genes and Papaemmanuil 111 genes plus 
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cytogenetic subgroups).  The sequencing methodology is modular and target regions can be 
redefined to include any newly discovered gene mutations without significant changes to 
laboratory protocols and with only marginal increases in costs, with the main cost in this 
experiment being redesign of custom target baits.  
There is an increasing demand for testing all genes from recognised functional 
groups, such as cohesion complex, spliceosome, signalling proteins and histone-modifying 
proteins. The most common genes from these categories are represented in the test gene 
panel. However, other genes within these groups, which are individually rare, were 
researched in comprehensive studies. As a result, they are now considered mutually 
exclusive with other members of the group and typically one representative mutation is 
adequate for AML pathogenesis. Although rare, genes within these groups are now 
considered interchangeable and cumulatively comprise a group of clinically and relevant 
genomic alterations and interrogation of the larger set of cancer-related genes is required for 
most accurate classification. For example, untested cohesion complex genes STAG1 and 
SMC5 and spliceosome genes SF1, SF3A1, SF3B1, SRSF2, U2AF2, U2AF35, U2AF65, ZRSR2 and 
PRPF40B may need to be included for a comprehensive profile for AML diagnosis. 
4.8.3 CNV 
Copy number abnormalities and zygosity changes are key determinants of prognosis 
in many cancers including AML and MDS. For a comprehensive test for all types of genomic 
abnormalities, CNV and CN-LOH would be necessary to obtain a complete picture of genomic 
changes and replace the battery of existing conventional tests. Copy number analysis of a 
large number of polymorphic SNPs evenly spaced and consistent coverage would allow 
identification of genome-wide CNV and CN-LOH which has been shown to be informative – 
cost relative to information gained (Gronseth et al., 2015). In current diagnostic practice, 
large-scale genomic gains and losses are detected using karyotyping or FISH, but more subtle 
changes go undetected, as does CN-LOH. CNV analysis was not performed for these samples 
due to added complexity of experimental design and that markers would have to be designed 
to comprehensively cover the genome at high density, thereby increasing complexity of 
design and amount of sequencing required. Coverage was very consistent across different 
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samples and so by normalisation of gene coverage relative to each sample coverage, copy 
number status would have been possible without matched normal DNA (Bolli et al., 2015; 
McKerrell et al., 2016). Only few genomic targets were present on each chromosome and it is 
not anticipated that this would be informative. 
4.8.4 Minimal residual disease 
All AML patients will harbour acquired genetic abnormalities in their leukaemia cells, 
and NGS assays, such as the experimental technique, provide testing an extended set of 
genetic markers for the disease and offer the opportunity for the systematic assessment of 
minimal residual disease (MRD), applicable to all patients. The identification of clonotypic 
mutations at the molecular level breakpoints offers the potential for detection of MRD by 
gDNA at the cellular correlated to absolute cell numbers with advantages over gene 
expression. The recent development of microfluidics-based systems, (e.g. digital PCR) 
provides the potential to develop assays with higher sensitivity (Hindson et al., 2013) and 
personalisation of marker detection for a greater number of patients. However, this also 
presents challenges for bespoke design of individual assays, standardisation, validation of 
assays to accreditation standards, and interpretation of the clonal dynamics of a wide range 
of genetic lesions, which are known to vary in their relapse kinetics. The timescale of 
identification of a signature profiles and subsequent design of a testing regime for 
monitoring translation for its universal translation to clinical setting would be demanding. 
Consensus PCR primer sets would not be possible for any but the common recurrent 
mutations and gene fusions. However, there is large potential for the design of primers for 
specific qPCR reactions which can be constructed for patient-specific assays for DNA-based 
post-treatment MRD measurement, with broader applicability rather than the expression 
fusion transcripts assays using RNA that are currently necessary (Ommen, 2016). 
 
4.9 Feasibility of introducing NGS protocol into routine practice 
The successful trial of this novel NGS shows the principle that the assay is technically 
feasible and has the potential to offer benefit to patients for the diagnosis of AML. This is 
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encouraging that upon further trial, it could proceed to show analytical validity and clinical 
utility, to merit its validation for use in the medical laboratory (Mattocks et al., 2010; 
Association for Clinical Genetic Science, 2015). It is therefore worthy to consider the 
feasibility of its introduction into routine practice. The technical challenges are described 
above and would be overcome by gaining more experience in the use of the NGS platform 
and variant annotation. The performance of the sequencers themselves is no longer an issue 
for deep sequencing and variants with low allele fraction can be confidently called.  
The cost of generating sequencing data is also no longer a restriction; the costs of 
individual, targeted assays are reasonably priced and are in the same order of magnitude of 
other genetic and cytogenetic tests. The capital cost is not inconsiderable; taking into 
account automation, IT infrastructure and data storage capacity, as well as the cost of 
sequencers. However, this initial outlay is not insurmountable; the cost is transparent and 
therefore can be planned for. Many reliable analysers are available, from different 
companies, to meet the needs of different applications and are scalable to meet the needs of 
the laboratory and their price is no longer prohibitive (Goodwin et al., 2016). 
The need to achieve diagnostic standards for routine laboratory practice presents 
obstacles not typically encountered in research. For the molecular diagnosis of AML, a rapid 
diagnosis is necessary for the prompt assignment of therapy. The small amount of DNA used 
in this project can be transferred easily and does not rely on labile RNA preservation and 
transportation. The analysis of genomes in the clinical context might take several days of 
sample preparation and sequencing and the complex data, several more days of expert 
analysis. This brings with it the requirement to have scientific and technical staff with the 
necessary skills and expertise to deliver the new services. However, from the experience of 
this project, the timescale for data analysis from individual samples and the clinical 
interpretation of genome sequencing data with emerging frameworks to guide analysis is not 
a problem. Once the technique is established, it would be possible to run such assays on high 
or lower-throughput sequencers, to analyse up to 20 samples once or twice weekly and 
achieve clinically relevant turnaround times of less than 14 days, thus integrating 
comfortably into a diagnostic service (McKerrell et al., 2016). Batching tests to make best use 
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of sequencer capacity may be a problem at first. It is likely, however, for the near future, 
cancer genetics services must accommodate testing by simpler, cost effective methods, such 
as cytogenetics, FISH and PCR for rapid testing where necessary. Extensive testing would be 
necessary, for the validation of the new assay. An enormous amount of work is necessary to 
develop and validate the assay as diagnostic grade tests for clinical use, to standardise the 
methodology and demonstrate accurate, consistent and reliable performance for UKAS 
accreditation and for EQA. A significant change management programme would be necessary 
to deliver the full transformation of genomic services.   
Genome sequencing requires a ‘big data’ approach to analysis and interpretation, 
storage capacity and transfer of this data across networks. This is available in many research 
facilities but not in many NHS establishments. Data security will be a significant issue, to 
protect patient identifiable data with linked demographics and personal DNA sequence data. 
There is a serious practical challenge of the extensive use of genomic data in an expansive 
but under-resourced health service (Delon & Scott, 2016).  
The bioinformatics challenge is significant and presented the largest problems for this 
project. A multitude of freely available open source and commercial software is readily 
available for use but requires powerful computer hardware for its use, significant data 
storage capacity on a protected server, and expertise to choose the most appropriate 
software to set up and run. Complex data still requires the development and optimisation of 
mathematical algorithms to identify signatures characteristic of different AML subtypes 
(Medical Research Council, 2013). Complex bioinformatics is beyond the capability of small 
laboratories. For the time being, access to trained personnel is absolutely necessary and 
bioinformatics expertise is a key constraint. The balance between the capacity requirement 
of bioinformatics and interpretive genetic scientists is not clear; as algorithms are developed 
and the sector matures the necessary skill mix is likely to change (Delon & Scott, 2016).  
Genomic testing by NGS can realistically aid therapeutic decision making, to 
determine best standard or novel treatment options and to eliminate ineffective or possible 
harmful therapy. A number of challenges are still apparent for this to reach its full potential. 
Genomic profiling must be built into new care models and diagnostic pathways. Scientific 
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evidence of clinical utility is necessary to optimise treatment, which ultimately requires the 
genomic data to be incorporated into randomised controlled trials. The evidence base is 
gradually accumulating to give scientists the resources to assess the clinical utility of 
sequence variants and the technology is maturing to be able to deliver these goals. Changes 
in practice need to be closely aligned with a health economic assessment of their impact on 
laboratory infrastructure and on patient pathways; the cost of personalised medicine is 
significant. However, genomics is primed for progression to routine practice and the 
potential benefits of increasing personalisation of medicine will be significant. 
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5.0 Conclusion 
Cytogenetic and molecular genetic investigations are routinely carried out in AML. 
They aid diagnosis and are critical for prognostic stratification, to optimise therapy and 
enhance survival of patients. NGS technology can detect a large number of genetic variants, 
defining numerous abnormalities at high resolution, with patient-specific profiles. Advances 
in the understanding of the genomics of AML have defined a landscape of recurrent gene 
mutations. NGS-based assays will be employed to optimise the genetic profiling of AML, to 
enhance the efficacy of conventional therapies and maximise the appropriate use of 
available targeted therapies. This will allow patients with activating mutations in specific 
genes, which are not currently part of routine testing, to be identified for clinical trials and 
expand therapeutic possibilities for AML patients. It is anticipated that NGS will become a 
standard of care in AML within the next few years but optimised assays need to be devised 
and extensive testing is required for validation of these new platforms.  
This project describes a new molecular diagnostic strategy that enables extensive 
characterisation of the AML genome at diagnosis, which improves partitioning of patients 
into diagnostic and prognostic groups. The assay shows good performance for highly 
targeted NGS using genomic DNA, to detect all clinically relevant types of genomic 
abnormalities, including a broader range of abnormalities than multiple current clinical 
assays. The capability to identify gene fusions, to breakpoint resolution, adds to the 
understanding of the use of targeted sequencing for chromosomal translocation detection. 
This method appears to have the potential to be a powerful and reliable assay and that it 
could be refined for use in the diagnostic laboratory, with the potential to rationalise 
multidisciplinary workflows. The cost is comparable to standard testing by using targeted 
sequencing, facilitating optimal use of analyser capacity. The method justifies further 
investigation and consideration to develop as a validated assay, for clinical service. 
  In conclusion, these results suggest that this targeted NGS method, for AML genomic 
profiling, offers promise to reliably detect actionable genetic alterations across a panel of 
diverse types of cancer genes. This provides an alternative strategy to other panels for AML, 
 180 
 
currently in development. If deployed in the clinical diagnostic arena, its implementation has 
the potential to enhance the ability to identify AML patients at high risk of relapse as well as 
those that would benefit from molecularly directed therapies, to improve clinical outcomes. 
This may ultimately impact clinical practice by offering a categorical means to identify 
alterations of genes and pathways, targeted by existing and emerging drugs, thereby 
accelerating the practice of personalised cancer medicine.  
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7.1. Appendix 1. Concentration of DNA from samples used in the project 
Table 7.1 Concentration of DNA from 36 samples use in the project 
Sample ID 
  
  
Concentration 
Nanodrop 
(ng/µl) 
Concentration 
Qubit 
(ng/µl) 
  
  
Absorbance 
A260/280 
 
DIN 
Comments 
  
  
13.0816 21.2 110 1.85 8.8   
13.0881 26.4 71.6 1.85 8.2   
13.0883 34.9 34.6 1.95 7.1   
13.0886 38.3 79.4 1.95 7.3   
13.0895 767.0 1060 1.84 7.9   
13.0970 (tubeA) 9.6 13.1 1.74 8.2 2 tubes. Low yield 
13.0970 (tubeB)   12.8   8.8   
13.1004 15.9 17.9 2.02 7.8   
13.1027 14.7 24.2 1.76 7.4   
13.1050 84.7 63.6 1.98 8.3   
13.1141 (tubeA) 7.1 3.48 2.12 8.3 2 tubes. Low yield 
13.1141 (tubeB)   12   8.3   
13.1216 130.0 129.2 1.92 8.1   
13.1249 107.0 124.4 1.90 8.8   
13.1420 (tubeA) 8.0 2.92 2.06 OK 2 tubes. Low yield 1.5µg 
13.1420 (tubeB)   14.1   8.6   
13.1485 59.7 60.8 1.82 8.4   
13.1568 13.4 30.8 1.95 7.2   
13.1760 (tubeA) 12.8 16.2 1.96 8 2 tubes 
13.1760 (tube B)   5.36   OK   
13.1772 33.5 63.4 1.99 6.7   
13.1931 178.1 58.2 1.87 8.4   
13.2006 63.8 20.6 2.04 6.5   
13.2017 40.3 114 1.85 8.5   
13.2231 55.1 72.8 1.85 8.1   
13.2246 5.7 32.3 2.16 8.3 Low yield 2µg 
13.2326 31.9 41 1.87 8.4   
13.2412 74.9 66.6 1.86 8.8   
13.2419 31.4 28.6 1.91 7.4   
13.2540   14.5   8.6  Nanodrop n/a 
13.2541 37.9 27.8 1.93 8.5   
13.2679 49.8 17.7 2.03 8.1   
13.2680 97.9 79 1.93 8.9   
 221 
 
13.2758 243.4 207 1.87 9.6   
13.2878 42.0 40.4 1.84 9   
13.2957 77.4 17.8 2.00 6.4   
13.3005 68.9 75 1.84 8.3   
13.3120 45.1 7.8 1.96 OK   
13.3157 57.6 77.6 1.85 8.1   
13.3334 47.9 74.6 1.86 8.3   
 
DNA concentration was recorded in house using a Nanodrop lite at the time of extraction. 
Concentration was reassessed at the time of sequencing using a Qubit, which was considered 
to be more reliable. The Absorbance ratio (A260/280) was estimated by the Nanodrop and is 
used to assess the purity of nucleic acids, with pure DNA being ~1.8. DNA Integrity Number 
(DIN) is produced by the Agilent 2200 TapeStation instrument to score gDNA samples. The 
DNA integrity number (DIN) ranges from 1 to 10 and is a reliable and reproducible objective 
measure of gDNA degradation.  
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7.2. Appendix 2. Read Metrics from Main Sequencing Run on Illumina Nextseq 
 
Table 7.2  showing run statistics broken down into lanes for each of paired read 1 and 2. The 
number of tiles per lane (Tiles) and the density of clusters (in thousands per mm2) detected 
by image analysis, +/- 1 standard deviation (Density) and the percentage of clusters passing 
filtering, +/- 1 standard deviation (Cluster PF) are shown. Phase and Prephase are the 
percentage of molecules in a cluster for which sequencing falls behind (phasing) or jumps 
ahead (prephasing) cycles within a read, for the NextSeq, estimated empirically for every 
cycle and this figure is an aggregate value determined from the first 25 cycles. The number of 
reads (clusters in millions), the number of clusters (in millions) passing filtering (Reads PF), 
and the percentage of bases with a quality score of 30 or higher (%Q ≥ 30) and the number of 
bases sequenced which passed filter (Yield) are displayed.  150 cycles were error-rated using 
PhiX and the alignment rate for each read is shown (Aligned) and error ate calculated from 
the PhiX alignment is shown (Error Rate %) as well as error rate at specific cycles (35, 75 and 
100). The intensity at Cycle 20 (as a % of the intensity at Cycle 1 (Intensity at cycle 
20)/(Intensity at cycle 1) x100) is shown. 
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Table 7.2. Read Tables Metrics 
Lane Read Tiles Density 
(k/mm2) 
Cluster PF 
(%) 
Phase/ 
Prephase 
(%) 
Reads Reads PF %≥Q30 Yield 
(Gbp) 
Aligned 
(%) 
Error Rate 
(%) 
Error Rate 
35 Cycles 
(%) 
Error Rate 
75 Cycles 
(%) 
Error Rate 
100 Cycles 
(%) 
Intensity 
Cycle 
20/1*100 
1 1 216 203 ±6 91.59 ±1.68 0.148 / 
0.094 
131,999,848 120,908,800 88.2 18.14 0.96 ±0.09 0.89 ±0.25 0.23 ±0.19 0.33 ±0.21 0.44 ±0.20 5,244 ±524 
  2 216 203 ±6 91.59 ±1.68 0.187 / 
0.147 
131,999,848 120,908,800 82.03 18.12 0.93 ±0.09 1.31 ±0.43 0.31 ±0.13 0.58 ±0.24 0.76 ±0.28 5,789 ±534 
2 1 216 200 ±10 91.77 ±1.53 0.141 / 
0.086 
130,027,752 119,339,056 88.86 17.90 0.93 ±0.09 0.86 ±0.16 0.23 ±0.08 0.30 ±0.08 0.41 ±0.09 5,407 ±558 
  2 216 200 ±10 91.77 ±1.53 0.194 / 
0.150 
130,027,752 119,339,056 82.44 17.88 0.90 ±0.09 1.25 ±0.28 0.29 ±0.06 0.55 ±0.13 0.73 ±0.17 5,538 ±567 
3 1 216 195 ±5 89.21 ±1.86 0.135 / 
0.091 
126,349,864 112,689,376 86.23 16.90 0.83 ±0.04 1.25 ±0.22 0.37 ±0.22 0.50 ±0.20 0.65 ±0.19 3,413 ±267 
  2 216 195 ±5 89.21 ±1.86 0.189 / 
0.152 
126,349,864 112,689,376 78.16 16.90 0.80 ±0.03 1.96 ±0.26 0.46 ±0.11 0.88 ±0.15 1.16 ±0.18 4,194 ±622 
4 1 216 192 ±5 88.58 ±2.04 0.127 / 
0.090 
124,502,872 110,321,568 86.22 16.55 0.83 ±0.03 1.34 ±0.28 0.34 ±0.07 0.49 ±0.12 0.68 ±0.16 3,102 ±196 
  2 216 192 ±5 88.58 ±2.04 0.177 / 
0.152 
124,502,872 110,321,568 77.04 16.55 0.78 ±0.03 2.24 ±0.51 0.52 ±0.12 1.01 ±0.23 1.35 ±0.31 3,866 ±497 
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7.3. Appendix 3. Life Technologies Ion Torrent PGM sequencing  
Six Ion Torrent PGM chips were used to provide sequencing proton… sequencing for the 36 
AML samples. Sample DNA density varied significantly depending on the yield from the 
original sample, mean 114 ng/ul (range 3.7 – 786). Volumes added to the Chip were adjusted 
accordingly to ensure the correct amount of DNA. All samples used 10ng with the exception 
of 3 (mean 10.15, range 9.42 – 12.9). 
 
Table 7.3 Ion Torrent sequencing - Chip overview and metrics  
Mean no. mapped reads per sample 832258 (397752 - 1147952) 
Mean On Target % (range) 89.68 (75.18 - 97.04) 
Mean Depth (range) 3431 (1701-4889) 
Mean Uniformity % 96.3 
End to end reads % 85.9 
Amplicons with at least 500 reads % 97.93 (94.5 - 99.2) 
Mean Total reads per chip 5139307 (4533640 - 5583212) 
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7.4. Appendix 4. Published work 
7.4.1 Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with 
ETV6-LYN gene fusion.  
SNP microarray testing was performed in a limited number of cases during the course of the 
project, to gain experience in handling and analysing genomic data.  
The following article was published regarding the detection of an unusual 
chromosomal translocation in myeloproliferative neoplasm with eosinophilia and T-
lymphoblastic lymphoma. The methodology was not the same as that used for the NGS 
project and therefore is not referred to directly. This early work does not necessarily conform 
to the Manchester Metropolitan University ‘Institutional Codes of Practice and Research 
Degrees Regulations’.  
Blood Cancer J. 2016 Apr 8;6:e412. doi: 10.1038/bcj.2016.11. 
Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with 
ETV6-LYN gene fusion. 
Telford N(1), Alexander S(2), McGinn OJ(2), Williams M(3), Wood KM(4), Bloor 
A(5), Saha V(2)(6). 
Author information:  
(1) Oncology Cytogenetics, The Christie Pathology Partnership, The Christie NHS 
Foundation Trust, Manchester, UK. (2) Children's Cancer Group, Centre for Paediatric, 
Teenage and Young Adult Cancer, Institute of Cancer, University of Manchester, Manchester, 
UK. (3) Leukaemia Biology Group, Institute of Cancer, University of Manchester, Manchester, 
UK. (4)Department of Cellular Pathology, Royal Victoria Infirmary, The Newcastle upon 
Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK. (5)Haematology and 
Transplant Unit, The Christie NHS Foundation Trust, Manchester, UK. (6)Tata Translational 
Cancer Research Centre, Tata Medical Center, Kolkata, India. 
DOI: 10.1038/bcj.2016.11. PMCID: PMC4855251.PMID: 27058227  [Indexed for MEDLINE] 
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7.4.2 Germline GATA2 mutation in three siblings with familial Myelodysplastic syndrome 
 
This is an unpublished, draft report of a family with GATA2 germline mutation, whose MDS 
and AML samples were tested by the methodology described in the project. My analysis 
confirmed a frameshift deletion of CTTCTGGCGGC in GATA2 at exon 5 
c.1021_1031delGCCGCCAGAAG p.(Ala341SerfsTer39). A WT1 (32417910 G>T) missense 
substitution was also detected in the sibling with AML. 
 
Clinical and cytogenetic features of myeloid malignancy in three siblings with familial 
GATA2 frameshift mutation without syndromic features 
 
Nick Telford 1, Jamie Ellingford2, Jill Urquard2, Marion Schneider3, Rob Wynn4, Andrew Will4, 
Denise Bonney2, Bronwyn Kerr5, Graeme Black5, Stefan Meyer3,4,5 
 
Introduction 
Familial myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) are 
rare and their origins were obscure until recent advances in genomic testing revealed the 
genetic basis of these disorders. An increasing number of myeloid neoplasms with hereditary 
predisposition are now recognised and included as distinct entities in the latest diagnostic 
classification (Arber et al., 2016). In particular, heterozygous germline mutations of the GATA 
binding protein 2 (GATA2) gene were first identified in familial myeloid neoplasia (Hahn et 
al., 2011) and in several autosomal dominant disorders with an increased risk of MDS and 
AML; Emberger (Ostergaard et al., 2011) and MonoMAC syndromes (Hsu et al., 2011), and 
Dendritic cell, Monocyte and Lymphoid deficiency (DCML) (Dickinson et al., 2011). Patients 
with congenital neutropaenia were later detected (Pasquet et al., 2013; Ganapathi et al., 
2015). A complex assortment of diseases are now recognised, considered to be part of the 
same autosomal dominant genetic disorder, collectively known as ‘GATA2 deficiency 
syndrome,’ which can also include different neoplastic diseases, and a broad range of disease 
characteristics, including non-haematological and non-infectious complications (reviewed in 
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Crispino & Horwitz, 2017; Wlodarski et al., 2017). There is considerable variation in the 
presenting phenotypes of these disorders, with overlap of clinical features, different ages of 
onset and penetrance of features (Dickinson et al., 2014; Spinner et al., 2014; Collin et al., 
2015). The precise incidence of GATA2 deficiency is unknown, however, evidence suggests 
that disease penetrance is high and that the vast majority of mutation carriers will develop 
neoplastic disease or immunological problems during their lifetime (Spinner et al., 2014; 
Collin et al., 2015). 
 The GATA2 gene, located at 3q21.3, is one of a family of fifteen ‘GATA zinc finger 
domain containing’ genes (HUGO Gene Nomenclature Committee (HGCN) Database). GATA2 
encodes a transcription factor, with two zinc finger DNA binding regions (ZF1 and ZF2) 
involved in binding to the promoters and enhancers of numerous target genes to form 
functional heterodimers (Hahn et al., 2011). Furthermore, GATA2 (and GATA1) has been 
shown to be self-activating and regulators of their own transcription (Cortés-Lavaud et al., 
2015). GATA2 is a critical regulator of gene expression in haematopoietic cells and is 
necessary for the production and function of haematopoietic stem cells (HSC) and for the 
maintenance of the HSC reservoir (Tsai et al., 1994; de Pater et al., 2013). GATA2 controls the 
production of specific progenitors of monocytes, B and NK lymphocytes and dendritic cells. 
More than one hundred different germline GATA2 mutations are now known, approximately 
a third of which are inherited. Three main types have been described; approximately 60% are 
nonsense and frameshift mutations located at different positions within the gene, upstream 
of or within ZF2. 30% are missense single nucleotide substitutions, which cluster in ZF2 and 
the adjacent C-terminal domains, unlike somatic missense mutations, which are 
predominantly found in ZF1 (Vinh et al., 2010; Hahn et al., 2011; Hsu et al., 2011). Thirdly, 
recurrent noncoding variants are found within intron 4 (NM_032638.4), affecting the -9.5kb 
regulatory site containing E-box and GATA and ETS elements and are detected in up to 10% 
of patients (Johnson et al., 2012; Hsu et al., 2013). A few cases of GATA2 deficiency 
syndrome result from large, whole gene deletions, leading to complete hemizygosity and 
absent transcription of one allele. These cases could also involve deletion of contiguous 
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genes at 3q21.3, and are associated with wider spectrum of features including 
developmental delay and mental impairment. 
All heterozygous germline mutations are predicted to reduce or nullify GATA2 
transcriptional activity, resulting in GATA2 deficiency from haploinsufficiency. This creates an 
imbalance in the concentration-dependent equilibrium of GATA2, relative to other 
transcription factors, and leads to disordered expression of downstream target genes (Collin 
et al., 2015). Maintenance of HSC is acutely sensitive to the levels of GATA2 and 
haploinsufficiency leads to aberrant haematopoiesis and progressive depletion of the HSC 
pool (Crispino & Horwitz, 2017; Wlodarski et al., 2017). The main clinical features of certain 
subtypes of the syndrome are a distinct pattern of infections, which are the consequences of 
immunodeficiency brought about by the disturbance in production of specific cell lineages 
and resulting peripheral cytopenias (Hsu et al., 2011; Dickinson et al., 2011; Dickinson et al., 
2014; Spinner et al., 2014; Collin et al., 2015). 
Haploinsufficiency is common to all GATA2 deficiency and so a simple model is unable 
to explain the heterogeneity of disease types. Similar mutations have been observed 
amongst families with different clinical syndromes and it has been suggested that there are 
no clear associations between types of mutation and clinical features (Hyde & Liu, 2011; 
Kazenwadel et al., 2012; Spinner et al., 2014). The study of genotype–phenotype correlations 
is confounded by this discrepancy, as well as the variable onset of features and differences in 
penetrance. However, the molecular pathogenesis is becoming better understood; different 
studies have remarked that there is phenotype clustering in families with the same mutation 
(Spinner et al., 2014) and in a study of specific, recurrent germline missense mutations, 
clinical features were found to be remarkably consistent (Chong et al., 2017). Evidence of the 
variable effect of different types of GATA2 mutation influencing phenotypic features is slowly 
becoming apparent.  Differences may be partly explained that levels of GATA2 activity can be 
modified by residual mutant GATA2 expression and the DNA binding affinity of the mutant 
protein, affecting the dominant-negative transactivation of the wild-type allele and the 
degree of haploinsufficiency (Cortés-Lavaud et al., 2015; Chong et al., 2017). The importance 
of autoregulation of expression is demonstrated by the observation of GATA2 mutations 
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within the autoregulatory binding sites of its own promoter and enhancer and therefore lack 
the regulatory element responsible for maintaining the self-activation, but otherwise have 
intact coding sequences (Johnson et al., 2012; Hsu et al., 2013). It has been proposed that 
there are two classes of germline GATA2 mutation with ‘reduced’ or ‘greatly reduced’ DNA 
binding affinity (Chong et al., 2017). Furthermore, the differential binding of cofactors to 
GATA2 in haematopoietic differentiation, such as PU.1 (Chong et al., 2017) and impairment 
of interactions in a complex network of transcription factors, have the potential to affect 
downstream expression and changes in cellular responses, which could be critical to the 
development of disease and influence the disease phenotype. It appears that the mode of 
activity of GATA2 mutation is complex involving interplay with multiple factors, making 
geneotype-phenotype correlations difficult to interpret. However, the subtly different effects 
of specific mutation will eventually be revealed with growing evidence from new findings. 
The GATA2 gene is also critical for the development of the lymphatic vasculature 
(Kazenwadel et al., 2012) and when defective, can promote primary lymphedema, a key 
characteristic of Emberger syndrome (Collin et al., 2015). The majority of these patients tend 
toward an earlier age of onset; have frameshift or nonsense mutations which are predicted 
to eliminate GATA2 activity. Complete or nearly complete haploinsufficiency may be more 
disruptive to lymphatic development than missense mutations (Kazenwadel et al., 2012; 
Dickinson et al., 2014; Chong et al., 2017). Mutations, such as amino acid missense 
substitution, that have more likely to have reduced transcriptional activity but with residual 
function exclude Emberger and therefore might confer a resistance to lymphedema.  
GATA2 deficiency promotes clonal haematopoiesis, which is likely to contribute to 
pathogenesis in these disorders (Dickinson et al., 2014; Collin et al., 2015). However, it is 
unclear how germline loss-of-function mutations result in myeloid neoplasms (Wlodarski et 
al., 2017). GATA2 deficiency imparts a high risk of a familial myeloid neoplasia (Hahn et al., 
2011; Bodor et al., 2014; Holme et al., 2012; Wlodarski et al., 2016); overall prevalence is 
estimated to be approximately 75% amongst mutation carriers with a median age of onset of 
approximately 20 years, but with a wide range (<1~78 years) (Wlodarski et al., 2017). The risk 
of developing MDS or AML appears to be universal and not to be confined to distinct 
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germline GATA2 mutations (Collin et al., 2015), however, an exception may be that missense 
ZF2 mutations are more marginally associated with the familial MDS/AML phenotype (Hahn 
et al., 2015) or that the frequency of accessory features is reduced. An earlier age of onset 
has been reported in patients with antecedent accessory features (Pasquet et al., 2013). The 
non-neoplastic complications resulting from mononuclear cytopaenia has been described as 
an ‘accessory phenotype,’ and a significant proportion of patients present with a primary 
MDS or AML, apparently lacking other non-neoplastic haematological features, although 
large pedigrees demonstrating ‘pure’ familial MDS as the sole feature are unusual (Hahn et 
al., 2011; Bodor et al., 2014; Holme et al., 2012; Wlodarski et al., 2016). However, it is 
possible that cellular deficiencies could be overlooked if not thoroughly investigated or may 
not have been recorded in family histories (Collin et al., 2015). Development of MDS is often 
associated with acquisition cytogenetic abnormalities, especially monosomy 7 in 41% of 
patients and trisomy 8 in 14% (Wlodarski et al., 2017). Other studies have reported acquired 
ASXL1 mutations in about 30% of patients, often coinciding with the progression from 
hypoplastic MDS to a more proliferative disease and particularly CMML (Micol & Abdel-
Wahab, 2014; Bodor et al., 2014; West et al., 2014b; Churpek et al., 2015; Wang et al., 2015). 
We report a family of three siblings presenting in childhood with MDS or AML at different 
ages, who were found to have a novel frameshift GATA2 germline mutation inherited from 
the unaffected father. There were no apparent accessory features of germline GATA2 
deficiency syndrome and so myeloid neoplasias were the only presenting feature. The clinical 
and laboratory details of this unusual family are presented and the implications of the 
genetic changes on disease phenotype and clinical course are discussed 
 
Case studies and Family history  
The findings and routine clinical investigations of three siblings are described. 
Clinical description 
The family comprised three children, 1 boy, two girls (see Figure 1). 
Sibling 1 (boy, 11 years and 8 months) investigated for pancytopenia and diagnosed with 
MDS. Sibling haematopoietic stem cell transplant age using HLA compatible sister aged as 
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stem cell donor (Sibling 3). Developed severe chronic GVHD and died of pulmonary 
complications. 
Sibling 2 (girl, 12 years and 1). Acute presentation with high WCC (49 x 109/l). 
Morphologically and immunologically AML. Commenced treatment according to the AML 10 
protocol and had unrelated HSCT with FLU-ATG conditioning with minimal post-transplant 
complications. FU 12 year post HSCT minimal long term effects. 
Sibling 3 (16 years, donor for sibling 1 age 6?) presented with thrombocytopenia. Bone 
marrow morphology was consistent with MDS. Had unrelated HSCT with Flu ATG without 
significant complications.  Well 4 years post HSCT. 
 
Materials and methods  
Germline Sequencing 
Germline whole exome sequencing (WES) was performed to investigate the family and first 
detect the GAT2 germline mutation.   
Cytogenetics and microarray of leukaemic cells 
Cytogenetic analysis was performed to local adaptions of standard techniques (Czepulkowski, 
2001) and reported using standard nomenclature (ISCN 2016; An International System for 
Human Cytogenomic Nomenclature 2016). 
SNP Microarray. Normal and leukaemia DNA was tested by SNP microarray to look for 
evidence of germline and acquired abnormalities, with particular attention to chromosome 7 
due to monosomy in the tumour. 
Next Generation sequencing of DNA from leukaemic cells from diagnostic bone marrows 
DNA was extracted from previously cultured cells surplus to cytogenetic investigations, which 
had been stored in a 3:1 mixture of methanol and glacial acetic acid at -20oC. Stored cells 
were available from the time of diagnosis of the myeloid neoplasms in the three siblings. 
Post-treatment remission samples were available from Sibs 1 and 2 and a pre-symptomatic 
screening bone marrow, 7 years before diagnosis of MDS, was available from Sib 3, which 
were used as normal controls. 
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Sure Select solution phase cRNA biotinylated oligonucleotide baits (Agilent Technologies, 
Santa Clara, CA, USA) were designed to capture relevant sequences from 45 target genes, 
including all exons from the set of 30 genes known to be frequently recurrently mutated in 
acute myeloid leukaemia for the detection of single nucleotide variants. The exonic and 
intronic positions of typical junctions of FLT3 internal tandem duplications, KMT2A partial 
tandem duplications and typical breakpoints in genes of recurrent gene fusions in AML were 
also sequenced (see Table 2).  
GATA2 RT-PCR and sequencing 
RNA was extracted from viable bone marrow cells stored from Sibling 3. cDNA was made 
using oligo dT and hexamer primers and GATA2 was assessed by PCR using forward primer 
FW4 (GACAAGGACGGCGTCAAGTA) and reverse primer RV1 (CGCCCCTTTCTTGCTCTTCT). 
Unrelated cells from leukaemic cell line (OCI-AML5) with wild type GATA2 were used as 
normal control. The PCR was cleaned up using the Qiagen PCR clean up kit and then Sanger 
sequenced using either the FW4 or RV1 primers in separate reactions. 
 
Results 
GATA2 mutation analysis 
Whole exome sequencing revealed a deletion of CTTCTGGCGGC in GATA2 at exon 5 
c.1021_1031delGCCGCCAGAAG p.(Ala341SerfsTer39) (Annotated against Ensembl 68). This 
was confirmed by Sanger sequencing. The same germline deletion was detected in peripheral 
blood DNA of all three siblings and their father.  
 
Cytogenetics and microarray analysis of bone marrow aspirate specimens 
Conventional cytogenetic analysis of bone marrow aspirate specimens at the time of 
diagnosis of myeloid neoplasia showed abnormal karyotypes, with monosomy 7 in all three 
siblings and with trisomy 8 in a separate apparently unrelated cell line in sibling 3 (see Table 
1). Using SNP microarray, applying a cut-off of 50 kb, the tumour samples confirmed loss of 
the whole of chromosome 7. There was a 32kb deletion of chromosome 7 in the normal 
sample (pos 124,236,837-124,268,655), which was not reported in the Database of Genomic 
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Variants but there were no known genes in this region (http://dgv.tcag.ca/dgv/app/home). 
There were no other copy number variants in either the tumour or normal samples, which 
were not reported in DGV and so there was no indication of tumour predisposition genes. 
The deletions and duplications called in the tumour and not seen in the normal DNA were 
difficult to distinguish from background noise. 
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Next Generation sequencing of DNA from diagnostic bone marrows compared to normal 
controls 
Targeted next generation sequencing of DNA from dysplastic marrow or leukaemia cells from 
diagnostic bone marrows also showed germline GATA2 replacement of TCTTCTGGCGGC with 
T at chr3:128,200,774-128,200,784 (GRCh37/hg19 reference genome), confirming the 
findings of exome sequencing. A point mutation in exon 7 of WT1 (32417910 G>T), a 
nonsense mutation introducing a stop codon at S152* was identified in Sibling 2. This was 
detected in 168 variant reads at an overall read depth of 441 reads (VAF 0.38). Of note, 
somatic mutations of ASXL1 were not detected. Germline missense ASXL1 variants were 
found in our cohort; L815P as a homozygous variant in each of our siblings and E1102D as a 
heterozygous change in Sibling 2. Following realignment and further investigation for low 
frequency variants, two low VAF variants were observed in Sibling 3; homozygous, non-
homologous missense variant U2AF1 (chr21:44513243 G>A, p.S158L/S231L) was detected at 
VAF 0.052 (14/272 reads) and homozygous, non-homologous missense variant in IDH1 
(chr2:209116179 G>A, p.P33S) at VAF 0.048 (12/252 reads). 
 
RNA expression 
Test cDNA from the bone marrow specimen of Sibling 3 (from the forward sequence) showed 
expression of the mutated allele only; there was no evidence of the wild-type allele. There 
were two separate aberrant sequences, one corresponding to the expected GATA2 sequence 
with the deletion (deletion of GCCGCCAGAAG). A second cDNA sequence with the deletion 
appeared to represent an aberrant splice form three bases upstream of the deletion, and 
corresponding with sequence from within intron 6, which suggests that aberrant splicing was 
occurring. This might be due to the deletion as it is close to an intron/exon boundary and 
whilst not predicted to alter splicing it may change the binding of exon splice enhancers 
Testing of the control cell line (OCI-AML5) detected the expected intact GATA2 sequences. 
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Discussion 
The current study presents a family with a GATA2 germline mutation, inherited from 
the asymptomatic father by three offspring and presenting with MDS/AML without other 
features typical of subtypes of the GATA2 deficiency syndrome. Myeloid neoplasia is the 
presenting feature in up to 50% of cases of GATA2 deficiency (Collin et al., 2015) and the 
overall prevalence is estimated to be approximately 75%, with a median age of onset of 
approximately 20 years but with a wide range (<1~78 years) (Wlodarski et al., 2017). The 
lifetime risk of developing MDS is estimated to be near to 90% (Micol & Abdel-Wahab, 2014). 
However, the rate differs between families, and the risk is reduced in cohorts selected by a 
history of recurrent infections (Spinner et al., 2014). Prevalence estimates, therefore, depend 
on the ascertainment of the proband, compounded by a possible phenotype clustering effect 
in individuals with the same mutation. The three affected children in the current study all 
developed myeloid neoplasms of less than the median age of onset, albeit at different ages; 
11, 12 and 18 years, two with MDS and one with AML. 
GATA2 mutations do not confer poor prognosis in childhood MDS. In GATA2 
deficiency syndrome, the high risk of progression from cytpopaenia and MDS to AML informs 
the decision to proceed to timely haematopoietic stem cell transplantation (HSCT) (Wlodarski 
et al., 2016) and outcomes are less favourable after development of myeloid neoplasm or 
after the onset of chronic infection. Recovery of normal phenotype and reversion to full 
immune reconstitution following transplant can take as long as several years but many 
patients derive many years free of disease symptoms (Crispino & Horwitz, 2017). 
Unfortunately, potential related donors may share a familial GATA2 mutation, rendering 
them unsuitable and many patients may not be transplantation candidates. Transplantation 
from sibling carrier in our case 1 which now would probably be reconsidered with current 
understanding of the syndrome. 
The absence of additional haematological features of GATA2-deficiency is not 
uncommon; half of GATA2 mutation patients ascertained by presentation of a paediatric 
MDS lacked an accessory phenotype (Wlodarski et al., 2016). However, there is a high rate of 
de novo GATA2 mutation and the majority of GATA2-related MDS patients present irregularly 
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with no family history of MDS. Therefore, a significant proportion of probands present with 
no prior features to indicate GATA2 deficiency. Usually, within GATA2-related MDS 
pedigrees, all affected relatives were diagnosed with MDS/AML as children or young adults. 
Within paediatric GATA2-related MDS, the low number of silent carriers are consistent with 
supporting high penetrance and expressivity (Wlodarski et al., 2016). The typical appearance 
of large hereditary MDS/AML kindreds, therefore, is with younger generations with clear 
DCML deficiency and MDS (Collin et al., 2015) and pedigrees with multiple members with 
GATA2-related MDS without additional accessory phenotypes are uncommon. 
The father is a clinically silent carrier of the germline GATA2 mutation, which is 
unusual, whereas his offspring apparently have a highly penetrant and expressive disease 
(Wlodarski et al., 2016). Such phenotypic discordance of MDS has been noted previously 
within kindreds (Spinner et al., 2014); a father of children with MDS with trisomy 8 and a 
family history of GATA2-related malignancy was clinically asymptomatic (kindred 40) and in a 
separate family (kindred 4), a father of two children presenting with later onset MDS (at ages 
26 and 19) was unaffected until the age of 78 when he developed CMML. Only 8 silent 
carriers were apparent in more than 200 GATA2 individuals (Micol & Abdel-Wahab, 2014). 
Evidence suggests that the father is at risk of myeloid (or other) malignancy and that a series 
of somatic mutations and clonal expansion are required for overt neoplastic disease to 
develop; a cooperating ‘second hit’ mutation or chromosomal abnormality is necessary. 
There is growing evidence from chromosomal studies and mutational profiling in GATA2 
deficiency of the significance of secondary acquired abnormalities. 
Neoplastic disease develops from the stepwise acquisition of additional mutations 
and clonal expansion, which is different from the other features of GATA2 deficiency and is 
unlikely to show the same course and timing. It is accepted that additional somatic genetic 
abnormalities are acquired in addition to the germline defect leading to transformation to 
overt neoplastic disease. Cytogenetic abnormalities are well-documented in GATA2-related 
MDS and the most common are monosomy 7 (30%), trisomy 8 (25%) and der(1;7) and other 
abnormalities resulting in deletion of 7q (Wlodarski et al., 2016). Monosomy 7 is found in all 
three affected individuals in this family and trisomy 8 in one (see Figure 2). The study 
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acquisition of molecular somatic mutations as routes of neoplastic disease progression 
requires further study. However, ASXL1 mutations have been identified in up to 30% of 
GATA2-related MDS, as a major route of leukaemia progression. Acquired ASXL1 mutation is 
strongly associated with the presence of monosomy 7, bone marrow hypercellularity and 
chronic myelomonocytic leukaemia (West et al., 2014b; Micol & Abdel-Wahab, 2014; Bodor 
et al., 2014; Lubking et al., 2015; Churpek et al., 2015). However, when corrected for 
ascertainment bias, large studies suggest that this is an overestimate and it is no larger than 
the general frequency in paediatric MDS without germline GATA2 mutations  (Wlodarski et 
al., 2017). Acquired ASXL1 mutations were not detected in our cohort but germline missense 
ASXL1 variants were detected; L815P as a homozygous variant in each of our siblings and 
E1102D as a heterozygous change in Sibling 2. c.L815P has not been fully characterised and 
its effect on ASXL1 protein function is not known but it does not appear to lie within any 
known functional domains of the ASXL1 protein (UniProt.org). ASXL1 missense variant 
p.E1102D has been previously reported as a pathological mutation, presumably due to it not 
appearing as a commonly reported SNP (dbSNP 147) (Szpurka et al., 2010; West et al., 
2014b). This variant appears in the germline in our patient which supports its interpretation 
as a non-pathological polymorphism, as other studies of the gene (Clin Var) (Carbuccia et al., 
2010; Perez et al., 2010; Stein et al., 2011). 
With the exception of ASXL1, there are few other investigations of acquired somatic 
mutations. Whole genome analysis from a single patient with trisomy 8 found mutations in 
EZH2, HECW2 and GATA1 from that may contribute to MDS/AML (Fujiwara et al., 2014). In a 
study of three GATA2 germline families, 4 out of 6 individuals showed mutations in RUNX1, 
GATA2, GPRC5A, STAG2, WT1, NRAS, TP53, SETBP1 and ASXL1 and others at low frequency 
(Wang et al., 2015). Frameshift mutations in PDS5B, a cohesion family gene, was found in a 
GATA2 patient and a germline RUNX1 patient in a study of familial MDS/AML, as well as 
recurrent mutations in BCOR, DNMT3A, ASXL1, PTPN11, and STAG2 genes (Churpek et al., 
2015). After conservative filtering of our data from a targeted panel of common AML-
associated genes matched against the paired normal samples by removal of common SNPs 
and variants unlikely to be pathogenic, only one mutation in WT1 was detected at a 
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significant variant allele frequency (VAF). HECW2, GATA1 and PDS5B genes were not tested 
in our panel. WT1 mutations are common in paediatric malignancy and one was detected in a 
previous patient with GATA2 mutation (Wang et al., 2015). The WT1 mutation in Sib II.2 with 
AML was found in exon 7 (32417910 G>T) 168 variant reads at overall read depth of 441 
reads (VAF 0.38), a nonsense mutation introducing a stop codon at S152*. WT1 exon7 stop 
mutations represent the vast majority of acquired WT1 mutations in AML, resulting in a 
truncated protein with loss-of-DNA binding function by elimination of the zinc finger domain 
or nonsense-mediated RNA decay and complete loss of expression (Rampal & Figueroa, 
2016). Homozygous, non-homologous missense variant U2AF1 (chr21:44513243 G>A, 
p.S158L/S231L) was detected at VAF 0.052 (14/272 reads) and homozygous, non-
homologous missense variant in IDH1 (chr2:209116179 G>A, p.P33S) at VAF 0.048 (12/252 
reads). These are included to be comparable to previous studies (Wang et al., 2015) and 
although the quality of the reads was satisfactory, the small number of reads from previously 
fixed tissue casts doubt on the significance of these findings. 
 The spectrum of recurrently mutated genes in GATA2 familial MDS/AML appears to 
be different from sporadic disease, albeit with considerable overlap in the genes and gene 
families that serve to enhance the disease progression. The common driver mutations and 
gene fusions found in sporadic, such as NPM1, FLT3-ITD, RUNX1-RUNX1T1, CBFB-MYH11, 
KMT2A fusions and NUP98 fusions, are notoriously absent from familial disease. 
Furthermore, it has been reported that the mutational burden of familial disease is less. The 
relative paucity of mutations in these diseases and lack of additional recognised powerful 
driver events, may indicate that the most significant and prevalent genetic abnormalities 
have already been demonstrated; GATA2 germline mutations, together with monosomy 7 
and trisomy 8 and ASXL1 mutations, particularly in CMML.  
The current family was found to have a germline GATA2 mutation involving an 11bp 
deletion (CTTCTGGCGGC/GCCGCCAGAAG) at position 128,200,774-128,200,784 
(GRCh37/hg19 reference genome) of chromosome 3. This is a frameshift mutation in exon 5 
of GATA2 and is predicted to change the amino acid sequence of the translated protein from 
amino acid position 341, 71% along the amino acid sequence of the protein 
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(ENST00000341105), towards the C-terminus (see SIFT analysis Table 2). This has not been 
reported in the literature and is not on the ClinVar database (accessed 21/09/2017). A 
heterozygous 4-bp insertion (c.1025GCCG) in GATA2 gene, at the same genomic position 
GATA2:c.1021_1024dupGCCG (p.Ala342Glyfs) has been reported in a patient with Dendritic 
cell, monocyte, B lymphocyte, and natural killer lymphocyte deficiency and later aplastic 
anaemia. This frameshift was predicted to result in premature termination 
(Ala342GlyfsTer41), which may explain the different phenotype (Mace et al., 2013). Our 
family’s GATA2 mutation is novel although frameshifts are generally amongst the most 
common nonsense mutations causing the syndrome and have been found previously in MDS; 
e.g. 18 truncating mutations (including frameshifts) were identified in a large cohort with 
childhood MDS as the presenting feature (Wlodarski et al., 2016). They occurred randomly in 
advance of C-terminal end of ZF2, almost all of which are unique because they are not 
derived from simple base pair changes. Amino acid 341, in our case, is towards the end of the 
first zinc finger domain and this is predicted to replace the subsequent 140 amino acid 
sequence with a 38 amino acids, including complete disruption of the ZF2. Consistent with 
the zinc finger domains being critical for effective GATA2 function, unsurprisingly, the 
majority of nonsense mutations eliminate the ZF domains and non-synonymous missense 
substitutions of single amino acids are found within ZF2, affecting protein function. Gene 
deletions have a minimal region of deletion encompassing zinc fingers (Collin et al., 2015). 
It appears that this frameshift mutation, c.1021_1031delGCCGCCAGAAG 
p.(Ala341SerfsTer39), does not predispose accessory features of GATA2 deficiency. The 
children present with MDS/AML without other features and the father is asymptomatic at 
age ?. However, patients with GATA2 germline mutation can lack a disease phenotype as 
cellular deficiency tends to evolve gradually over several decades and could remain 
subclinical (Dickinson et al., 2014). The age of onset of clinical symptoms was highly variable 
with 50% of individuals being without any symptoms of the disease by age 20 and peak age 
for haemato-immunologic disease manifestation is in the second and third decade of life 
(Spinner et al., 2014). It was reported that frameshift mutations favour an earlier onset age 
of cellular deficiency, compared with missense mutations but this may depend on the 
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underlying mechanism of GATA2 deficiency (see below) (Dickinson et al., 2014). The 
development of MDS and AML, however, appears to be an equal risk with all types of GATA2 
mutation and depend on the chance acquisition of secondary driver genetic abnormalities 
(Dickinson et al., 2014; Spinner et al., 2014; Collin et al., 2015). These observations are 
consistent with the theory that the cytopaenia phenotype is progressive whereas that 
leukaemic onset is multimodal, reflecting different causative factors. Therefore, it is feasible 
that the earlier the malignancy presents, the less likely non-haematologic accessory features 
will develop as a presenting feature. 
Despite random variation within families and an unpredictable influence of 
environmental factors, particularly infectious exposure, the accumulation of evidence 
suggests that the clustering of similar disease within family groups is influenced by the 
specific underlying genetic constitution. Each specific mutation is likely to have subtly 
different activity and exert different phenotypic affects (Hahn et al., 2011; Chong et al., 
2017). This has been demonstrated previously with differences in their ability to inhibit HSC 
differentiation and maintain the progenitor phenotype, thereby disrupting the balance in the 
HSC pool from hyperstimulation, and depletion of HSCs in the cytopaenic subtypes of the 
syndrome (Tipping et al., 2009; Cortés-Lavaud et al., 2015). The activity of mutant GATA2 
expression, the length and precise structure of the residual GATA2 mutated protein, 
retention of the ZF binding domains, and whether nonsense mediated decay (NMD) occurs 
would all determine the (non- or hypo-) functionality of GATA2 protein. The findings of 
Cortés-Lavaud and colleagues (2015) support haploinsufficiency being not just a function of a 
quantitative reduction of intact GATA2 but induced by impaired binding of mutant GATA2 to 
the promoter 2.4kb upstream of wild type GATA2, leading to secondary loss of expression 
from the intact allele due to reduced GATA2 occupancy at its own promoter. GATA2 germline 
mutations could affect DNA binding other GATA2 transactivation target genes, lead to 
putative dysregulation of specific GATA2 targets and therefore exaggerate the variable 
degree of functional haploinsufficiency in different families. 
Furthermore, nonsense mediated decay (NMD) is a cellular mechanism of mRNA 
surveillance to detect nonsense mutations and prevent the expression of truncated or 
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erroneous proteins and may result in undetectable transcription of one allele (SIFT). SIFT has 
predicted from the absence of a premature STOP codon in the last exon or within 50 
nucleotides from the end of the of the second to last exon, that NMD does not occur with 
this mutation (Nagy & Maquat, 1998). This is demonstrated by the detection of transcribed 
mutant mRNA in bone marrow cells of sibling II.3 in our study (as cDNA by reverse 
transcriptase-PCR). From our tentative evidence (?), it appears that the active expression of 
GATA2 p.(Ala341SerfsTer39) but complete disruption of the DNA binding domain of mutant 
GATA2 has resulted in no detectable expression of wild-type GATA2. This is surprising but 
would support the observations of Cortés-Lavaud et al (2015) that GATA2 protein 
transactivates its own transcription and in the present case, this process is suppressed in a 
dominant negative fashion by expressed mutant alleles with defects in the zinc finger 
domains, results in loss of DNA-binding ability and leading to the wild-type GATA2 deficiency. 
Previous analyses that found differentially affected genes depending on the mutation (Hahn 
et al., 2015; Chong et al., 2017) explain in part the clinical heterogeneity amongst patients 
with GATA2 deficiency. Symptoms could differ from a pure haploinsufficiency phenotype. 
This effect is postulated to be different for various mutation types which might be subtle for 
simple single amino acid change missense mutation. This effect would be less subtle for the 
protein disruption resulting from frameshift mutation, as in our family. Frameshift or null 
mutations have been linked to a higher risk of lymphedema and severe viral infections and 
Emberger (Hyde & Liu, 2011; Spinner et al, 2014). However, frameshifts with residual GATA2 
mutant function, without NMD, may behave as missense mutations.  
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Table 1 – presenting features and acquired genetic abnormalities detected in the kindred 
 
 Age at 
diagnosis 
Diagnosis Karyotype CGH Targeted NGS 
Sibling 1  MDS 45,XY,-7[10]/46,XY[1]   
Sibling 2  AML 45,XX,-7[10]  WT1 
(32417910 
G>T), 
Sibling 3  MDS 45,XX,-
7[7]/47,XX,+8[3]/46,XX[10] 
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Table 2. Results of SIFT analysis to predict the effect of germline GATA2 mutation 
c.1021_1031delGCCGCCAGAAG on protein function (http://sift.jcvi.org/ accessed 02/02/2017) 
 
Input Coordinates 3,128200773,128200784,-1,-/,TCTTCTGGCGGC/------------  
Gene ID ENSG00000179348 
Transcript ID ENST00000341105 
Substitution Type FRAMESHIFT 
Region CDS 
Amino acid position change 340-480 
Indel Location 71% (towards C-terminus of the protein) 
Nucleotide change CGGCT-cttctggcggc-CGACT 
Amino acid change KRRLSaarragtccancqtt*->KRRLSsrhllcklsddnhhl* 
Causes NMD NO 
Transcript visualisation 3'<---3'UTR[e5][*.e4]--[e3]--[e2]--[e1]5'UTR—5'UTR-----|5' 
Gene Name GATA2 
Gene Desc 
Endothelial transcription factor GATA-2 (GATA-binding protein 2)  
[Source:UniProtKB/Swiss-Prot;Acc:P23769] 
Protein Family ID ENSFM00500000269911 
Protein Family Desc RECNAME: FULL=GATA BINDING 
Transcript Status KNOWN 
Protein Family Size 5 
Protein Sequence Change ENST00000341105 change mismatch for this transcript in red 
Original Protein Sequence >ENST00000341105; MISMATCH = 340-480 
  
MEVAPEQPRWMAHPAVLNAQHPDSHHPGLAHNYMEPAQLLPPDEVDVFFNHLDSQGNPYYANPAHARARV
SYSPAHARLTGGQMCRPHLLHSPGLPWLDGGKAALSAAAAHHHNPWTVSPFSKTPLHPSAAGGPGGPLSVYP
GAGGGSGGGSGSSVASLTPTAAHSGSHLFGFPPTPPKEVSPDPSTTGAASPASSSAGGSAARGEDKDGVKYQVS
LTESMKMESGSPLRPGLATMGTQPATHHPIPTYPSYVPAAAHDYSSGLFHPGGFLGGPASSFTPKQRSKARSCSE
GRECVNCGATATPLWRRDGTGHYLCNACGLYHKMNGQNRPLIKPKRRLSaarragtccancqtttttlwrrnangdpvc
nacglyyklhnvnrpltmkkegiqtrnrkmsnkskkskkgaecfeelskcmqeksspfsaaalaghmapvghlppfshsghilptptpih
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pssslsfghphpssmvtamg 
Modified Protein Sequence >ENST00000341105; MISMATCH = 340-378 
  
MEVAPEQPRWMAHPAVLNAQHPDSHHPGLAHNYMEPAQLLPPDEVDVFFNHLDSQGNPYYANPAHARARV
SYSPAHARLTGGQMCRPHLLHSPGLPWLDGGKAALSAAAAHHHNPWTVSPFSKTPLHPSAAGGPGGPLSVYP
GAGGGSGGGSGSSVASLTPTAAHSGSHLFGFPPTPPKEVSPDPSTTGAASPASSSAGGSAARGEDKDGVKYQVS
LTESMKMESGSPLRPGLATMGTQPATHHPIPTYPSYVPAAAHDYSSGLFHPGGFLGGPASSFTPKQRSKARSCSE
GRECVNCGATATPLWRRDGTGHYLCNACGLYHKMNGQNRPLIKPKRRLSsrhllcklsddnhhlmapkrqrgpclqrlw
pllqaaqc 
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Figure 2; Karyotypes from sibling 2.III showing 1. monosomy 7 and 2. trisomy 8 
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Figure #; germline DNA sequencing of GATA2 germline DNA sequencing from mother and  
 
Daughter (F). The same germline sequence is present in the other two siblings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3; Sequence of cDNA from expressed mutant allele from leukaemia cell line of sib 
2.III 
Daughter F
rev
Mother
rev
 
Exon 6 Exon 7
GAAGACTG
ACGCTTTGCCGCTTGAAA
TCGAGCCGGCACCTGTTG
delGCCGCCAGAAG
Matches sequence in intron 
6 - ?splice variant
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Table 3. QC statistics of NGS run for acquired mutations in bone marrow cells from MDS/AML samples 
Sib Reads in 
BAM 
passing 
quality 
filters  
Reads 
discarded 
% 
duplicate 
reads 
Reads in 
Covered 
regions 
% in 
covered 
regions 
Average 
read 
length 
Average 
read 
depth 
Bases 
with 
≥50 
reads  
Bases 
with 
≥100 
reads  
Regions 
with 
≥50 
reads  
Regions 
with 
≥100 
reads  
1 3813753 22 2.61 1657325 43.46 142 400 95.44 91.1 96.41 93.35 
2 3127903 16 2.28 1353498 43.27 143 328 94.97 89.79 96.26 93.53 
3 3285266 20 2.52 1452149 44.2 142 349 95.09 90.48 96.41 93.82 
 
 
 
 
 
 
 
